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Abstract
The human telomerase core enzyme consists of an essential structural RNA (hTERC) 
with a template domain for telomeric DNA synthesis and of a catalytic protein (hTERT) 
with reverse transcriptase activity. Expression of the hTERC and hTERT are essential for 
telomerase activity. Variation in telomerase activity is correlated with cellular senescence 
and tumour progression. Recent studies indicate that the regulation of telomerase activity 
is multifactorial in mammalian cells. The primary mode of control of hTERT appears to be 
transcriptional regulation but very little is known about the molecular mechanisms 
involved in the regulation of hTERC transcription. In this study, I have cloned and 
characterised the genomic sequences and promoter of the hTERC gene to provide 
evidence that transcriptional mechanisms are involved in hTERC gene regulation. 
Transient transfection with a series of 5'-deletion mutants demonstrated that between -
5.0 kb and -51 bp of the hTERC gene is responsible for high promoter activity, the 
minimal promoter region was defined as 176 bp (-107 to +69 bp). With the aid of in vitro 
DNase I footprinting, electrophoretic mobility shift assays (EMSAs) and mutagenesis 
analysis, four Sp1 binding sites and one CCAAT-box bound by the transcription factor NF- 
Y were identified to be involved in regulation of hTERC transcription. Co-transfection 
experiments showed that Sp1 and the retinoblastoma protein (pRb) are activators of the 
hTERC promoter and Sp3 is a potent repressor. Mutation of the CCAAT-box or the 
coexpression of a dominant negative nuclear factor-Y (NF-Y) significantly attenuated the 
transactivation by pRb and Sp1, suggesting that NF-Y binding is a prerequisite for pRb 
and Sp1 to activate the hTERC promoter. The different transcriptional regulators appear 
to act in a species-specific manner. Whilst Sp1 and Sp3 act on the human, bovine and 
mouse TERC promoters, pRb activates only the human and bovine promoter and NF-Y is 
important for the human TERC gene. The hTERC gene is expressed during 
embryogenesis and then down-regulated during normal development but is re-expressed 
in tumour cells, the h TERC promoter activity was therefore further investigated and a 
higher promoter activity in immortal cells than in two mortal cell strains (WI38 and IMR90) 
was shown. In conclusion, hTERC promoter contains sequence elements that allow 
interactions with several different transcription factors. The interplay between NF-Y, pRb, 
Sp1 and Sp3 within the architecture of the h TERC promoter may combine to enable a 
wide variety of cell types from mortal to immortal to regulate h TERC expression through 
transcriptional control.
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Chapter 1 Introduction
1.1 The End-Replication Problem
The genetic material of eukaryotic cells is dispersed on multiple linear chromosomes, with 
a total of 46 chromosomes in each human somatic cell (for example Figure 1.1). One 
could imagine that the presence of these multiple independent chromosomes offers great 
selective advantages during evolution due to the potential for variation. However, linear 
chromosomes pose two problems for the cell: how to protect the free DNA ends from 
degradation and fusion, and how to replicate the extreme termini of the DNA. Exposed 5' 
and 3' termini of DNA are highly susceptible to nuclease degradation. In addition, such 
exposed DNA ends are highly recombinogenic and can ligate with other free DNA ends or 
can integrate into the heart of chromosomal DNA (Haber & Thorburn; 1984).
The mechanisms of DNA replication in linear chromosomes is different for each of the two 
strands (called leading and lagging strands, see Figure 1.2, Morin, 1997). The lagging 
strand is made as a series of discrete fragments, each requiring a new RNA primer to 
initiate synthesis. The DNA between the last RNA priming event and the end of the 
chromosome cannot be replicated because there is no DNA beyond the end to which the 
next RNA primer can anneal, thus this gap cannot be filled in (this is referred to as the 
"end replication problem"). Since one strand cannot copy its end, telomere shortening 
occurs during progressive cell divisions. The shortened chromosomes are inherited by 
daughter cells and the process repeats itself in subsequent divisions (Olovnikov, 1971; 
Watson, 1972).
1.2 The telomere
1.2.1 Telomeres cap the chromosome end
In the early 1970s, the end replication problem was put forth as a dilemma for maintaining 
the integrity of linear chromosomes. Given the limitations of conventional DNA
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polymerases, genetic information was predicted to be lost with each round of replication, 
causing the chromosomes to shorten each cell cycle (Watson, 1972 ; Olovnikov, 1973 ). 
In 1985, Greider and Blackburn identified telomerase activity in the ciliate protozoa, 
Tetrahymena (see Table 1.1 for history). In 1987, Greider and Blackburn demonstrated a 
new and unexpected mechanism of DNA replication-telomere extension by reverse 
transcription. Eukaryotic telomeres generally consist of simple arrays of tandem G rich 
repeats that run 5’ to 3’ at chromosome ends, with the C rich complementary strand 
sometimes recessed, forming a G rich 3’ overhang. Single stranded G rich telomeric 
sequences can form intra- and interstrand structures, but their biological importance is 
unclear (Fang & Cech, 1993).
Telomere sequences can vary from species to species, but a given organism has a 
characteristic repeat at all telomeres, and their function is the same: (1) they form specific 
complexes with telomere-binding proteins; (2) they protect chromosome ends from 
exonuclease digestion; (3) they prevent aberrant recombination; and (4) telomeres 
prevent the chromosome ends from activating checkpoint controls that sense DNA 
damage. Telomeres have been implicated in a large number of cellular processes: 
chromosome length maintenance, chromosome stability, transcriptional silencing, and 
chromosome positioning in the nucleus, chromosome healing, recombination, 
chromosome fragmentation and cellular senescence.
Therefore, telomeres are specialised heterochromatin structures that act as protective 
caps at the ends of the chromosomes. One critical difference between normal and tumour 
cells lies at the ends of their chromosomes. Normal somatic cells progressively shorten 
their telomeres due to the end-replication problem with increasing cell divisions until a 
growth arrest (senescence/age) occurs. Tumour cells have elongated telomeres due to 
expression of telomerase. An enzyme called telomerase is the key to maintaining the 
length of the telomeres and overcome the end-replication problem.
3
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1.2.2 Telomeres in cellular aging and molecular biologic clock
In human and all vertebrates studied, a single telomere sequence (TTAGGG) is found at 
chromosome ends (Figure 1.1) (Moyzis et al., 1998). In human, telomeres are made up of 
an average of 5000-15000 base pairs of (TTAGGG)n repeats and telomere-binding 
proteins. Every time a cell divides it loses 25-200 DNA base pairs off the telomere ends. 
Once this pruning has occurred about 100 times, a cell senesces (or ages) and does not 
continue dividing. Eventually, shortening of the telomeric DNA at chromosome ends is 
postulated to limit the lifespan of human cells, such DNA deletion would lead to the loss of 
cell viability. In mouse, telomeres are approximately 40 kb long (Kipling & Cooke et al., 
1990; Starling et al., 1990; Prowse & Greider, 1995), mouse cells lacking telomerase 
would require many more doublings to exhaust telomeric sequences compare to human 
cells (de Lange & Jacks, 1999).
Telomeres are shorter in all somatic tissues from older than from younger individuals 
(Hastie et al., 1990; Lindsey et al., 1991) and in somatic tissues than in germline cells 
(Cooke & Smith, 1986; Allshire et al., 1988). Telomeres in normal cells from young 
individuals progressively shorten when grown in cell culture (Harley et al., 1990), and 
children born with progeria have shortened telomeres compared to age-matched controls 
(Allsopp et al., 1992). Finally, experimental elongation of telomeres extends the 
proliferative capacity of cultured cells (Wright et al., 1996b; Bodnar et al., 1998).
It has been proposed that entry into senescence is initiated when a critically shortened 
telomere length is reached (Harley, 1991; Allsopp et al., 1995) perhaps by the induction of 
a DNA damage checkpoint pathway. Thus mounting evidence suggests that the 
sequenctial shortening of telomere DNA may be an important intrinsic molecular timing 
mechanism, or replicometer. Telomeres may both protect chromosome termini from 
degradation and recombination (Blackburn, 1991; Zakian, 1989) and promote correct 
mitotic segregation of sister chromatids (Kirk et al., 1997), as well as provide a buffer of 
expendable non-coding DNA to accommodate the end-replication problem.
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Figure 1. 1 The Telomeres
Fluorescence in situ hybridisation of 
human telomeres in a metaphase 
chromosome spread from human cells. 
The metaphase chromosomes were 
hybridised with a FITC-labeled PNA 
(TTAGGG)3 probe. The chromosomes 
were counterstained with propidium 
iodide. Telomeric TTAGGG repeats 
show as yellow dots at ends of the 
human chromosomes. The 92 telomeres 
in cells are considered essential for 
maintaining chromosome structure and 
function. They are composed of the 
hexameric nucleotide repetitive 
sequence TTAGGG (thymidine, 
thymidine, adenosine, guanosine, 
guanosine, and guanosine). Telomeres 
shorten each time a cell divides and may 
be the timing mechanism that limits the 
growth of normal cells.
Table 1.1 A brief h istory of telomerase in relation to cell senescence and 
cancer
Date Events
1961
1971
1985
1986
1987
1989
1990
1990
1992
1994
1995 
1995 
1997 
1997
1997
1998
1998
1999 
1999
L. Hayflick describes cellu lar aging or senescence
Soviet scientist, A.M. O lovnikov proposes loss of telom eres lim its cell division 
C.W. G reider & E.H. B lackburn identify te lom erase activity in the ciliate protozoa, 
Tetrahymena.
H. Cook at the MRC in Edinburgh showed te lom ere shortening in som atic tissues relative 
to germ line cells
Greider & B lackburn dem onstrated a m echanism  of DNA replication-te lom ere extension by 
reverse transcription
G.B Morin identified human te lom erase activ ity in HeLa cell lines
N. Hastie et al. At the MRC in Edinburgh show telom ere reduction in human colorectal
cancer
C.B. Harley, A.B. Futcher and C.W. Greider, propose te lom erase necessary for
im m orta lisation
Geron Corporation form ed
Kim et al. Publish the TRAP assay for the detection of te lom erase activity 
Telom erase RNA gene, h TERC, c loned by Feng et al. (Science, 277: 1236)
First dem onstration that inhibition of te lom erase can kill a cancer cell (Science, 277: 1236) 
Telom erase knockout m ouse (Cell, 91: 25)
Telom erase protein com ponent gene cloned (Science, 277: 955, Cell 90: 785)
Keith et al. at the CRC Dept of Medical O ncology, G lasgow, identify am plification of the 
te lom erase RNA gene in human cancers (Oncogene, 14: 1013)
Extension of pro liferative life span of norm al cells by forced expression of telom erase 
(Science 279: 349)
Keith et al. at the CRC Dept of Medical O ncology, G lasgow, identify the prom oter 
sequences for the te lom erase RNA gene (Oncogene, 16: 1345)
Identification of prom oter sequences for the te lom erase protein com ponent gene 
Most recent exam ples of inhib ition of te lom erase leading to cell death (Nature M edicine 
5:1164)
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Figure 1.2 Model for telomerase addition of repeats at chromosome ends
The two components of human telomerase hTERC and hTERT are indicated. The 
putative template domain of the RNA component of human telomerase is shown aligned 
against an arbitrary 3' end of a human telomere. This primer template configuration allows 
extension of the telomere in the first round of elongation until the extended product 
reaches the 5' end of template domain. Translocation then moves the extended DNA 
back one repeat relative to the template domain, positioning it for another round of 
elongation in which a full repeat (ggttag) is added to the 3' end of the chromosome 
(adapted from Greider & Blackburn 1985). DNA replication doesn’t reach the end of the 
chromosome on one of the strands of DNA when a human cell divides, One strand is left 
with a gap at its end. That end gets shorter after each division until the cell can on longer 
divide. Adding the enzyme telomerase lengthens the strand opposite the gap. Another 
enzyme then fills in the gap, keeping the strand at youthful length and allowing the cell to 
keep dividing.
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---------------------------  GGGTTAG 3'" 0H
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(after removal of 
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RNA component of telomerase hydrogen bonds 
with terminal deoxynucleotides of DNA
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dNTPs
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telomerase adds deoxynucleotides, using 3’ end of DNA 
as primer and RNA component of telomerase as template
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Figure 1. 2
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The proliferative capacity of normal cells is thought to be controlled by an endogenous 
generation clock (Ouellette &Smith, 1999; Allshire et al., 1988; Allsopp et al., 1995; 
Greider, 1990; Harley et al., 1990; Hastie et al., 1990; DeLange et al., 1990). The 
shortening of telomeres appears to be the cellular clock that determines the number of 
cell divisions, and this in turn, appears to control the ageing of the cells. Extension of 
replicative lifespan and perhaps immortalization of human cells will have many important 
applications for the treatment of age-related diseases. Significantly, the expression of 
telomerase in normal mortal cells extends their life-span without transforming them into 
malignant cancer cells, demonstrating that telomerase makes tumour cells immortal, but 
that other genetic alterations are responsible for the malignant characteristics of cancer 
cells. These results suggest that telomerase is both an important target for cancer and for 
the treatment of age-related disease.
1.3 Telomerase
Telomerase is a ribonucleoprotein complex that contains several protein subunits, as well 
as an RNA component (Figure 1.3). The RNA component (hTERC, in human) contains a 
domain that is complementary to one hexameric unit of the DNA telomeric repeat 
sequence, TTAGGG. The protein moiety contains the recently cloned catalytic subunit 
(hTERT, in human) that is homologous to reverse transcriptase. Thus, this enzyme 
complex comprises both template and polymerase activity. Telomerase binds to the 3’ 
ends of DNA strands and extends them by copying its own RNA template in multiples of 
the hexamer repeat sequence and thus stabilising telomeres (Greider & Blackburn, 1985; 
Blackburn, 1992), telomerase enzyme function results from a collaboration of both protein 
and RNA functional groups contributed by TERT and TERC (Blackburn, 2000).
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Figure 1.3 A speculative model of human telomerase com plexes
A speculative model of human 
telomerase ribonucleoprotein complex 
is shown. The p127 catalytic subunit 
(human telomerase reverse 
transcriptase, hTERT) is drawn 
overlaying the RNA-binding subunit, the 
telomerase associated protein (TP1, or 
TEP1, shown in green), and the 
substrate DNA-binding subunit, p95, 
with its anchor site. Also shown are the 
small p43 subunit, which has no known 
function to date, and the telomere 
repeat-binding factors 1 and 2 (TRF1 
and TRF2), which are involved in 
regulating telomerase activity.
Tankyrase, a poly adenosine 
diphosphate ribose polymerase,
(PARP), adds poly (ADP) ribosyl 
complexes to TRF1, which can then 
dissociate from the telomere. The 
human counterparts of the ciliate p95 and p43 subunits have yet to be cloned. The 
catalytic subunit is shown in the process of copying the RNA template (yellow) using its 
reverse transcriptase function (from McKenzie et al., 1999).
1.3.1 Telomerase RNA com ponent (TERC)
The telomerase RNA component, TERC, was first identified in Tetrahymena (Greider & 
Blackburn, 1987) and subsequently cloned from a number of other organisms. The full- 
length RNA can serve as template for target-primed reverse transcription. Because of this 
specialisation, the recent studies in the T. thermophila telomerase suggested that 
telomerase RNA gene must have a minimum of three functional motifs: (1), the template, 
(2), the TERT binding site, and (3), additional sequences required to form a catalytically 
competent polymerase active site.
P127
TP1
p43
s  RNA 
template
p95
New
teiomere
repeatTR FI Anchor
siteTRF2
Poly(ADP-ribose)
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The template region itself is an unlikely candidate for a high-affinity protein binding site 
because it is accessible to chemical modification in the ribonucleoprotein (RNP) (Zaug & 
Cech, 1995) and can be altered without preventing RNP assembly in vitro and in vivo 
(Collins et al., 1999). Expressing mutant telomerase RNA genes in vivo have suggested 
that non-template regions of telomerase RNA are important for telomerase activity. Thus, 
the RNA sequences required for activity independent of templating and TERT binding 
could serve a variety of roles, including involvement in substrate binding, active site 
conformation, or catalysis (Licht & Colline, 1999).
1.3.1.1 h TERC transcribed region
Telomerase RNAs have been identified from 24 ciliate species (148 to 209 nucleotides 
[nt] in length), two yeasts (-1,300 nt), and 35 vertebrate species [382 to 559 nt including 
mouse (397 nt), bovine (-443 nt), and human (451 nt)] (Singer and Gottschling, 1994 ; 
Blasco et al., 1995 ; Feng et al., 1995 ; McEachern and Blackburn, 1995 ; Tsao et al., 
1998 ; Chen et al., 2000; Collins, 1999). The human telomerase RNA gene, hTERC, has 
been well studied by several groups from different angles. The 5' and 3' boundaries of the 
transcribed region of hTERC have been determined using in vitro assembly systems 
derived from rabbit reticulocyte lysates and human cell extracts (Tesmer et al., 1999). The 
region spanning nucleotides +33 to +325 of hTERC is the minimal sequence required to 
produce levels of telomerase activity that are comparable with that made with full-length 
hTERC (Figure 1.4). In addition, two regions of hTERC (nucleotides +33 to +147 and 
+164 to +325) have been shown to be unable to produce telomerase activity when 
combined separately with hTERT but can function together to assemble active 
telomerase (Tesmer et al., 1999). Sequences upstream of the template of hTERC are not 
essential for producing active telomerase in vitro, although they do contribute to the 
overall level of activity. Consistently, Autexier et al. (1996) have shown that the residues 
1-44, 5' to the template region (residues 46-56) are not essential for telomerase activity. 
However, removal of the first 43 nt of hTERC, but not the first 32 nt, reduces the level of 
active telomerase, suggesting that nt +33 to +43 may aid in assembly or in catalysis,
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perhaps by anchoring the template region of hTERC on hTERT and facilitating 
translocation during processive elongation. The significance of sequence in this region of 
UTERC is unknown. Telomerase activity was abolished when the template region of 
hTERC (nt +46 to +56) was deleted. All together, the hTERC functional region for 
reconstitution of active telomerase can be defined as +44 to +325 nt (Figure 1.4) with a 
requirement for a functional template region (Tesmer et al., 1999).
Telomerase RNA templates from several organisms have been mutated and studied, 
including those from Tetrahymena. thermophila (Autexier and Greider, 1994; Gilley et al., 
1995; Gilley and Blackburn, 1996), Kluyveromyces lactis (McEachern and Blackburn, 
1995), human (Marusic et al., 1997; Tesmer et al., 1999) and Saccharomyces cerevisiae 
(Prescott and Blackburn, 1997). Biochemical studies of such mutated telomerase 
(assembled in vivo and extracted from cells) have shown that base changes in the 
template RNA are usually copied into DNA products. Template mutations can also cause 
specific changes in enzymatic properties in vitro. Expression of mutant hTERC in 
immortal human cells resulted in the appearance of mutant telomerase activity and in the 
synthesis of mutant telomeres. These results suggest that the presence of mutant 
telomerase, even if coexpressed with the wild-type enzyme, can be deleterious to cells, 
possibly as a result of the impaired function of hybrid telomeres (Marusaic et al., 1997).
1.3.1.2 Conserved structure
These TERC RNAs vary remarkably in their size and sequence, with comparison of 
sequences from vertebrate, yeast, and ciliates revealing no obvious similarity among 
these three distantly related groups. However, a conserved secondary structure has been 
established using phylogenetic comparative analysis (Figure 1.5) (Romero and Blackburn, 
1991 ; ten Dam et al., 1991 ; Lingner et al., 1994 ; McCormick-Graham and Romero, 
1995 ).
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The human telomerase RNA gene, hTERC, transcribed region
Region 1
^  00 ^  U) CD
+ + + + +
kasataaaa'
Region 2
S Telomerase+ Position Actjvjty
1-451
33-451
44-451
58-451
44-325
| telomerase RNA transcript region j....... ■ mutation region
template region transcriptional start site
*  minimal contiguous sequence required for activity nts from +44 to + 325 bp
Figure 1.4 Schematic model for the hTERC transcribed region
The 451 nucleotides (nt) hTERC sequence is represented schematically with respect to 
the template region (nt +46 to +56). Truncations are denoted by the transcribed 
nucleotides within h TERC. The sizes of the transcribed RNAs are also indicated. The two 
fragments of h TERC (nt +33 to +147 and +164 to +325) that cannot produce telomerase 
activity when combined separately with hTERT but can function together to assemble 
active telomerase are indicated as Region 1 and Region 2. Relative activity was 
determined by defining the level of activity with full-length h TERC  as 100% (++++). 
(Adapted from Tesmer et al., 1999 and Autexier et al., 1996)
Figure 1.5 Consensus structure of 
ciliate and vertebrate telomerase 
RNA
The outline of the minimum- 
consensus structures of ciliate and 
vertebrate telomerase RNAs are 
shown. Template regions are 
indicated with red filled boxes. 
Vertebrate-specific structural
elements are shaded. The diagram 
on the left illustrates a possible 
evolutionary course from the 
ancestral telomerase RNA to ciliate 
and vertebrate RNAs (Adapted from 
Chen et al., 2000).
Ancestor
Pseudoknot
Helix lllb Helix I I -
 mi iiiiiiiim ii
Pseudoknot Domain
CR7 Domain
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A study of 35 TERC genes has proposed a secondary structure model for vertebrate 
telomerase RNA based on phylogenetic comparative analysis (Chen et al., 2000). The 
most remarkable feature of this structure is the evolutionary conservation of four 
structural domains: the pseudoknot domain, the CR4-CR5 domain, the Box H/ACA 
domain and the CR7 domain (Figure 1.5). Each conserved structural domain in the 
consensus structure might play a distinctive role in either the function, stability, 
processing, or localisation of telomerase RNA. These regions are also good candidates 
as binding sites for TERT or other telomerase accessory proteins. This proposed 
structure of vertebrate telomerase RNA displays striking similarities in overall architecture 
to the structure of ciliate RNAs (Chen et al., 2000). Experiments with hTERC have also 
shown that the pseudoknot structure is required for human telomerase function in vivo. A 
mutant human telomerase RNA with a 17-base insertion at position 176, which changes 
the natural structure, failed to reconstitute telomerase activity (Feng et al., 1995 ; Autexier 
et al., 1996 ; Weinrich et al., 1997). Secondary structure predictions reveal a putative 
double-stranded element adjacent to the template of telomerase RNA in several other 
species, including S. cerevisiae and human (Tzfati et al., 2000). A study of yeast TERC 
has demonstrated that the phylogenetically conserved, long-range base-pairing 
interaction adjacent to the template specifies one boundary of the telomerase template, 
thus determining the end of the telomeric repeat synthesised. Thus, it would appear that 
the RNA structure, rather than its sequence, specifies the template boundary, and entire 
structure is important for active telomerase function (Tzfati et al., 2000).
1.3.1.3 Transcription o f TERC
The 5' ends of the human and mouse telomerase RNA transcripts were previously
mapped by both RNase-protection and primer-extension analyses (Hinkley et al., 1998).
The 5' end of human RNA is 45 nt upstream of the template sequence, the mouse 5' end
is only 2 nt upstream from the template sequence. Biochemical evidence suggests that
both the human and mouse telomerase RNA genes are transcribed by RNA polymerase II
(Feng et al., 1995; Zhao et al., 1998; Hinkley et al., 1998; Chen et al., 2000). The
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upstream region of each vertebrate telomerase RNA gene contains sequence elements 
typical of RNA polymerase II promoter (Chen et al., 2000).
A comparison of the proximal pomoter regions of several ciliate telomerase RNA genes 
detected two highly conserved sequence elements, a proximal sequence element (PSE) 
at -55, and an A/T-rich element at -25 position, which constitute the promoter of the T. 
Thermophila TER1 gene. The metazoan U6 small nuclear RNA which is transcribed by 
RNA polymerase III appears to have a similar promoter architecture to the ciliate 
telomerase RNA gene suggesting that ciliate telomerase RNA gene are likely to regulated 
by RNA polymerase III (Hargrove et al., 1999). In contrast to the ciliate TER1 and 
vertebrate snRNA gene promoters, the 5' regions of the human and mouse telomerase 
RNA genes lack a PSE. The putative difference in transcription may reflect an increased 
complexity of regulation of telomerase in vertebrate species compared to that in the 
ciliates, however, the transcriptional regulatory mechanisms of the telomerase gene are 
not well defined to the date.
1.3.2 Telomerase Reverse Transcriptase (TERT)
1.3.2.1 hTERT protein
The human telomerase reverse transcriptase (hTERT) previously referred to as hTRT 
(Nakamura et al., 1997), hEST2 (Meyerson et al., 1997), and hTCS1 (Kilian et al., 1997), 
is the catalytic protein subunit that is responsible for the enzymatic activity of telomerase 
(Harrington et al., 1997b; Feng et al., 1995; Nakamura et al., 1997; Nakayama et al., 
1997; Meyerson et al., 1997). The hTERT gene encompasses more than 37 kb and is 
subdivided into 16 exons and 15 introns varying fundamentally in size. The hTERT gene 
encodes a 1,132-amino acid polypeptide with a molecular weight 127 kD (Meyerson et al., 
1997; GenBank AF015950). Like other reverse transcriptase family members, hTERT 
contains seven highly conserved reverse transcriptase (RT) motifs (Wick et al., 1999; 
Lingner et al. 1997). These RT motifs, as well as the telomerase-specific T motifs, are 
encoded either alone or in pairs on distinct exons. In contrast, the less conserved N-
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terminal and C-terminal regions of hTERT are encoded by two exons or one large exon, 
respectively. However, the specific exon-RT motif-assignment differs fundamentally 
between the human and yeast S. pombe TERT genes (Nakamura et al., 1997), 
suggesting that TERT genes of evolutionary distant organisms have a highly conserved 
function but show a phylogenetic diversity in their genomic structure (Wick et al., 1999). 
Recent analysis of all of the cloned TERTs revealed several salient features of their 
structural organisation: (i) all of the RT motifs are located in the C-terminal half of the 
protein; (ii) a telomerase-specific motif (T motif), located just N terminal to the RT motifs, 
can be discerned in all TERTs; and (iii) a motif positioned further toward the N terminus 
appears to be much more highly conserved among all the ciliate telomerases and may 
perform a function specific to ciliate telomere formation (Bryan et al., 1998a; Xia et al., 
2000). hTERT has been demonstrated to be an important factor for telomerase activity 
both biologically and enzymatically (Hahn et al., 1999; Nakayama et a!., 1998; Counter et 
al., 1998a, b). This issue will be discussed further in section 1.5.2.
1.3.2.2 hTERT promoter
Genomic sequences that encompassed the complete hTERT transcription unit have been 
cloned by different groups to investigate the regulation mechanisms of hTERT gene 
expression. The essential promoter region controlling hTERT expression has been 
identified (Kyo et al., 2000; Takakura et al., 1999; Cong et al., 1999; Horikawa et al., 
1999; Oh et al., 1999; Wick et al., 1999; Devereux et al., 1999; Fujimoto et al., 2000). 
Transient transfections of immortal human cells with potential regulatory 5’-sequences 
linked to a reporter, combined with deletion analysis of these sequences, indicated that 
elements responsible for promoter activity are contained within a region extending from 
330 bp upstream of the ATG. Assays in different cell types showed that the hTERT 
promoter is inactive in normal and in transformed pre-immortal cells, but, like telomerase, 
it is activated with cell immortalization.
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The hTERT promoter is GC-rich, lacks TATA and CCAAT boxes, and contains at least 
five Sp1-consensus sites and two c-Myc consensus binding sites in the core promoter 
region (Figure 1.6) (Kyo et, 2000; W ick et al., 1999; Cong et al; 1999). Additional 
luciferase assays using a series of constructs containing unidirectionally deleted 
fragments revealed that a 59-bp region (-208 to -150) is required for the maximal promoter 
activity (Horikawa et al., 1999). Multiple binding motifs for myeloid-specific zinc finger 
protein 2 (MZF-2) are present within a 400 bp region of the hTERT promoter between - 
776 and -378 bp upstream of the proximal core promoter (Fujimoto et al., 2000). The 
Wilms' Tumour 1 (WT1) regulatory sequence, GCGCGGGCG, is located between -307 
and -423 bp (Oh et al., 1999). A palindromic estrogen receptor element (ERE) and an 
Sp1/ER element, targeted by estrogen, are present at -2677 and -873 bp respectively 
(Kyo et al., 1999). All these elements, and possibly others, combine to regulate hTERT 
gene expression. A large CpG island with a GC content 70% was identified in the 5'- 
flanking hTERT gene sequence spanning from -900 bp into exon 2. One additional 
smaller CpG island with a GC content >60% is located further upstream at position -4300 
to -4600 bp (Wick et al, 1999). Because of this, methylation status of the hTERT promoter 
has been investigated to determine if this plays a part in gene regulation, however no 
correlation with expression levels was found (Devereux et al., 1999; Dessain et al., 2000). 
It would therefore appear that hTERT expression may be subject to multiple levels of 
control and may be regulated by different factors in different cellular contexts. Specific 
transcription factors involved in the regulation of hTERT promoter will be further 
discussed in section 1.5.2.
h- t O) co ^
Core promoter region
r *  Transcriptional start site f  Sp1 site [] MZF-2 site
0 |  E-box |  ERE site Q W T 1  site
Figure 1.6 Schematic diagram of hTERT promoter region
The identified transcriptional elements between -3.3 kb and +1 bp in the hTERT promoter 
region are shown. Binding sites for c-Myc and Sp 1 in the core promoter of hTERT (-181 
bp; yellow box) are shown. The transcriptional start site (TSS) upstream of the ATG 
initiation codon is marked as “+1”. The numbers indicate the position of DNA-binding sites 
relative to the TSS.
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Figure 1.7 Telomerase-Telomeric 
complexes
Schematic representations of the
composition of telomeric complexes of (a) 
the yeast S. cerevisiae  telomere and (b) 
the human telomere (from O ’Reilly et al.,
1999). Telomeric and nontelomeric DNA 
are represented as red and grey tubes, 
respectively. Histone octamers are
depicted as orange cylinders. Other 
components of the telomere complex are 
labelled.
Table 1. 2 Proteins in the telomeric complexes
Genes Mammalian Function Effect telomere
Homologue length
Est2 T E R T Telom erase enzym e component +
TLC1 TER C Telom erase enzym e component +
Cdc13p Recruitment of telom erase to the +
E stlp chromosome end +
Cdc13p TRF2? Protect telomere ends from +
S tn lp degradation +
H d flp +
Hdf2p +
Rad50p Rad51 Telom erase independent +
Rag51p mechanisms of telomere +
Rad52 m aintenance +
M re 1 1P Mre11p +
Xrs2p ALT in mammals? +
R a p lp TRF1 Inhibit telom erase access to the -
Rif 1 TIN2? chromosome end -
Rif2p -
TeMp ATM Positively regulate telom erase +
Tel2p +
Pif 1 p DNA polymerase Affect telom erase indirectly -
Cdc17p G 4-D N A -dependent +
K em lp nuclease +
Cdc44p DNA replication -
Dna2p factor C +
Rad27p +
(EST4)
i g I - 3
repeats
E s tlp
TER (TLC1)
C dc13p
TERT 
(EST2)
TTAGGG
repeats
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1.3.3 Proteins in the Telomeric Complexes
During the past few years, much of the emphasis in the study of telomeres has been on 
telomeric DNA, but it is becoming clear that proteins are major players and will be a key 
to understanding what actually goes on at the chromosome end. Human/vertebrate 
telomeres consist of many kilobases of (TTAGGG)n together with various associated 
proteins (Kipling, 1995). Studies of telomerase-positive immortalised cells (Bryan et al., 
1998b; Jones et al., 1998) and of telomerase-negative normal cells (Martens et al., 1998) 
reveal evidence for the existence of factors other than telomerase that regulate telomere 
length.
The list of known proteins with effects on the structure and function of telomeres 
continues to grow (Figure 1.7, Table 1.2). In conjunction with the RNA template these 
proteins act as a committee to maintain the telomere. One group includes protein 
components of telomerase (TERT/Est2), proteins essential for the in vivo activity of 
telomerase, and proteins isolated by virture of physical association with the enzyme. The 
other group includes proteins that constitute the telomeric complex (e.g., Rap1, TP1, 
TRF1 and TRF2, some of which will be discussed below). This group contains proteins 
that affect the sizes of the telomere but do not necessarily appear to be essential for 
telomerase activity (this group may include the proteins preventing chromosome end-to- 
end-fusion, for which the DNA repeats may act primarily as anchor points). These two 
groups may overlap since several of the telomeric proteins are thought to affect the 
activity of telomerase.
To the date, over 25 genes affect telomere length in addition to Est2(TERT) and TLC1
(telomerase RNA component in yeast, Figure 1.7a). Some of these gene products may
help recruit telomerase to the end of the chromosome (e.g., Cdc13p and Estlp) (Nugent
et al., 1996; Virta-Pearlman et al., 1996) or protect the ends from degradation (e.g.,
Cdc13p, Stnlp, Hdflp, and Hdf2p) (Garvik et al., 1995; Boulton & Jackson, 1996; Porter
et al., 1996; Grandin et al., 1997; Gravel et al., 1998; Laroche et al., 1998; Nugent et al.,
1998; Polotnianka et al., 1998). Some may be important in alternative pathways of
telomere length maintenance that use DNA recombination (Rad52p, Rad50p, Rad51p,
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Mre11p, and Xrs2p) (Lundblad & Blackburn, 1993; Lendvay et al., 1996; Le et al., 1999), 
some have been suggested to negatively (e.g., Raplp, Rif2p, and Riflp) (Hardy et al., 
1992; Kyrion et al., 1992; Marcand et al., 1997b; Wotton and Shore, 1997) or positively 
regulate telomerase activity (e.g., TeMp and Tel2p) (Lustig & Petes, 1986; Greenwell et 
al., 1995; Morrow et al., 1995; Runge & Zakian, 1996), while others may affect 
telomerase activity indirectly (Cdc17p, Piflp, Kemlp, Cdc44p, Dna2p, and Rad27p) 
(Carson & Hartwell, 1985; Schulz & Zakian, 1994; Liu et al., 1995; Adams & Holm, 1996; 
Formosa & Nittis, 1999; Parenteau & Wellinger, 1999). The mechanisms by which most of 
these gene products actually regulate telomere length are unclear. There is a rapidly 
increasing list of proteins reported to bind to the telomere and/or affect telomere length 
(Table 1.2), a few of which are discussed here, hTERT having been discussed previously 
(section 1.3.2.1).
1.3.3.1 Telomerase-associated proteins
In T. Thermophila two proteins, p80 and p95 have been identified which interact with 
telomerase RNA and TERT, and p95 has also been shown to bind single-stranded 
substrate DNAs (Collins et al., 1995; Collins & Gandhi, 1998; Gandhi & Collins, 1998). 
The mammalian TP1 protein has sequence homology to p80 and also interacts with 
telomerase RNA and TERT (Licht & Colline, 1999; Harrington et al., 1997a, b; Nakayama 
et al., 1997). The mouse/rat TP1 (2629 aa) and human TP1 (2627 aa) proteins (-230-240 
kDa) lack any RNA-dependent DNA polymerase domain indicating that TP1 is not the 
catalytic subunit of telomerase but it may be associated with a catalytic subunit in a 
multiple component telomerase complex.
1.3.3.2 Telomere repeat-binding proteins
TRF1 was the first mammalian telomere binding protein to be identified (Zhong et al., 
1992). Homodimers of TRF1 bind double-stranded telomeric repeats but not single-
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stranded DNA, through a Myb-type DNA-binding domain (reviewed in Griffith & de Lange, 
1998; Smith & de Lange, 1997). TRF1 belongs to a large family of proteins conserved 
during evolution which contain one or two related myb repeats, such as for example the 
Raplp yeast protein (Brun et al., 1997). Raplp controls telomere length, telomeric 
silencing and telomere stability in yeast. Recent studies have demonstrated that Raplp, 
in concert with Rifs (Rap1 interacting factors), serves as a sensor of the telomere length, 
leading either to onset or to repression of the telomerase activity.
TRF1 is located at the telomeric end (Hanish et al., 1994) and is involved in the regulation 
of telomere length. It behaves as a negative regulator of telomere maintenance since 
TRF1 deletion results in a faster telomere elongation (van Steense & de Lange, 1997). 
Over-expression of TRF1 in the tetracycline-responsive human fibrosarcoma cell line 
HTC75 results in a gradual decline in telomere length at a rate of -10 bp/population 
double level (PDL). Conversely, the expression of a dominant negative allele of TRF1, 
which removes endogenous TRF1 from telomere, leads to telomere elongation. In this 
system, TRF1 did not affect the activity of telomerase detectable in cell extracts, 
suggesting that TRF1 does not affect telomerase activity globally in the cell. Instead, 
TRF1 acts in c/'s as a negative length regulator at each individual telomere (Hanish et al., 
1994; van Steense & de Lange, 1997).
During the search for proteins interacting with TRF1, tankyrase that is a new protein 
localised to telomere, has been identified (Smith et al., 1998). Tankyrase presents ankyrin 
repeats (involved in the interaction with TRF1) and a catalytically active region 
homologous to poly(ADP)-ribose polymerase (PARP). Tankyrase is catalytically active 
towards itself and TRF1 and modifies TRF1 such that it is unable to bind DNA. This 
suggests that negative regulation of telomerase by TRF1 might occur through a 
poly(ADP)-ribosylation reaction, performed by this telomere-specialised enzyme.
A second telomere binding protein, TRF2, is a distantly related homologue of TRF1 which 
also binds to double-stranded telomere repeats and is ubiquitously expressed (Broccoli et 
al., 1997a, b). TRF2 has the same general protein architecture as TRF1 except that its
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amino terminus carries mostly basic residues instead of the acidic residues seen in TRF1. 
Overexpression of dominant negative alleles of TRF2 in human cells caused loss of the 
terminal single-stranded 3’ overhang, an increase in chromosome end-to-end fusion, and 
irreversible growth arrest in a senescence-like state (van Steesel et al., 1998). It was also 
reported that cells forced to express a dominant negative allele of TRF2 rapidly initiate an 
apoptotic pathway (Karlseder et al., 1999). It is not known whether TRF2 serves to protect 
the G-rich overhang directly (which would seem unlikely, as TRF2 cannot bind single­
stranded DNA in vitro) whether it stimulates the formation of G tails by recruiting an 
exonuclease or other factor, or whether TRF2 recruits other telomere binding proteins that 
protect G tails.
In human cells, both TRF1 and TRF2 are predominantly located at chromosome ends 
where they contribute to the protection and maintenance of telomeric DNA. Based on 
biochemical studies, the formation of t-loops, which engage the 3' single-stranded DNA 
overhang in an interaction with double-stranded telomeric repeats, was proposed to 
involve both TRF1 and TRF2. TRF1 has the ability to induce bending, looping, and pairing 
of duplex telomeric DNA (Bianchi et al., 1997, 1999; Griffith et al., 1998, 1999), activities 
that could facilitate the folding back of the telomere. TRF2 was found to induce the 
invasion of the 3' single-stranded TTAGGG repeat tail into duplex telomeric DNA, forming 
t-loops in vitro (Griffith et al., 1999; Smogorzewska et al., 2000). Thus, a t-loop-based 
mechanism for telomere length regulation would predict that both TRF1 and TRF2 are 
required for the length homeostasis of human telomeres (Smogorzewska et al., 2000). 
The complete functions of TRF1 and TRF2 proteins in regulating telomerase and 
telomeres require further studies.
1.3.3.3 Mapping hTERC and hTERT genes
Both hTERC and hTERT are required for telomerase activity and expression of both is 
upregulated in cancer cells (Meyerson et al., 1997; Yi et al., 1999; Soder et al., 1998). 
hTERC and hTERT genes have been mapped in our own and other Labs to 3q26 and
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5p15 respectively (Bryce et al., 2000; Soder et al., 1997a; Heselmeyer et al., 1997; 
Bjorkqvist et al., 1998). Interestingly, some tumour types show increases in copy number 
of hTERC and hTERT. 5p15, and more specifically 5p15.3, has been found at increased 
numbers in such tumours as uterine cervix cancer (Heselmeyer et al., 1997), non-small 
cell lung carcinoma (Bjorkqvist et al., 1998), squamous cell carcinoma of the head and 
neck (Bockmuhl et al., 1996; Liehr et al., 1998; Wolff et al., 1998; Pack et al., 1999). It 
seems increasing the copy number of hTERT was common, with 5p isochromosoimes 
seen in 2 cell lines (HeLa and SiHa). No Copy number alterations were observed in the 
WI38 normal mortal cell line or in normal lymphocytes. Increasing the copy number of 
hTERT in cancer cells may titrate out repressors, or compensate for low levels of 
transcriptional activators, thus allowing a tumour to increase the levels of the catalytic 
subunit of telomerase (Bryce et al., 2000). Over-representation of 3q26 has been 
demonstrated for uterine cervix cancer, squamous cell carcinoma of the head and neck, 
small cell and non-small cell lung carcinoma (Heselmeyer et al., 1997; Bjorkqvist et al., 
1998; Wolff et al., 1998; Pack et al., 1999; Ried et al., 1994). It has been demonstrated 
that hTERC was involved in this region of amplification (Soder et al., 1997a), and recent 
study has narrowed down the region of lung and cervix tumours to 1 to 2Mb centred 
around hTERC, further supporting it as a potential target (Sugita et al., 2000). These 
gains in both 3q26 and 5p15 are potentially interesting given the presence of the hTERC 
and hTERT genes.
1.4 Patterns of Telomerase Expression
In recent years, telomerase has attracted much attention because of its potential utility as 
both a diagnostic marker and a therapeutic target in cancer. This enzyme is present in 
almost all cancer, but not in normal somatic cells. Understanding telomerase structure, 
expression, and activity regulation is pivotal for the prospects of using it as a target in 
cancer therapy, with respect to both therapeutic and undesirable side effects.
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1.4.1 Telomerase in somatic cells and germline cells
All normal human somatic tissues and cells show progressive telomere shortening. In 
contrast, germline and certain stem cell populations must have a mechanism to 
compensate for the continuous telomere erosion as they manage to divide indefinitely 
without telomere shortening. This difference has been shown to be due to the absence or 
presence of telomerase.
During normal embryogenesis, the germline (Wright et al., 1996a; Mantell & Greider, 
1994) and somatic cells express telomerase activity (Wright et al., 1996b), which persists 
in the male germline, fully maintaining telomere length. However, repression of 
telomerase occurs in most somatic tissues during development, with the exception of a 
small number of cells in renewal tissues (Hiyama et al., 1996; Taylor et al., 1996; Harle- 
Bachor et al., 1996; Ramirez et al., 1997; Hiyama et al., 1995; Iwama et al., 1998; Kyo et 
al., 1997; Saito et al., 1997; Brien et al., 1997). Thus, low levels of telomerase are 
detected in activated lymphocytes (Counter et al., 1995; Hiyama et al., 1995; Iwama et 
al., 1998), intestinal crypt cells (Hiyama et al., 1996), premenopausal endometrium (but 
only in the proliferative phase) (Kyo et al., 1997; Saito et al., 1997; Brien et al., 1997), and 
the basal layer of the skin (Taylor et al., 1996; Harle-Bachor et al., 1996; Ramirez et al.,
1997). Although telomerase is "on" in the proliferating cells of these renewal tissues, its 
level is insufficient to fully maintain telomere length and the telomeres of these tissues 
progressively shorten (Hastie et et, 1990; Lindsey et al., 1991; Hiyama et al., 1995; 
Iwama et al., 1998). Proliferating normal cells without detectable telomerase have the 
greatest rate of telomere attrition and eventually undergo senescence or proliferative 
growth arrest. The stem cells of renewal tissues maintain a low or intermittent level of 
telomerase that may provide the increased proliferative capacity required for these 
tissues, which have a high rate of turnover.
Telomerase RNA and hTERT are necessary and sufficient for the production of human
telomerase, as demonstrated by the recent in vitro reconstitution of telomerase using only
these two components (Weinrich et al., 1997). Transient telomerase expression is
sufficient to elongate critically short telomeres, resulting in an increase of the life span of
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normal human fibroblasts (Steinert et al., 2000). Transfection of only the hTERT into 
normal human cells without detectable telomerase results in restoration of telomerase 
activity. Normal human cells with stable expression of introduced telomerase demonstrate 
extension of life span, providing direct evidence that telomere shortening controls cellular 
aging (Bodnar et al., 1998; Vaziri et al., 1998). In the presence of limited expression of 
hTERT, long telomeres shorten while short telomeres are maintained by the expression of 
telomerase, suggesting that cellular factors preferentially recruit hTERT to critically short 
telomeres (Ouellette et al., 2000).
Table 1. 3 Telomerase activity detection in human tissue
Pathology No. Positive/no. tested Telomerase positive(%)
Normal* 1/196 0.5
Preinvasive(benign) 125/410 30
Malignant 1734/2031 85
Adjacent to malignant 77/660 11
*Cells from renewal tissues (intestinal crypts, basal layer of skin) as well a
inflammatory cells have low but detectable telomerase activity (review see Holt & 
Shay, 1999a).
Table 1. 4 Telomerase activity detection in human cancer
Cancer Type Positi ve/T ested (%) Cancer Type Positive/Tested (%)
Lung 113/140 (81%) Stomach 72 / 85 (85%)
Colon 123/ 138 (89%) Liver 149/ 173 (86%)
Breast 300 / 339 (88%) Leukemias 142/194 (73%)
Prostate 52 / 58 (90%) Brain 90/ 131 (69%)
Pancreatic 41 / 43 (95%) Kidney 95/ 115 (83%)
Ovarian 21 / 23 (91%) Skin 94/102 (92%)
Cervical 16/16 (100%) Head/Neck 112/ 130 (86%)
(for review see Shay & Wright, 1996)
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1.4.2 Telomerase in tumour development
The advent of a highly sensitive telomere repeat amplification protocol (heretofore 
referred to as the TRAP assay) allowed screening of a variety of human tumours, utilising 
less than 5 ug of protein for each sample (Kim et al., 1994; Wright et al., 1995b). A recent 
literature search indicated more than five hundred manuscripts published on telomerase 
since 1994, and most of them published in the past four years. Telomerase is specifically 
associated with all of the 20 broadly defined cancer types investigated, including lung, 
colorectal, breast, prostate, pancreatic, ovarian, cervical, stomach, liver, leukaemia, brain, 
kidney, skin, head/neck, and other cancers. Across all cancer types, telomerase is 
detectable in an average 85% of specimen samples (see Table 1.3 and 1.4). No other 
cancer marker offers this level of universality and specificity.
While some highly proliferative normal cells have detectable telomerase activity, most 
exhibit levels of activity significantly lower than those found in cells extracted from high- 
grade malignant tumours. The use of telomerase as a screen for the early detection of 
human cancer, prior to progression to high-grade malignant status is of potential interest. 
For instance, many precarcinoma lesions have detectable telomerase activity (on the 
order of 15%; Shay & Wright, 1996), yet are classified as premalignant by standard 
cytopathology and histopathology. Detection of telomerase activity in these samples may 
indicate that these seemingly benign lesions contain a small subset of malignant cells and 
may assist in patient risk stratification. The hope is that telomerase measurements may 
have a place in early cancer diagnostics and prognostics. However, additional studies on 
the level and distribution of telomerase activity in the early stages of cancer are needed to 
determine the utility of telomerase detection in early diagnosis, especially as it relates to 
clinical outcome. Several studies have proposed detection of telomerase activity as a 
predictor of poor clinical outcome (Hiyama et al., 1995a,b 1996). One example of this is 
the childhood cancer, neuroblastoma, where certain subclasses (stages III and IV) have 
high levels of detectable telomerase activity and poor prognosis (Hiyama et al., 1995a). 
Interestingly, one subclass (stages IV-S) has been shown to spontaneously regress and 
coincidentally is telomerase negative. Therefore, without telomerase, the tumour
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undergoes telomere shortening, the cells senesce, and the cancer is eventually cleared 
from the body. This study also demonstrates that while telomerase or another mechanism 
is likely required for the sustained growth of advanced tumours, it is not required for the 
initiation of cancer.
Another area of interest is monitoring patients for residual or recurrence of disease using 
telomerase as a marker. As can be seen in Table 1.3 and 1.4, telomerase activity is 
detected in adjacent, presumably cleared regions in more than 10% of tumour specimens 
obtained during biopsy. In these instances, occult micrometastases of the primary tumour 
can invade the surrounding normal tissue and small amounts of tumour may remain 
undetected by pathologists. Recurrence of cancer could be monitored by fine needle 
aspiration of cancer patient tissues to assess the regression of the tumour due to this 
micrometastatic event using telomerase detection.
1.5 Regulation of Telomerase
1.5.1 Regulation requires both hTERC and hTERT
Several telomerase-associated proteins have been identified in various organisms, 
however, h TERC and hTERT are both necessary and sufficient for telomerase activity in 
vitro (Weinrich et al., 1997; Beattie et al., 1998). Telomerase genes have been reported to 
have different expression profiles in normal somatic cells, and also two molecular 
mechanisms have been described that may contribute to the regulation of telomerase 
activity in human: transcriptional regulation of hTERC and hTERT and post-transcriptional 
alternative splicing of hTERT (Feng et al., 1995; Nakamura et al., 1997; Meyerson et al., 
1997; Harrington et al., 1997b; Kilian et al., 1997; Ulaner et al., 1998).
1.5.1.1 Reconstitution require both hTERC and hTERT
Recently, some groups reported in vitro reconstitution of telomerase and demonstrated
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the essential role of hTERT and hTERC (Beattie et al., 1998; Weinrich et al., 1997; Holt et 
al., 1999; Riou, 1998; Masutomi et al., 2000). Using the dominant-negative mutation of 
hTERT abrogated this in vitro reconstitution assays (Hahn et al., 1999) suggesting the 
hTERT and hTERC are the minimal essential components for telomerase activity 
(Masutomi et al., 2000). It has been reported that the production of active recombinant 
telomerase in Tetrahymena requires a factor in rabbit reticulocyte extract that promotes 
ribonucleoprotein assembly (Licht & Collins, 1999; Bachand & Autexier, 1999). Other 
factors such as Hsp90 and p23 may participate in reconstitution for telomerase activity 
with recombinant hTERT synthesised de novo in rabbit reticulocyte extract in vitro (Holt et 
al., 1999b).
1.5.1.2 Interaction between hTERC and hTERT
Normal human diploid cells contain the integral RNA component of telomerase (hTERC) 
but generally lack the mRNA for the catalytic subunit (hTERT) (Meyerson et al., 1997; 
Nakamura et al., 19997), although there are some cases in which alternative splicing 
forms of hTERT are present in telomerase-negative cells (Kilian et al., 1997; Ulaner et al., 
1998). The catalytic subunit is thought to be the only missing component necessary for at 
least a minimally functional enzyme. This is based on two lines of evidence: transfection 
of plasmids directing the expression of hTERT into telomerase-negative cell types results 
in the appearance of telomerase activity, and in vitro-transcribed hTERC mixed with in 
w'fro-translated hTERT in a rabbit reticulocyte lysate results in detectable telomerase (Yi 
et al., 1999; Beattie et al., 1998; Bodnar et al., 1998; Counter et al., 1998; Vaziri et al., 
1998; Weinrich et al., 1997). A 3- to 10-fold increase in steady-state levels of hTERC has 
been observed in a variety of immortal cells (Avilion et al., 1996), indicating that some 
regulation of hTERC is associated with the acquisition of telomerase activity. In situ 
hybridisation of human biopsy specimens indicates that the relative levels of hTERC in 
tumour cells are sufficiently different from those in adjacent tissues to be clinically useful 
in the diagnosis of cancer (Soder et al., 1997a; Morales et al., 1998a,b; Yashima et al., 
1997a,b).
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It is known that the hTERT binds the structure hTERC RNA and this complex interacts 
with the telomeres. A physical complex formation between hTERT protein and hTERC 
was detected by EMSA in vitro when equimolar amounts of two molecules were mixed, 
these complexes were specifically eliminated by excess amounts of nonlabeled hTERC 
(Masutomi et al., 2000). These studies provide direct evidence that hTERT as a RNA- 
binding protein interacts with RNA component of telomerase.
1.5.2 Transcriptional regulation of telomerase
Mvc Up to date, several gene products have been demonstrated directly or indirectly 
targeting the promoter to regulate hTERT transcription or telomerase activity (Figure 1.6 
and Table 1.5). Wang et al (1998) has firstly reported that Myc induces telomerase in both 
normal human mammary epithelial cells (HMECs) and normal human diploid fibroblasts. 
Myc increases expression of hEST2 (hTRT/TP2) and can extend the life span of HMECs. 
Furthermore, this activation has been proven in transcription level. Over-expression of c- 
Myc/Max resulted in a significant increase in transcriptional activity of the core promoter 
(Kyo et, 2000; Oh et al., 1999a; Horikawa et al., 1999; Takakura et al., 1999) and 
telomerase activity (Wu et al., 1999). Levels of activation depended upon the Myc/Max 
ratio used.
Mad1 Other studies by Gunes et al. (2000) showed that over-expression of Mad1 in 
transient transfection assays in U937 cells resulted in a consistent and significant 
decrease of hTERT promoter activity, and this repressive effect of Mad1 was dose 
dependent and required for an intact proximal E-box. Thus, c-Myc and Mad1 exert their 
transcriptional effects via the same site in the hTERT promoter. It was discussed that 
Mad1 repression of the hTERT promoter may involve an active repression mechanism 
rather than simple competition with c-Myc.
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Sp1 was shown to be a potent transactivator of hTERT, and Sp1 function was required 
for Myc-mediated activation of hTERT. Myc/Max and Mad/Max regulate hTERT 
transcription differently in a cell type-specific manner, and transactivation by Myc/Max is 
achieved with the cooperative action of Sp1 (Kyo et al., 2000). It was reported that levels 
of c-Myc and Sp1 expression were correlated with the transcriptional activity of hTERT in 
various cell types, and expression of c-Myc and Sp1 increased during malignant 
progression of fibroblast cells, in association with telomerase activity. Therefore, c-Myc 
and Sp1 cooperatively function to activate hTERT transcription and up-regulation of these 
expressions might be critical for telomerase activation during carcinogenesis (Kyo et al.,
2000).
Estrogen Telomerase activity in estrogen receptor (ER)-positive MCF-7 cells was up- 
regulated by the treatment with 17 beta-estradiol. This activation accompanied up- 
regulation of the telomerase catalytic subunit, hTERT mRNA. Gel shift assays revealed 
that the imperfect palindromic estrogen-responsive element in the hTERT promoter 
specifically binds to ER. Transient expression assays using luciferase reporter plasmids 
containing various fragments of hTERT promoter showed that this imperfect palindromic 
estrogen-responsive element is responsible for transcriptional activation by ligand- 
activated ER. Furthermore estrogen has been shown to activate c-Myc expression in 
MCF-7 cells, and E-boxes in the hTERT promoter that bind c-Myc/Max play additional 
roles in estrogen-induced transactivation of hTERT. Estrogen thus activates telomerase 
via direct effects on the hTERT promoter (Kyo et al., 1999).
WT1 and MZF-2 The Wilms' tumour 1 suppressor gene (WT1) has been shown to 
repress hTERT promoter activity in 293 kidney cells but not in HeLa cells which express 
no endogenous WT1. WT1 represses the endogenous hTERT promoter and telomerase 
enzyme activities suggesting that WT1 may be a transcriptional repressor of the hTERT 
gene, at least in some specific cells (Oh et al., 1999). In addition, Fujimoto et al (2000) 
have recently identified a 400 bp silencer of the hTERT promoter between -776 and -378 
upstream of the proximal core promoter. The myeloid-specific zinc finger protein 2 (MZF- 
2) has been demonstrated to recognise this region. Mutation introduced in these MZF-2
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sites resulted in significant activation of hTERT transcription. Over-expression of MZF-2 in 
cells led to down-regulation of hTERT transcription as well as telomerase activity. MZF-2 
may be an effector of negative regulation of hTERT (Fujimoto et al., 2000).
To the date, identified factors in regulating of hTERT promoter are listed in Table 1.5. 
Taken together, these studies demonstrate that expression of hTERT is regulated mainly 
at the transcriptional level and that the promoter of the hTERT gene is essential for 
transcriptional activation in cancer cells and immortalised cells. Up- or down-regulation of 
these factors during the course of carcinogenesis is therefore thought to be responsible of 
telomerase regulation.
Table 1. 5 Factors regulating the hTERT gene promoter
Proteins Binding
sites
EMSA Regulation 
of hTERT 
promoter
Regulation of
telomerase
activity
Telomerase activity in the cell 
lines
c-MYC E-box C+S activation activation IMR90, HMEC, C33A, SiHa
Sp1 Sp1 C+S activation
Estrogen ER, ERE C+S activation activation MCF-7
WT1 WT1 C repression repression 293, COS, BHK
Mad1 E-box S repression
MZF-2 MZF-2 C+S repression repression C33A, SiHa
C=competition; S= antibody supershift
1.5.3 Regulation of hTERT expression
High levels of expression of hTERT have been observed in telomerase-positive tumour 
tissues and immortal cell lines, but not in normal tissues and telomerase-negative cells 
(Nakamura et al., 1997; Meyerson et al., 1997). There is significant correlation between 
level of hTERT expression and telomerase activity in a variety of types of cancers (Ito et 
al., 1998; Kanaya et al., 1998; Kyo et al., 1999b; Takakura et al., 1998). Introduction of 
hTERT cDNA into telomerase-negative normal cells leads to activation of telomerase in 
these cells (Nakayama et al., 1998; Weinrich et al., 1997) and normal cell clones with 
high levels of hTERT expression attain immortal capacity (Bodnar et al., 1998; Hahn et 
al., 1999a). The ectopic expression of the hTERT in combination with two oncogenes (the
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simian virus 40 large-T oncoprotein and an oncogenic allele of H-ras) results in direct 
tumourigenic conversion of normal human epithelial and fibroblast cells (Hahn et al., 
1999a). Therefore, regulation of hTERT expression levels is an important mechanism 
used in a variety of developmental contexts to determine the amount of telomerase 
activity present in specific cell lineages. Interestingly, studies in Kathleen Collins group 
have also shown that hTERC is necessary for telomerase or immortalisation in real cells 
(Mitchell et al., 1999b). Up-regulation of hTERT and hTERC message may be an 
important mechanism through which telomerase becomes activated during both cellular 
immortalization and the progression of malignant tumours (Meyerson et al., 1997; Mitchell 
et al., 1999b).
Expression of a mutant catalytic subunit of human telomerase results in complete 
inhibition of telomerase activity, reduction in telomere length and death of tumour cells. 
Expression of this mutant telomerase eliminated tumorigenicity in vivo (Hahn et al., 
1999b). Alteration of the carboxyl terminus of hTERT does not affect telomerase 
enzymatic activity but impedes the ability of this enzyme to maintain telomeres. 
Telomerase-positive cells expressing this mutant enzyme fail to undergo immortalization, 
further tightening the connection between telomere maintenance and immortalization 
(Counter et al., 1998a). Inducible dominant-negative mutants of hTERT dramatically 
reduced the level of endogenous telomerase activity in tumour cell lines, it has been 
reported that telomerase inhibition in cells with short telomeres lead to chromosomal 
damage, which in turn trigger apoptotic cell death (Zhang et al., 1999). These results 
provide the first direct evidence that telomerase is required for the maintenance of human 
tumour and immortal cell viability, and suggest that tumours with short telomeres may be 
effectively and rapidly killed following telomerase inhibition.
1.5.4 Onco- and cellular- proteins regulate telomerase activity
Evidence accumulated over the past several years has shown that telomerase is 
activated in many different kinds of human cancer (Harley et al., 1994) and tumour-
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suppressor genes have joined oncogenes on centre stage. One pathway by which 
telomerase can be directly activated has recently been identified. Human papillomavirus 
(HPV) E6 and MYC activate telomerase activity (Klingelhutz et al., 1996; Kiyono et al., 
1998; Wang et al., 1998), and hTERT is the target for MYC activation and co-operates 
with E7 in immortalization. These findings are evidence for the complexity of telomerase 
control mechanisms and constitute a point of departure for piecing together an integrated 
picture of telomerase structure, function, and regulation in aging and tumour development 
(Liu, 1999a).
1.5.4.1 Cellular oncoprotein MYC activates telomerase
Expression of the MYC oncogene in primary human epithelial cells that lack telomerase 
activity leads to telomerase activation (Wang et al., 1998). By contrast, several other 
cellular and viral oncoproteins, including MDM2, RASV12, cyclinDI, CDC25C and 
CDC25A, do not activate telomerase. Expression of MYC activates telomerase by up- 
regulating the mRNA encoding the hTERT. The activation of telomerase by E6 might also 
be a MYC-mediated event. Expression of E6 leads to the activation of MYC (Auewarakul 
et al., 1994; Kinoshita et al., 1997b) and subsequent activation of telomerase in epithelial 
cells. This pathway appears to be cell type specific. In fibroblasts, expression of E6 does 
not activate MYC (Wang et al., 1998). In some cell types telomerase activation leads to 
an increase in telomere length, while in other cell types it does not, suggesting that 
different factors are required to facilitate telomere elongation by telomerase. As described 
in section 1.5.2., the c-Myc activates telomerase activity by acting on the hTERT gene 
promoter through the E-box. The up-regulation of telomerase by MYC might help to 
elucidate the pathway of telomerase activation in human cancer.
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1.5.4.2 Viral oncoprotein HPVE6 activates telomerase
One pathway by which telomerase can be directly activated has recently been identified. 
HPV infections are linked to human cervical cancer; HPV type 16 and 18 predispose 
normal human cells to tumour formation (Zur Hausen, 1991; Howley, 1991). Two viral 
genes, E6 and E7, are primarily responsible for this tumourigenicity. In cell-culture 
models, the HPV16 E6 and E7 oncogenes cooperate to allow primary cells to become 
immortalised (Munger et al., 1989), and in transgenic mice both genes are necessary for 
tumour formation (Pan & Greip, 1994). Expression of E6 alone directly activated 
telomerase in pre-immortal human keratinocytes (Klingelhutz et al., 1996), however, this 
induction of telomerase activity did not lead to telomere elongation (Stoppler et al., 1997; 
Klingelhutz et al., 1996). In fact, experiments from a number of groups have shown that 
cells expressing HPV E6 and E7 do not show telomere elongation until after cells have 
passed through crisis (Shay et al., 1993; Klingelhutz et al., 1994). Recent evidence 
suggests that the activation of telomerase by E6 occurs, at least in part, through the 
activation of the MYC oncogene (Wang et al., 1998). This suggests that, although 
telomerase activity is present, either the levels are too low, or that in some cell types 
other factors might be needed to recruit telomerase to telomere.
1.5.4.3 Telomerase co-operates with HPV E7 in cellular immortalization
hTERT expression elongates telomeres and extends the lifespan of primary human cells 
(Bodnar et al., 1998) leading to the speculation that such ectopic expression of 
telomerase might allow cellular immortalization and, thus, promote tumour formation (de 
Lange, 1998). Expression of HPV E6 or E7 alone will extend the life span of primary 
human keratinocytes past the normal senescence checkpoint. When expressed together 
E6 and E7 cooperate to allow the generation of immortal variants, which survive after the 
culture undergoes crisis (Galloway & McDougall, 1996). hTERT expression from a 
retroviral vector induces telomerase activity but does not immortalise cells in 
keratinocytes and human mammary epithelial cells. When hTERT is expressed along with
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HPV E7, established cell lines were selected after crisis (Kiyono et al., 1998). The ability 
of hTERT to cooperate with E7 in cellular immortalization suggests that telomerase fulfils 
one definition of cooperative oncogenes (Land et al., 1983).
1.5.4.4 Regulation o f telomerase by the c-Abl tyrosine kinase
Recently Kharbanda et al. reported that hTERT associates directly with the c-Abl protein 
tyrosine kinase. c-Abl phosphorylates hTERT and inhibits hTERT activity. Exposure of 
cells to ionising radiation induces tyrosine phosphorylation of hTERT by a c-Abl- 
dependent mechanism, phosphorylation of hTERT by c-Abl is associated with inhibition of 
telomerase activity. The finding that c-Abl-mediated phosphorylation of hTERT inhibits 
telomerase activity supports a function in negatively regulating telomere length 
(Kharbanda et al., 2000). Ubiquitously expressed c-Abl tyrosine kinase is activated by 
DNA double-strand breaks (Kharbanda et al., 1995), and protein involved in the repair of 
these lesions function on telomere control (Laroche et al., 1998; Polotnianka et al., 1998; 
Nugent et al., 1998a). These findings of functional interactions between c-Abl and hTERT 
support a role for c-Abl in the regulation of telomerase function.
1.5.4.5 Chromosome 3 represses telomerase activity
It has been reported that introduction of chromosome 3 but not chromosomes 7 or 11 
resulted in repression of telomerase activity, followed by progressive telomere shortening, 
and after 60-90 days, inhibition of cell proliferation. Direct inhibition of telomerase activity 
using micro-cell-mediated chromosome 3 transfer has no immediate effect on cellular 
proliferation but does result in gradual telomere shortening and the eventual renewal of 
the senescence program (Ohmura et al., 1995). Experiments by Ohmura et al. (1995) 
utilised introduction of a normal human chromosome 3 to a renal cell carcinoma cell line 
(RCC23), which contains significant rearrangements and deletions of genes on the short 
arm of chromosome 3. While fusion using other chromosomes showed no changes in
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telomeres or telomerase, RCC23 with introduced chromosome 3 exhibited a marked 
decline in telomere lengths coupled with repression of telomerase activity. These 
microcell hybrids continued to proliferate with similar growth rates as wild-type RCC23 
cells and eventually senesced after 30 to 40 PDs (Ohmura et al., 1995). Follow-up 
experiments have shown that introduction of chromosome 3 results in a substantial 
decrease in hTERT mRNA expression and after growth arrest, expression of a stress 
response and senescence-activated p-galactosidase (Horikawa et al., 1998). These data 
suggest that there is a functional telomerase repressor on chromosome 3 and that 
repression of telomerase activity in tumour-derived cell lines results in progressive 
telomere shortening and reprogramming of cellular senescence. Microcell mediated 
transfer of chromosome 3 results in telomerase inhibition by repression of hTERT 
transcription (Horikawa et al., 1998). This telomerase repressor region on chromosome 
3p has been narrowed to 3p12-p21.1 and 3p21.3-p22 (Cuthbert et al., 1999), 3p13-p14.2 
(Vieten et al., 1998), 3p14.2-p21.1 (Tanaka et al., 1998), and 3p14.2-p21.2 and 3p24.1- 
p24.3 (Mehle eta!., 1998).
1.6 Telomerase in Therapeutics
The finding that normal somatic cells lack telomerase expression may well lead to a highly 
specific treatment with fewer side effects than conventional chemotherapy (Morin, 1995; 
Shay, 1995; Harley & Villeponteau, 1995; deLange, 1994). The high frequency of 
telomerase expression in certain cancers reinforces the notion that the telomerase 
enzyme and the telomeric structure are exciting targets for potential anti-cancer 
strategies. Indeed, inhibition of telomerase in cancer cells in culture results in cell death, 
giving strong support to efforts to develop telomerase inhibitors for clinical use. Different 
strategies can be used to inhibit telomerase; (1) Small molecule or protein inhibitors can 
be directed against hTERT; (2) Antisense directed against hTERC results in the 
shortening of telomeres and cell death, after 20 cycles, of tumour cells; (3) Gene therapy 
can be conducted with a suicide gene under the control of the hTERT, hTERC, or/and
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hTERC/hTERT promoter. Our knowledge of the basic biology of telomere length 
maintenance suggests that discovery of drugs that target telomerase would represent a 
new class of therapeutic agents that act through a novel mechanism. Telomerase is a 
complex enzyme that offers many targets for the design of inhibitors, and their 
development and testing will provide the only sure way to address the telomerase 
challenge to drug discovery.
Numerous potential therapeutic strategies have been proposed with the telomere or 
telomerase enzyme as the molecular target. Telomerase-interactive compounds currently 
being developed include peptide nucleic acids, antisense oligonucleotides, ribozymes and 
reverse transcriptase inhibitors, with both the catalytic and RNA components as the 
target. For example, recent studies suggest that targeting h TERC may prove particularly 
beneficial in the treatment of small cell lung cancer, a common cancer associated with 
very poor prognosis. hTERC gene expression was detectable by RNA in situ hybridisation 
in 98% of small cell lung cancer samples, making it the best available candidate for 
targeted therapy in this cancer type (Sarvesvaran et al., 1999).
A major unmet clinical need in the treatment of cancer is accurate determination of the 
aggressiveness, or stage, of cancer. Knowing the stage of a cancer guide the physician in 
treatment decisions is impacting the patient's chance of survival. For example, 70% of 
early stage breast cancer patients will be cured after primary surgery; no additional radio 
or chemotherapy is usually recommended. However, this practice does not benefit the 
30% of patients who will experience recurrent cancer and perhaps could be helped by 
additional therapies. An accurate prognostic marker that could identify high risk early 
stage breast cancer patients has been one of the most sought after tests in breast cancer 
management. Telomerase has significant potential in predicting the aggressiveness of 
cancer in multiple cancer types, and assisting the oncologist to treat more effectively.
Another example of the importance of developing additional diagnostic screens is the use 
of telomerase in detecting bladder cancer as an adjuvant to normal cytology. Almost 50% 
of early-stage bladder tumour cases are initially missed due to the lack of effective
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cytological markers for detection. Telomerase can be detected in the majority 
(approaching 90%) of bladder cancers using less invasive biopsy techniques (bladder 
washings or voided urine; Lin et al., 1996; Dalbagni et al., 1997; Kinoshita et al., 1997a; 
Yoshida et al., 1997). Detection of telomerase activity relative to human cancer 
development is likely to be an important and novel method, in combination with traditional 
cytology, for early cancer diagnosis.
It has been shown that inhibition of human telomerase in immortal human cells leads to 
progressive telomere shortening and cell death (Herbert et al., 1999). Telomerase 
inhibitors could target any one of several features of human telomerase. These include: 
the hTERT active site; the 11-base RNA template; the 'anchor site' where hTERT 
interacts with telomeric DNA; the extended telomere, possibly a G-quadruplex structure; 
additional, as yet unknown interacting proteins; or antisense targeting of the mRNA for 
either hTERC or hTERT. The hTERT would be a preferred target in this antisense- 
targeting strategy because hTERT is not expressed in telomerase negative cells. In a 
variation in this theme, the gene for an inactive hTERT mutant could be delivered to 
telomerase positive cells and suppress telomerase activity though a dominant-negative 
approach. The progress of investigations of described inhibitors is discussed in following 
section and outlined in Table 1.6.
1.6.1 Nucleotide inhibitors
Telomerase shares substantial identity with reverse transcriptase, so it is not surprising 
that nucleotide analogs known to inhibit polymerase, such as AZT (azidothymidine) 
(Strahl & Blackburn, 1996; Gomez et al., 1998), 7-deaza-ATP (Fletcher et al., 1996), ddG 
(Ku et al., 1997; Pai et al., 1998) and carbovir (Yegorov et al., 1996), also inhibit 
telomerase. Unfortunately, these molecules also inhibit other polymerases, making it 
difficult to relate changes in cell proliferation to inhibition of telomerase. Identification of 
nucleotide inhibitors that are selective for telomerase may be able to take advantage of 
reverse transcriptase inhibitors synthesised during programs to investigate inhibition of
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other polymerases, some of which may have been poor inhibitors of their original targets. 
The recent cloning of h TERC and hTERT and possession of reconstituted enzyme will 
facilitate development of protocols for mass screening of these derivatives. Identification 
of hTERT and hTERC should lead to high-resolution structural information, and this 
should also facilitate development of nucleotide analogs.
Table 1. 6 Reported inhibitors of human telomerase activity
Inhibitor Proposed target
Expression of antisense RNA hTERC
Peptide nucleic acid hTERC template
Phosphorothioate DNA h TERC template/hTERT
2'-0-methyl RNA h TERC template
Retroviral antisense h TERC template
Phosphodiester DNA oiigos h TERC template
Anthraquinone derivatives G-quadruplex/telomere
Cationic porphyrin G-quadruplex/telomere
Perylenetetracarboxylic dimide G-quadruplex/telomere
Nucleoside derivatives hTERT active site
Tea catechins Unknown
Oligonucleotide with 2'-5' A linkage hTERC/RNase L-mediated
Small molecules Different protein
Ribozyme h TERC
Phosphorothioate DNA Anchor site
4-(hydroxyphenyl)retinamide (4HPR) Unknown
Trichostatin A (TSA) hTERT in HAC1 cell
(For review see Pitts & Corey, 1999)
1.6.2 G-quadruplex interactive agents
An approach to telomerase inhibition that has been the focus of much attention is the 
design of small molecules that bind G-quartet structures. Two classes of them, 
anthraquinone derivatives (Sun et al., 1997) and cationic porphyrins (Whealhouse et al.,
1998), have been demonstrated by NMR spectroscopy to interact with G-quadruplex 
structures, and both molecules also inhibit telomerase in vitro.
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1.6.3 Oligonucleotides as inhibitors
The 11-base template within hTERC is intrinsically accessible to binding by telomere ends 
and this recognition is essential for maintaining telomere length, suggesting that 
telomerase should be an ideal target for inhibition by oligonucleotides that target this 
sequence. It has been found that peptide nucleic acids (PNAs) complementary to the 
template inhibit telomerase with IC50 values of 1-10 nM (Hamilton et al., 1997). There 
have been two reports of anti-telomerase oligonucleotide causing cell death soon after 
addition, results that are contrary to the dogma that telomerase inhibitors require a lag 
phase before their effects become apparent. One involves a hexamer oligonucleotide 
directed to the template region of hTERC (Mata et al., 1997), while a second contains a 
2'-5' adenosine linkage that is meant to direct RNase L-mediated cleavage to a non­
template region predicted to be accessible (Kondo et al., 1998). Phosphodiester-linked 2'- 
0-methyi-RNA, however, proved to be a highly selective inhibitor and displayed a potency 
comparable with the best PNA inhibitors (Pitts & Corey, 1998). Introduction of 
phosphorothioate linkages at the 3'- and 5'- termini of the 2'-0-methyl-RNA increased 
stability towards nuclease digestion without sacrificing potency or specificity. This 
modified 2'-0-methyl-RNA inhibited telomerase within cells upon delivery with cationic 
lipid. These intriguing reports could indicate that telomerase inhibitors can function by a 
mechanism other than gradual telomere erosion.
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1.7 Aims of This Thesis
Recent studies indicate that the regulation of telomerase activity in mammalian cells is 
multifactorial. It is known that expression of the hTERC and hTERT are essential for 
activity, and the primary mode of control of hTERT appears to be transcriptional 
regulation. However, very little is known about the molecular mechanisms involved in the 
regulation of hTERC. The main target to be studied of this project is to detect the 
telomerase RNA gene functional promoter region and to investigate whether transcription 
is involved in regulation of the RNA component (see Figure 1.8 for strategy). The hTERC 
and mTerc 5'-flanking region cDNA will be cloned and sequenced (Chapter 3). Secondly, 
the sequence elements bound by transcription factors will be investigated to clarify the 
molecular basis involved in regulation of telomerase RNA gene expression (Chapter 4). 
To elucidate the regulatory mechanism of telomerase RNA gene transcription, the major 
regulators of the hTERC promoter will be identified. The hTERC promoter could allow 
targeting by several regulators including viral oncoprotein or tumour suppresser gene 
products to effect the hTERC gene expression phenotype in certain cell situation, the 
candidate gene products such as E1A and pRb will be further tested. The regulation of 
mammalian TERC genes from different species will be also studied by comparison of 5' 
flanking transcriptional region (Chapter 5). This study may offer a way to identify 
molecular mechanisms participating in the modulation of telomerase activity during 
tumourgenesis and also open up possibilities for the gene therapeutics (Chapter 6).
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Chapter 3
•Clone and sequence hTERC/mTerc genomic DNA 
•isolate putative promoter from genomic clone 
•Develop functional assay
Identify cis-acting DNA elements and trans­
acting factors
Sp1 binding sites as positive/negative 
regulatory elements 
CCAAT-box is essential for h TERC 
promoter activity
Successful 
development and 
functional assay
Chapter 4
Sequence and 
function comparison 
between species
Successful identify 
hTERC/mTerc functional 
promoter region
Chapter 5
•identification of CCAAT-binding factor NF-Y 
•Determine relevance of factors 
“ Sp1, pRb, and E1A as activators 
“ Dominant-negative NF-Y and Sp3 as repressors 
•Comparison of TERC promoter from different species
t
Chapter 6
•Discussion 
•Advanced studies
Figure 1.8 Structure of this thesis for analysis of the h TERC transcriptional
regulation mechanism
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Chapter 2 Materials and Methodology
2.1 Materials
2.1.1 Plasmids
Human P1 clone. 9913, is derived from a human foreskin fibroblast P1 library. Mouse P1 
clone, 11792, is derived from a mouse C127 fibroblast P1 library.
pGL.3 Basic plasmid (Promega) contains the firefly luciferase gene with no promoter or 
enhancer. pGL3 Control plasmid contains the firefly luciferase gene driven by the SV40 
promoter and enhancer.
pEGFP-1 vector (Clontech) contains a green fluorescent protein (GFP) reporter gene 
without the promoter. pEGFP-NI protein fusion vector contains a GFP reporter driven by 
the CMV promoter.
pPCR-Script Amp phagemid (Stratagene) was used as a cloning and sequencing vector.
pSEAP2 Basic Vector (Clontech) is used for expression of the reporter gene secreted 
alkaline phosphateas (SEAP) with no promoter. pSEAP2 Control Vector is a positive 
control vector under control of the SV40 early promoter and SV 40 enhancer.
The Sp1 expression vectors, pCMVSpI . were generously provided by Dr. Robert Tjian, 
University of California, Berkeley. pCMVSp3 was a gift from Dr Guntram Suske, Institut 
fur Molekularbiologie und Tumorforschung, Germany. pCMV control plasmid was created 
by deletion of the Sp3 Bgl 11/BamH I fragment from pCMVSp3.
pCMV-Rb. the wild-type human Rb expression construct driven by CMV promoter, was a 
gift from Dr. Lee F. Johnson, University of Ohio State. pSV40-Rb. the wild-type human Rb 
expression construct driven by SV40 promoter, was a gift from Dr. Lee F. Johnson, 
University of Ohio State.
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Dominant-negative mutants pNF-YA13m29 and wild-type PNF-YA13 were generously 
provided by Dr. Roberto Mantovani (Universita Degli Studi Di Milano) and were 
constructed from NF-YAm29 and NF-YA cDNA cloned in down-stream of SV40 promoter 
(Mantovani et al., 1994).
pE1A wt. expression vector with full-length E1A gene, was a gift from Dr David Gillespie 
(Beatson Laboratories).
2.1.2 Kits and Enzymes 
Products
Protein Assay Dye Reagent Concentrate 
Luciferase Assay System 
Gel Shift Assay System 
T4 Polynucleotide Kinase 
Restriction enzyme 
T4 DNA Ligase, ver. 2.0 
Qiaquick Gel Extraction Kit 
Superfect Transfection Reagent( 1.2ml) 
Qiaquick Nucleotide Removal Kit 
Calf Intestine Alkaline Phospatase 
SureTrack Footprinting Kit 
pCR Bluescript II Cloning kits SK+
DNA Ligation Kits
Taq DNA Polymerase PCR Kit
Quick Change Site-Directed Mutagenesis Kit
Lyse-N-Go PCR Reagent
Sentinel Molecular Beacon GAPDH Detection kit
[y32_P] ATP, >5000Ci/mmol, 10mCi/ml 
[a32-P] dCTP, >3000Ci/mmol, 10mCi/ml
Supplies
BioRad Labs: 500 0006
Promega: E1500
Promega: E3300
New England BioLabs: 201S
GIBCO
MBI:EL0332
Qiagen: 28704
Qiagen: 301305
Qiagen: 28304
Cambridge Bioscience: 8410 1 
Pharmacia Biotech: XY-029-00-05 
Stratgaene: 212206XXX 
Stratagene: 203003 
Boehringer Mannheim: 1435094 
Stratagene: #200518 
PIERCE: #78882)
Stratagene: #200571 
Amersham: AA0018 
Amersham: AA0005
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2.1.3 Antisera
Table 2.1 Antisera
Antisera for EMSA Supplier
Anti-NF-YA rabbit monoclonal antibodies A gift from Dr Roberto Mantovani
Anti-NF-YB rabbit polyclonal antibodies A gift from Dr Roberto Mantovani
CBF-A (C-19): goat polyclonal IgG, Santa Cruz : sc-7711X
CBF-C (N-19): goat polyclonal IgG, Santa Cruz : sc-7715X
CBF-B (C-18): goat polyclonal IgG, Santa Cruz : sc-7712X
CBF-B (N-19): goat polyclonal IgG, Santa Cruz : sc-7713X
Sp1 (1C6): mouse monoclonal IgG, Santa C ruz: sc-420X
Sp3 (D-20)-G: rabbit polyclonal IgG, Santa C ruz: sc-644-GX
Ap2 (C-18): rabbit polyclonal IgG, Santa C ruz: sc-184X
Ap1 (D): rabbit polyclonal IgG, Santa C ruz: sc-44X
Ets-2 (C-20): rabbit polyclonal IgG, Santa Cruz : sc-351 X
NF-1 (N-20): rabbit polyclonal IgG, Santa C ruz: sc-870X
c/EBPa (14AA): rabbit polyclonal IgG, Santa Cruz : sc-61 X
Rb (C-25-G): goat polyclonal IgG, Santa C ruz: sc-50-GX
NF-YA: purified mouse IgG, Pharmingen:65131A
2.1.4 Consensus oligonucleotides and sequence primers
Table 2. 2 Commercial consensus oligonucleotides
Oligos Sequence* Source
Sp1 ATTCGATCGGGGCGGGGCGAGC Promega E323A
TFIID GCAGAGCATATAAGGTGAGGTAGGA Promega E322B
AP2 GATCGAACTGACCGCCCGCGGCCCGT Santa Cruz: sc-2513
AP1 CGCTTGATGAGTCAGCCGGAA Promega E320B
NF-kB AGTTGAGGGGAC I I I CCCAGGC Promega E329B
c/EBP TGCAGATTGCGCAATCTGCA Santa Cruz: sc-2525
NF-1 TTTT G G ATT G AAG CC AATAT GAT AA Santa Cruz: sc-2553
NF-Y ATTTTT CT GATT G GTTAAAAGT Becton Dickinson UK Ltd
Ets-2 GATCTGGAGCAGGAAGTTCGA Santa Cruz: sc-2555
CBF AG ACCGT AGGT G ATTGGTT AAT CT CTT Santa Cruz: sc-2591
T7 T AATACG ACT C ACTAT AG G G Promega: Q5021
T3 ATT AAC C CTC ACT AAAG G G A Promega: Q5741
RVprimer3 CTAGCAAAATAGGCTGTCCC Promega: E4481
GLprimer2 CTTTATGTTTTTGGCGTCTTCC Promega: E1661
LucR1 TTT G AAT CTT GT AAT CCT G AA
LucF1 CTACCGTGGTGTTCGTTTC
* Nucleotide sequences are given in uppercase letters from 5’ to 3’. T7 and T3 are 
the sequencing primers for pPCR-Script Amp or pCR Bluescript SK (+) cloning vector 
(Stratagene). Rvprimer3 and Glprimer2 are the sequencing primers for the pGL3 
luciferase reporter plasmid (Promega). LucR1 and LucF1 primer are for PCR semi­
quantitation.
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Table 2. 3 Oligonucleotides for hTERC promoter
Oligos Position Sequence* Purpose
hTR14R +46 to +69 ggatccTACGCCCTTCTCAGTTAGGGTTAG For deletion mutation (with BamH I site)
hTR17F -436 to -417 ggatccACTGAGCCGAGACAAGATTC For deletion mutation (with BamH I site)
hTR20F -798 to -779 gcgctcgagAGCTACTCAGGAGGCTGAGA For deletion mutation (with Xho I site)
hTR21 F -627 to -609 gcgctcgagcATCAAGACACAGCACTACT For deletion mutation (with Xho I site)
hTR22F -272 to -253 gcgctcgagGTCTGGTCTGCAGAGGATAG For deletion mutation (with Xho I site)
hTR23R +46 to +69 c g c a a g c t t  TACGCCCTTCTCAGTTAGGGTTAG For deletion mutation (with Hindlll site)
hTR5mF -473 to -452 gcgctcgAGGAAAAAGGTTCAGGGTTGGA ASp1.5 mutation (with Xho I site )
hTR5F -473 to -452 qcqctcqAGGAAAAAGGGGCAGGGTTGGA For deletion mutation (with Xho I site )
hTR26n -51 to -28 gcgctcgaGTGCGGTCGGCGGCCGCTCCCTTT For deletion mutation (with Xho I site)
hTR29F -107 to -88 qcqctcqAGCCCGCCCGAGAGAGTGAC For deletion mutation (with Xho I site)
h 4a -110 to -91 ACCAGCCCGCCCGAGAGAGT h4 DNA footprinting region
h41ma -110 to -91 ACCAGCCCGAACGAGAGAGT ASp1.2, from cc to aa, (-101/-100)
h 5a -471 to -452 GAAAAAGGGGCAGGGTTGGA h5 DNA footprinting region
h5m a -471 to -452 GAAAAAGGTTCAGGGTTGGA ASp1.3, from gg to tt, (-463M62)
h 9a -44 to -17 CGGCGGCCGCTCCCTTTATAAGCCGACT h9 DNA footprinting region
h91a -44 to -21 CTTACGCCGCTCCCTTTATAAGCC h9 mutation from ggcg to ttac, (-43/-40)
h910b -53 to -29 CCGTGCGGTCTTACGCCGCTCCC h9 mutation from ggcg to ttac, (-43/-40)
h911 a -44 to -21 CGGCGTAAACTCCCTTTATAAGCC h9 mutation from gccg to taaa, (-39/-36)
h92 3 -44 to -21 CGGCGGCCATAGCCTTTATAAGCC h9 mutation from gctc to atag, (-36/-33)
h921 3 -44 to -21 CGGCGGCCGCTCATGCTATAAGCC h9 mutation from cctt to atgc, (-32/-29)
h93 3 -44 to -21 CGGCGGCCGCTCCCTTCGACAGCC h9 mutation from tata to cgac, (-28/-25)
h930b -38 to -14 CCGCTCCCTTCGACAGCCGACTCGC h9 mutation from tata to cgac, (-281-25)
h9con b -49 to -20 GCGGTCGGCCCCCGCCCCGTTTATAAGCCG Point mutation from gg to cc(-39/-40), t
to c(-34), c to g(-31)
h10 3 -63 to -42 CTTGGCCAATCCGTGCGGTCGG h10 footprinting region containing CCAATbinding site
h101 3 -63 to -42 CTTGGAGTCTCCGTGCGGTCGG ACC AAT, from ccaa to agtc, (-58/-55)
h10m11 b -74 to-45 GCGAGAGTCAGCTTGGAGTCTCCGTGCGG ACCAAT, from ccaa to agtc, (-58/-55)
h10m2 a,b -63 to -42 CTTGGCCAATCCTGATGGTCGG h10 mutation from gtgc to tgat, (-51/-47)
h11 3 -2 to +36 CCGGGTTGCGGAGGGTGGGCCTGGGAGGGGTGGT Sp1.3 (+11+16) and Sp1.4 ( +26, +31)GGCC binding site
hi 11 3 CCGGGTTGCGGAAAATGGGCCTGGGAGGGGTGGT ASp1.3, from ggg to aaa (+11/+13,)GGCC
h112 3 “ CCGGGTTGCGGAGGGTGGGCCTGGGTAAGGTGGTGGCC
ASp1.4, from agg to taa (+24/+26)
hi 13 3 “ CCGGGTTGCGGAAAATGGGCCTGGGTAAGGTGGT ASp1.3 and ASp1.4 bindingGGCC site(+11/+13, +24/+26)
h11c 3 -2 to +23 CCGGGTTGCGGAGGGTGGGCCTGGG Sp1.3 binding site
h11d 3 + 14 to +36 GCCTGGGAGGGGTGGTGGCC Sp1.4 binding site
h112b a,b +15 to +36 GGGCCTGGGTAAGGTGGTGGCC ASp1.4, from agg to taa, +24/+26
h112C 3,b GGGCCTGGGTAAGGTAATGGCC ASp1.4, from aggggtgg to 
taaggtaa(+24/+26, +30/+31)
h11e 3 GGGCCTGGGAGGGGTAATGGCC Mutation from gg to aa (+30/+31)
* Nucleotides corresponding to promoter sequences are given in uppercase 
letters from 5’ end to 3’ end; The core sequences mentioned in the Purpose 
column are underlined. Bold characters indicate mutated nucleotides and 
lowercase letters indicate flanking nucleotides that introduce restriction enzyme 
sites.
a Complementary sequence for EMSA not shown.
bFor PCR-directed in vitro mutagenesis, complementary sequence not shown.
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2.1.5 Oligonucleotides for PCR and EMSA
All oligodeoxynucleotides used were obtained from GENOSYS (Genosys 
Biotechnologies, Europe, Ltd). Each oligonucleotide was resuspended in deionised H20  
according to the manufacturers product information; the concentration of 250 pmolar was 
calculated by: 250pM = Oligo Weight (mg/ml) X 4 / Molecular Weight. Oligonucleotide
solutions were stored at - 20 °C.
For PCR cloning, primers from hTR14R to hTR29F in Table 2.3 (F, sense; R, antisense) 
including a restriction enzyme recognition sites (lowercase), respectively, were used for 
construction of the plasmids. DNA fragments with mutation of specific DNA element(s) 
were generated by introducing a mutated nucleotide into PCR primers when the mutation 
was directed into the middle region of the DNA fragment. For EMSA experiments, 
oligonucleotides h4, h5, h9 and h10 were used for construction of each DNase I 
footprinting protection region.
Table 2. 4 Oligonucleotides for m7erc promoter
Oligos Position Sequence* Purpose
mTR25F -190 to -99 gcgctcgagGTGTCTCACAGCAAGAAACA For deletion mutation (w th Xho I site)
mTR26 F -129 to -1 10 gcgctcgagGTGACTGGCTAGGAAGAGTG For deletion mutation (w th Xho I site)
m TR 27F -549 to -5 30 gcgctcgagTGTGACCTTGAACTACAGAC For deletion mutation (w th Xho I site)
m TR28F -339 to -3 20 gcgctcgagGGACTGGGTTGAAGGTGGAA For deletion mutation (w th Xho I site)
m TR 29F -379 to -360 g c g c  t  cgagTGCGCCACTTTTCCCCACTT For deletion mutation (w th Xho I site)
m TR 30R -180 to +59 cgcaagctTCCGCTGGAAGTCAGCGAGAA For deletion mutation (w th Hind III site)
mTR31 R cgcaagctTTGTAGGCGGGTACGGGACTG For deletion mutation (w th Hind III site)
mTR32 R cgcaagctTTGACAGAGGCGGAGCTCTTC For deletion mutation (w th Hind III site)
m TR 33F g c g c  t  cgaGGCTCTTAGAAGGCACCGTGG For deletion mutation (w th Xho I site)
m TR 34R -8 to +27 cgcaagcttCTAGCCG CCCTCGACCTTAA For deletion mutation (w th Hind III site)
m TR 35R cgcaagctTCTAGAGTTGAAAGTAGGGAT For deletion mutation (w th Hind III site)
m TR 36F -55 to -34 gcgctcgagTCGACCAATCAGCGCGCGCCAT For deletion mutation (w th Xho I site)
mTR37R -34 to -55 C g c a a g c t  tATGGCGCGCGCTGATTGGTCGA For deletion mutation (w th Hind III site)
* Nucleotides corresponding to promoter sequences are given in uppercase 
letters from 5’ end to 3’ end. Lowercase letters indicate flanking nucleotides 
that introduce restriction enzyme sites.
a Complementary sequence for EMSA not shown.
bFor PCR-directed in vitro mutagenesis, complementary sequence not shown.
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2.1.6 General laboratory supplies and miscellaneous
Beatson Institute Central Services
LB-Medium (Luria-Bertani Medium)
Sterile distilled water
Sterile phosphate-buffered saline (PBS)
Sterile phosphate-buffered saline (PBS)+EDTA(PE)
Sterile glassware and pipettes 
Penicillin (7.5 mg/ml)
Streptomycin (10gm/ml)
Amphotericin B (250ug/ml)
Tissue culture
Gibco Europe Life Technologies Ltd.
DMEM, RPMI 1640,
200mM glutamine 
100mM sodium pyruvate 
7.5%(w/v) sodium bicarbonate 
2.5%(w/v) trypsin
2.2 DNA Recombination Techniques
The human P1 clone, 9913, is derived from a human foreskin fibroblast P1 library and the 
mouse P1 clone, 11792, is derived from a mouse C127 fibroblast P1 library. Briefly, in 
order to subclone the promoter regions, the P1 clones were digested with EcoRI/Hindlll 
and ligated into pCR Bluescript to create phTR (1765 bp) and pmTR (4040 bp). Colonies 
containing telomerase RNA gene sequences were identified by hybridization with PCR 
generated probes as previously described (Soder et al., 1997a, b). Plasmid DNA was 
prepared from positively hybridizing colonies, and inserts sequenced on both strands 
using the ABI PRISM dye terminator cycle sequencing kit (PE Applied Biosystems,
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Warrington, UK). DNA fragments with various lengths of 5’-flanking regions were 
generated by PCR amplification.
2.2.1 Polymerase Chain Reaction
The amplification of DNA fragments using the polymerase chain reaction is performed in 
either the Perkin-Elmer Cetus DNA Thermal Cycler or the Perkin-Elmer Cetus Cycler 
9600, by adding the following reagents to a 0.5 ml PCR tube in a total volume of 50 pi: 50 
ng plasmid DNA or 1 pg genomic P1 clone as template, 25 pM sense (F) and antisense 
(R) primers (Table 2.3 and 2.4), 10 mM dNTP’s, 10 X PCR buffer and 5 units Taq DNA 
polymerase (Boehringer). The cycling protocol consisted of 30 cycles of three 
temperatures: strand denaturation at 95 °C for 30 seconds; primer annealing at 55 °C for 
30 seconds; primer extension at 72 °C for 1 or 2 minutes. The reaction mixtures were 
overlaid with two drops of mineral oil. After PCR, 5 pi aliquots of the mixture, typically, 
were analysed by agarose gel electrophoresis to detect amplified product.
2.2.2 Cloning PCR products
Isolation and purification To clone the PCR products, 45 pi of PCR products were 
incubated with 2 pi of Xho I and Hind III (10 U/pl) enzyme at 37 °C for 60 minutes. DNA 
fragments to be used for cloning were separated from unwanted products of the 
restriction digest reaction by electrophoresis on 1 % non-denaturing agarose gels. The 
fragment band was cut out of the gel using a clean scalpel blade and the gel slice placed 
in a sterile microcentrifuge tube. Extraction of the DNA fragment from the agarose was 
achieved using a QIAquick gel extraction kit (Qiagen) following the manufacturer's 
instructions. Each of the digested PCR fragments were ligated into Xho I/Hind III 
linearized pGL3 Basic vector (Promega), pEGFP-1 vector (Clontech) or pPCR-Script™ 
SK (+) vector (Stratagene).
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Ligation and transformation Standard DNA ligations were performed in 10 pi by 
incubating DNA inserts with 1 pi of linearized vector in the presence of buffer, 50% PEG 
rATP, and T4 DNA ligase (MBI, Lithuania), reactions were incubated at room-temperature 
for 1 hour. Then the ligation reaction was mixed with 50 pi competent DHa.5 E.coli (Gibco, 
Life Tech) and incubated on ice for 45 minutes. The cells were placed in a 42 °C water- 
bath for 45 seconds and transferred to ice for 5 minutes. After this step 200 pi SOC 
medium (2% Bacto-tryptone, 0.5% bacto-yeast extract, 20 mM Glucose, 10 mM NaCI, 10 
mM MgCy was added and incubated for 1 hour in an orbital shaker at 37 °C. After 
completion of this step, 50 to 100 pi cells were plated to bacteriological grade dishes 
(Bibby Sterilin) coated with 1.5% Agar containing L-Broth and with the appropriate 
selection antibiotic. Plates were incubated in an inverted position in a 37 °C incubator for 
18 to 24 hours.
2.2.3 Cloning of site-directed mutagenesis constructs
The basic strategy for site-directed mutagenesis of the proximal hTERC promoter 
consisted of the following steps, illustrated in Figure 2.1. The PCR mutageneses were 
performed separately by using a site-directed mutagenesis kit (Stratagene, 
QuikChange™) following the manufacturer's instructions. An oligonuleotide, 
complementary to the single-strand template except for the mutated nucleotide of 
interest, was synthesised and annealed with the single-strand template DNA. The mutant 
strand was then synthesised by extending the oligonucleotide with DNA polymerase 
followed by annealing, to create double-stranded DNA. The mutant forms of hTERC (- 
107/+69) were constructed using oligonucleotides designed with the mismatches shown 
in Table 2.3. The mutant sequences did not create any known binding site for 
transcription factors as predicted by TFSEARCH and TESS data base searchs.
The PCR reactions were performed using the following standard conditions. All PCRs
were performed using 2 pi of pC2923 (-107/+69) plasmid DNA (50 ng/pl, 3.1 Kb) as
template, 1.5 mM MgCI2,0.2 mM dNTP’s, 25 nM of appropriate mutagenic primers in the
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sense orientation and 1.0 pi (2.5 U/pl) Pfu DNA polymerase in 50 pi reaction volume. The 
same oligonucleotides mentioned above were used as antisense primer. A total of 16 
cycles (16 cycles at 95 °C for 30 sec, 55 °C for 30 sec, and 68 °C for 6 or 10 min, 2 
minutes/Kb plasmid length) were used after originally denaturing at 95 °C for 30 seconds 
in either the Perkin-Elmer Cetus DNA Thermal Cycler or the Perkin-Elmer Cetus Cycler 
9600.
5 pi aliquots of the PCR products were then analysed on a 1% agarose gel and the 
remainder of the reaction was digested by adding 1 pi of Dpn I (10 U /p l) at 37 °C for 60 
minutes to remove all pure parental DNA template. Then, 2 pi of Dpn I treated PCR 
products were transformed into competent XL-2 Blue cells (Stratagene). After 
amplification of DNA in E.coli., the mutations were verified by DNA sequencing.
Then, mutants of luciferase reporter construct were constructed by subcloning Xho I/Hind 
III digested fragment into linearized pGL3 Basic vector. 5 pg of mutant construct which 
cloned in pPCR-Script™ AMP(+) vector (Stratagene) were digested by Xho I/Hind III at 
37 °C for 60 minutes. Then, DNA was applied for 1.5% agarose gel or 6% PAGE for 
electrophoresis to purify 0.2 Kb insert.
The mutant sequences are shown in Table 2.3. For example, the Sp1.1 binding site- 
replaced mutant, pLh92(ASp1.1), was constructed by subcloning Xho I/Hind III digested 
pC92 Xho I/Hind III fragment amplified with the primer set h92 a . The Sp1.1 and Sp1.2 
double site-replaced mutant, pLh29m292(ASp1-1.2), was constructed by using pC92 as 
template for PCR amplification with the primer set h41m a. The multiple site-replaced 
mutant, pLh114(ASp1.1, ASp1.2, ASp1.3, ASp1.4), was created by using pC29m292 as 
template for three separate PCR amplifications with the primer sets hi 11aa b, hi 12ba,b and 
hi 12cab, respectively. All mutation constructs were sequenced from both 5' and 3' ends to 
confirm orientation and sequence.
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Figure 2. 1 The strategy of proxim al prom oter mutagenesis
Table 2. 5 The h TERC site-directed m utation constructs
Name Mutation Sites Mutation and position
pLh2923 none wild type
pLh29m 223 A S p 1 .2 cc to aa, -101 to -100
pL h1 011 A n f -y ccaa to agtc, -58 to -55
pLh102 gtgc to tgat, -51 to -47
pLh910 ggcg to ttac, -43 to -40
pL h 9 1 1 gccg to taaa, -39 to -36
pLh92 ASp1.1 gctc to atag, -36 to -33
pLh921 ASp1.1 cctt to atgc, -32 to -29
pLh930 A t a t a tata to cgac, -28 to -25
pL h2 9111 A S p 1 .3 ggg to aaa, +11 to +13
pL h2 9112 A S p 1 .4 agg to taa, +24 to +26
pLh29m 292 A S p 1 ,2; ASp1.1 -101/-100; -36/-33
pLh29m921 A S p 1 ,2; ASp1.1 -101/-100; -32/-29
p L h 111 A s p 1.2 : A s p l.1. A s p 1 3 -101/-100; -36/-33; +11 /+13
p L h 1 12 A s P 1 2 ; A sp  1.1 . A s p l 4 -101/-100; -36/-33; +24/+26
p L h 1 13 A s p 1.2 ; A s p l 1 ; A s p 1 3, A s p 1 4. -101/-100; -36/-33; +11 /+13; +24/+26
p L h114 A s p 1 2 ; A s p l 1. A s p l 3; A s p l 4 -1 01 /-100; -36/-33; +11 /+13; +24/+26; +30/+31
pLh471 A n f -y
ccaa to agtc, -58 to -55 in pLh2223
A Indication of the site-directed mutation.
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As shown in Table 2.3, the Sp1.1 core binding sequence 5’-GGCCGCTCCC-3’ has been 
replaced by 5’-GGCCATAGCC-3’. NF-Y core binding sequence 5’-CCAAT-3’ has been 
replaced by 5’-AG7~CT-3’. two motifs of Sp1 site core sequence 5’- 
GGGTGGGCCTGGGAGGGGTGGTGG-3’ have been replaced by 5- 
AAATGGGCCTGGG7AAGGTAATGG-3’. The resultant plasmid DNAs were prepared and 
sequenced to confirm specific nucleotide changes. The site-directed mutation constructs 
that have been made in this study are shown in Table 2.5.
2.2.4 Glycerol Stocks
750 pi of the overnight culture, which contained exponentially growing cells, was added to 
750 pi 50% sterile glycerol in a 1.5 ml Nunc cryotube. The mixture was vortexed to ensure 
that the glycerol was mixed throughout the bacterial cell suspension and frozen rapidly by 
placing the tube in dry-ice for 5 minutes. Glycerol stocks were stored at -70 °C.
2.3 DNA Analysis
2.3.1 Minipreparation of plasmid DNA
Bacterial pellets were recovered in a 0.5 ml PCR tube by centrifugation at top speed in a
microcentrifuge. The pellet was resuspended in 270 pi STET solution (0.1 M NaCI, 10mM
Tris.HCI, pH8.0, 1mM EDTA, pH8.0, 5% Triton X-100) containing 0.667 pg/pl lysozyme,
by vortexing briefly. After 5 minutes incubation on ice, the reaction was treated at 97 °C
for 60 seconds in either the Perkin-Elmer Cetus DNA Thermal Cycler or the Perkin-Elmer
Cetus Cycler 9600. Next, the reaction was chilled on ice for 5 minutes and the insoluble
matter spun down at room temperature for 10 minutes, then removed with the assistance
of tooth picks. DNA was precipitated by adding 140 pi isopropanol and centrifugation. The
pellet was washed by 100% (v/v) ethanol, and air dried for 5 min. The pellet was
resuspended in 50 pi TE (pH 8.0) containing heat-treated RNase (10 pg/ml), vortexed for
20 seconds and incubated at 55 °C for 5-10 minutes. Diagnostic digestion was performed
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by using 2 |jl miniprep DNA, 2 pi reaction buffer, 0.1-0.2 units of restriction enzyme in a 
20 pi reaction which was incubated at 37 °C for 1 hour. 10 pi aliquots of the reaction 
mixture were loaded onto an agarose gel and electrophoresed to detect restriction 
fragments.
2.3.2 Maxipreparation and purification of plasmid DNA
0.5 ml fresh cultures from bacterial stocks were added into 100 ml of L-Broth containing 
appropriate antibiotic [20 pg/ml ampicillin + 80 pg/ml methicillin (Sigma M-6535)] and 
incubated overnight in an orbital shaker at 37 °C. The cultures were divided into two 50 ml 
falcon tubes and centrifuged at 4,000 rpm for 10 minutes at 4 °C in a Beckman GS-6R 
centrifuge.
The supernatant was discarded and the cell pellet was resuspended in 5 ml solution l(50 
mM Tris-HCI pH 8.0, 10 mM EDTA pH8.0) by vigorous vortexing. The tubes were placed 
on ice, 10 ml solution ll(0.2 M NaOH, 1% SDS ) was added, the lysate was mixed by 
careful inversion and incubated at room temperature for 10 minutes. After this step, 15 ml 
solution III (5 M Potassium Acetate, 11.5% v/v Glacial Acetic Acid) was added and the 
lysate was mixed thoroughly. Samples were incubated in ice for 10 minutes then 
centrifuged at 4,000 rpm for 10 minutes at 4 °C in a Beckman GS-6R centrifuge. The 
supernatant was filtered through gauze and 0.6 volumes of isopropanol (about 12 ml) 
was added, mixed, and the solution was left for 10 minutes at room temperature. Then 
the solution was centrifuged at 4,000 rpm for 10 minutes at 4 °C in a Beckman GS-6R 
centrifuge.
After centrifugation the supernatant was removed carefully, the pellet was resuspended in
1.0 ml TE (pH 8.0) containing heat-treated RNase (10 pg/ml) and the plasmid DNA 
incubated at 55 °C for 30 minutes. Then plasmid DNA was precipatated by adding 1.0 ml 
solution IV (13.5% Polyethylene Glycol 6,000, 1.6 M NaCI) and centrifugation at 4,000
53
(Zhao, JQ., Sept. 2000) Chapter 2. Materials & Methodology
rpm for 10 minutes at 4 °C in a Beckman GS-6R centrifuge. Plasmid DNA also was 
purified using a plasmid maxi kit (QIAGEN).
The pellet was resuspended in 0.4 ml TE by repetitive pipetting. Sample was transferred 
to 1.5 ml centrifuge tube and extracted twice with phenol/chloroform, precipitated with 1 
ml 100% (v/v) ethanol by centrifugation at 14,000 rpm for 10 minutes, then the pellet was 
washed with 70% and 100% (v/v) ethanol. After drying the pellet at room temperature, the 
pellet was dissolved with 0.4 ml TE to read concentration at OD260/280. Finally, plasmid 
DNA concentration was adjusted to 0.5 or 1.0 pg/pl.
2.3.3 Taq Terminator sequencing on ABI 373A
All of the constructs in this study were sequenced on both strands by dideoxy chain 
termination using the ABI PRISM dye teminator cycle sequencing kit (PE Applied 
Biosystems, Warrington, UK) and 25 ng oligonucleotide primers (Table 2.2). The 
sequence reaction was performed by mixing 1 pg of plasmid DNA, 3.2 pmoles of primer, 
8 pi premix from dye terminator cycle sequencing kit up to 20 pi. PCR was performed with 
the following conditions in Perkin Elmer 9600: Preheat to 96 °C, 96 °C 15 seconds, 50 °C 1 
seconds, 60 °C 4 minutes, and 25 cycles hold at 4°C
After amplification, the PCR product was transfered to a 0.5 ml eppendorf tube and 
precipitated by adding 2 pi of 3M Sodium Acetate (pH4.5) and 50 pi 100% ethanol. Dye 
labelled products were resolved and detected using the Applied Biosystems DNA 
sequencer ABI373 that was performed by Beatson Institute technical service staff. The 
sequence data was collected and analysed by using the Sequencing Analysis program 
v3.0 and ABI software.
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2.3.4 Quantitation of plasmid DNA for transfection
The concentration of nucleic acid in a solution was determined spectrophotometrically in a 
Beckman D U  650 spectrophotometer. Samples were diluted in TE and transferred to a 
quartz cuvette with a pathway of 1 cm. The spectrophotometer was initially calibrated 
using TE buffer only as a blank. The opticlal density reading were obtained a t 260 nm 
and 280 nm; an O .D .  reading of 1 at 260 nm ( A 26o= 1 )  corresponds approximately to a 
concentration of 50 pg/ml of double stranded D N A ,  for oligonucleotides an A 260 of 1 was 
taken to correspond to 35 pg/ml, and for R N A  an A 260 of 1 was taken to correspond to 40 
pg/ml. The ratio between reading at 260 nm and 280 nm ( O D 260: O D 280) provided an 
estimate of the sample purity: samples with ratio of between 1.8 and 2.0 were taken as 
being sufficiently pure for all the techniques undertaken in this study.
To use equal amount of mutant constructs for transfection assays, plasmid DNA was 
carefully diluted and quantitated via UV spectrophotometer first, then 1.5 pg of mutation 
plasmid DNA was used for Xho I/Hind III restriction enzyme digest at 37 °C for 1 hours. 
The samples were loaded onto an 6% PAGE gel and electrophoresed to detect 176 bp 
products. After EtBr (10 mg/ml) staining, the gel was visualised in UV light and insert 
amount of each DNA sample was analysed by a computing Phosphorlmager with 
ImageQuant analysis software (BioRad).
2.4 Cell Culture and Reporter Gene Assays
2.4.1 Mammalian cell lines
5637 cell line, originally established from the primary bladder carcinoma of a 68-years-old 
man in 1974, purchased from DSMZ (No: ACC 35). Swiss 3T3 feeders (ATCC CCL92), 
originally established in 1962 by G. Todaro and H. Green (Todaro and Green, 1963), are 
an immortalised mouse fibroblast cell line which were a kind gift from Rosewlyn 
McCaffery, Beatson Institute for Cancer Research, Glasgow. All cell lines used in this 
study are listed in Table 2.6.
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Table 2. 6 Cell lines in this study
Cell type Origin Rb status1 Telomerase
activity
HeLa Cervical carcinoma HPV 18 E7-pRB Positive Immortal cell
5637 Bladder carcinoma Gross rearrangement Positive Immortal cell
C33A Cervical carcinoma Partly deleted exon 20 Positive Immortal cell
GM847 Established fibroblast SV40 Negative Immortal cell
WI38 Diploid fibroblast Normal Negative Mortal cell
IMR90 Diploid fibroblast Normal Negative Mortal cell
CMo>
<
Areolar Adipose Positive Immortal cell
Swiss 3T32 Established fibroblast Positive Immortal cell
1Original references on pRb gene and protein status can be found in Bartek et al., 
(1992) and Lukas et al., (1994). In the cell lines expressing DNA virus oncogenes, pRB 
is inactivated through protein-protein sequestration (For review see Aagaard, 1995)
2AII cell types are of human origin, except for Swiss 3T3 and A9 (mouse).
2.4.2 Cell maintenance and storage
All cell lines were grown in medium supplemented with 10% FCS (450 ml suitable 
medium, 5 ml 200mM Glutamine, 2.5 ml Streptomycin/ Penicillin and 50 ml 100% FCS). 
Cell lines were trypsinized in 1.0 ml of PE/trypsin and resuspended in growth medium with 
10% FCS and divided to an appropriate number of dishes.
Parental cell lines and transfected stable cells were kept in liquid Nitrogen for long term 
storage. For such a purpose cell lines were washed once with PBS and 1 ml of PE/trypsin 
solution was added to the plate. After trypsinisation cells were centrifuged for 5 minutes at
1,000 rpm at room temperature and the trypsin-containing medium aspirated. For one 10 
cm dish 1 ml freezing solution (90% FCS, 10% DMSO) was added, mixed and the aliquot 
placed into a 2 ml Nunc tube and directly were transferred to -70 °C. After 2-4 days the 
aliquots were placed in liquid nitrogen barrels. To recover cells from nitrogen, vials were 
thawed in 37 °C dH20  and resuspended in growth medium with 10% FCS, centrifuged for 
5 minutes at 1,000 rpm at room temperature and the DMSO-containing medium 
aspirated. Immediately after this step, the cells were resuspended in growth medium with 
10% FCS and plated to 10 cm dishes.
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2.4.3 SuperFect Transfection
The day before transfection, 2-3 X 105 cells were seeded in each well of six-well plates (~ 
9.5 cm 2) in 2 ml of appropriate growth medium, and incubated at 37°C and 5% C02 
overnight to give 40% to 80% confluence. 1.5 pg of construct was dissolved in TE pH 8.0 
with cell growth medium containing no serum to a total volume of 75 pi. For co­
transfection of each individual site-mutation Luc-reporter construct, 3 pg plasmid DNA 
was mixed with 3 pg of Sp1, Sp3, pCMVb or 0.5 pg of NF-YAm29 expression vector, or 
0.25 pg pRb vector. 7.5 pi Superfect™ Transfection Reagent (QIAGEN) was added to the 
DNA solution and mixed by pipetting up and down 5 times. The mixtures were incubated 
for 10-15 min at room temperature to allow complex formation. Then, 0.4 ml cell growth 
medium (containing 10% FCS and antibiotics) was added to the tube containing 
transfection complexes and mixed by pipetting up and down twice. Growth medium was 
gently aspirated from the plate and the cells were washed once with 2.0 ml PBS. The 
complexes were immediately transfered to the cells and incubated with cells for 2-3 hours 
at 37 °C with 5% C02 in an incubator. Then, the medium containing the remaining 
complexes was removed from cells, and cells were washed once with 2 ml PBS, replaced 
with fresh 10% FCS growth medium, and incubated for a further 48 hours.
2.4.4 Luciferase activity assay
Cells were harvested for analysis after 48 hours transfection. Equivalent amounts of 
cellular protein as determined by Bio-Rad assay (BioRad), were used in the luciferase 
assay. Luciferase assays were performed according to the manufacturers protocols. 10 pi 
of cell extract was mixed with 50 pi of room temperature Luciferase Assay Reagent 
(Promega E1500). The reaction was placed in a luminometer or scintillation counter to 
measure the light produced for 10 seconds to 5 minutes. To ensure reproducibility in the 
assays, particular care was taken over the following: DNA was quantified by 
spectrophotometry and direct visualisation by gel electrophoresis. All transfections were 
carried out in duplicate wells and we found this to be a good measure of the
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reproducibility of transfection. In each experiment, all deletion constructs were analysed 
together with both the basic cloning vector, pGL3-Basic, and the positive control vector, 
pGL3-Control, which contains SV40 promoter and enhancer sequences. Each extract 
was measured for luciferase activity at least twice. All transfections were carried out at 
least three times. Initial transfection conditions were determined by using promoter 
fragments linked to a green fluorescent protein (GFP) reporter gene (Clontech), as this 
allowed direct visualisation of promoter activity in live cells. The means and standard 
deviations of duplicate samples from representative transfections are shown and all 
experiments were carried out at least three times in duplicate.
2.4.5 SEAP reporter gene assay
A useful reporter, which is the secreted form of human placental alkaline phosphatase 
(SEAP), was used in transient transfections as an internal control against which the 
efficiency of transfection can be adjusted for (Clontech, cat. # 6049-1). An important 
advantage of this reporter for some purposes is that the reporter protein is secreted into 
the culture medium, allowing reporter detection without cell lysis. 1.5 pg SEAP plasmid 
DNA was co-transfected with the construct of interest using Superfect™ Transfection 
Reagent (QIAGEN). 48 post-transfection, SEAP protein maintained in culture was 
quantified by chemiluminescent detection, using Clontech's kits. The transfected cells can 
be harvested for luciferase assay at a later time. SEAP activity assays were performed 
according to the manufacturers protocols.
2.4.6 PCR quantitation of plasmid DNA for transfection
The Great EscApe™ SEAP System (Clontech) was used to control for transfection 
efficiency in experiments with the mutant promoter constructs. In keeping with others the 
Sp1 and Sp3 expression vectors modulated the activity of the SV40 promoter used in the 
pSEAP2-Control vector (Conn et al., 1996; Chen et al., 1998). For these experiments
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semi-quantitative PCR of transfected plasmid was carried out using luciferase specific 
primers (for primer sequence see Table 2.2) and products adjusted relative to input 
genomic DNA.
The nuclear pellet after luciferase assay was directly resuspended in 50 pi of Lyse-N- 
Go™ PCR Reagent (PIERCE, #78882) and homogenised by pipetting the sample up and 
down. Then, a thermal cycling program was performed for up to three cycles as follows: 
65 °C for 30 seconds; 8 °C for 30 seconds; 65 °C for 90 seconds; 97 °C for 180 seconds; 
8 °C for 60 seconds; 65 °C for 180 seconds; 97 °C for 60 seconds; 65 °C for 60 seconds; 
then hold on 80 °C for about 20 minutes. I.O pi of lysis sample was used as template for 
25 pi total volume of PCR amplification by adding luciferase specific primers or GAPDH 
primers (suppled in Sentinel™ Molecular Beacon GAPDH Detection kit, Cat~200571; 
Stratagene). The cycling protocol consisted of : (i) 25 cycles of three temperatures for 
amplification of luciferase DNA, strand denaturation at 95°C for 30 seconds, primer 
annealing at 60 °C for 50 seconds and primer extension at 72 °C for 40 seconds, (ii) one 
cycle of 95°C at 3 minutes for denaturation of genomic GAPDH DNA, followed by 30 
cycles of three temperatures for amplification of genomic GAPDH DNA, 95°C for 15 
seconds, primer annealing at 60 °C for 30 seconds and primer extension at 72 °C for 60 
seconds. After PCR, 10 pi aliquots of the mixture, typically, were analysed by agarose 
gel electrophoresis and by a computing Phosphorlmager with ImageQuant software 
(BioRad).
2.5 DNA-Protein Interaction
2.5.1 Preparation of nuclear protein extracts
Nuclear protein preparation: Approximately 1010 cells were washed in PBS and then twice 
with TMS (5 mM Tris-HCI pH 7.5, 2.5 mM MgCI2, 125 mM sucrose). Cells were lysed in 
200 ml of TMS plus 0.25% Triton X-100, and nuclei were harvested by centrifugation 
(1,600 x g, 20 minutes). Nuclei were washed three times in 200 ml of TMS and
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resuspended in approximately 5 ml of TMS (5 to 10 mg of DNA per ml), and 0.1 volumes 
of 4 M NaCI was added dropwise with stirring. The solution was centrifuged at 10,000 x g 
for 20 minutes, and the supernatant was spun at 10,000 x g for 60 minutes. Solid 
ammonium sulfate was added to 0.35 g/ml and left on ice for 30 minutes. The precipitate 
was pelleted at 10,000 x g for 30 minutes and re-dissolved in 5 ml of E50 buffer (50 mM 
ammonium sulfate, 20 mM HEPES, pH 7.9, 5 mM MgCI2, 0.1 mM EDTA, 0.1%[v/v] Brij 
35, 20%[v/v] glycerol, 1 mM DTT) and dialysed for 16 hours against 1 litre of storage 
buffer (50 mM NaCI, 20 mM HEPES, pH 7.9, 5 mM MgCI2, 20%[v/v] glycerol, 1 mM DTT). 
The crude protein extract was cleared by centrifugation at 10,000 x g for 60 minutes, and 
aliquots were stored at -70°C.
A microscale technique for the preparation of DNA-binding protein was also employed for 
electrophoretic mobility shift assays (EMSAs). Where possible, microscale and large- 
scale nuclear protein preparation were compared in EMSAs and found to produce 
identical results. All manipulations were carried out on ice, and all solutions contained 0.5 
mM phenylmethylsulfonyl fluoride, 0.5 mM benzamidine, 10 mM sodium butyrate, 10 mM 
jS-glycerophosphate, 2 mM levamisole, 50 mM sodium orthovanadate, pH 8.0, and 1 ug 
(each) of leupeptin, aprotinin, bestatin, and pepstatin per ml.
2.5.2 In vitro DNase I footprinting
As shown in Figure 2.1, plasmid pLh2223(-272/+69) or pLh2123(-628/+69) were used for 
the hTERC promoter DNA footprint analysis and pL2530 (-188/+80) was used for the 
m7erc promoter DNase I footprinting analysis. Digestion of pLh2223 and pL2530 plasmid 
with Xho I/Hind III, pLh2123 with Xho l/EcoR I or EcoR I/Hind III released the promoter 
fragment to be investigated. The sense strand was labelled by filling in the Xho I (or EcoR 
I) site by using Klenow fragment in the presence of [a-32P]dATP (Amersham), and the 
antisense strand was labelled by filling in the Hind III (or EcoR I) site.
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Figure 2.2 The strategy for DNase I 
footprinting analysis of h TERC 
promoter
The footprinting protocol was performed 
according to the SureTrack Footprinting Kit 
instructions (Pharmacia Biotech, XY-029- 
00-05). Labelled DNA (-20 ,000 cpm) was 
incubated for 30 minutes with 2 pg of 
poly(dl-dC) and 80 pg of nuclear protein 
extract in a final volume of 50 pi (8% 
glycerol, 20 mM Tris-HCI pH7.5, 100 mM 
NaCI, 5 mM MgCI2 and DTT). For 
competition experiments oligonucleotide competitors (100-fold molar excess) were 
included in the binding reaction. To determine the optimal conditions, a titration was 
performed for each probe using increasing concentrations of DNase I for the same 
amount of nuclear extract. 5-10 milliunits of DNase I in DNase I buffer (2 mM MgCI2, and 1 
mM CaCI2) were added and, following a 2-minutes incubation at room temperature, the 
reaction was terminated by the addition of 140 pi of DNase I stop solution (192 mM 
sodium acetate, 32 mM EDTA, 0.14% SDS and 64 pg/ml yeast RNA). After a 10 minute 
incubation at room temperature reactions were extracted twice with 
phenol/chloroform/isoamylalcohol and ethanol-precipitated before analysis in a 6% 
polyacrylamide, 7 M urea sequencing gel. DNA-protein complexes were autoradiographed 
on Kodak X-Omat films. For G+A sequence markers, the radiolabeled DNA was added to 
4 pi of a standard sequencing gel loading buffer consisting of demonised formamide 
(98%), 0.05% each of Bromophenol blue and xylene cyanol FF and 20 mM Tris acetate 
adjusted to the desired pH 8.0. The samples were heated at 95°C for 20 minutes, cooled 
on ice and then loaded onto a sequencing gel (Song et al, 1997).
Xho I (-628) EcoH  I (-306) H lnd  111 l 'l'69)
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312 bp In length 
of Fragment I
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2.5.3 Oligonucleotide and EMSA
2.5.3.1 Oligonucleotide Design
Depending on the DNase I footprinting results, new oligonucleotide has been designed. 
Synthesise the oligonucleotide on either the ABI 392 or the Beckman Oligo 1000 
automated DNA synthesizers according to manufacturers' instructions (Genosys 
Biotechnologies, Europe, Ltd). Single-stranded oligomers and their complementary 
sequences corresponding to the wt or mutants were synthesised as shown in Table 2.3 
and 2.4. Computer program (described in section 2.6) analysed to prevent new DNA- 
binding site when mutagenesis wt DNA-binding site. The human Sp1 double-stranded 
oligodeoxynucleotide corresponding to the Sp1 consensus sequence 
ATTCGATCGGGGCGGGGCGACC was purchased from Promega. The some consensus 
oligonucleotides are shown in the Table 2.2.
2.5.3.2 Annealing and gel purification o f oligonucleotides
To anneal the two complementary oligonucleotides, equal molar quantities of 
oligonucleotides were mixed in dH20  or TE buffer, the oligomers were treated at 95 °C for 
5 minutes in either the Perkin-Elmer Cetus DNA Thermal Cycler or the Perkin-Elmer 
Cetus Cycler 9600, then the Cycler was switched off to cool down slowly (about 4.5 
hours). Annealing oligonucleotides were loaded in the 12% PAGE gel and run for 1 hour, 
DNA band was excised and placed into a 10 ml tube with 1 ml TE and allowed to elute 
overnight with agitation. The eluate was filter-treated through a pre-wetted acrodisk (0.2 p 
m) (GelmanSciences), the eluate was collected and then 5 ml butanol was added. The 
mixture was vortexed for 30 seconds and spun at 3,500 rpm for 5 minutes. Organic (top) 
phase was removed and aqueous phase was placed into an eppendorf tube and the 
volume was adjusted to 500 ul with TE (pH8.0), followed by phenol/chloroform extraction 
and ethanol precipitation with 10 mM NaACO. After incubation at -20 °C overnight, the 
sample was spun 13,000 rpm for one hour, pellet was washed in 100 pi 70% (v/v) 
ethanol. Oligonucleotides were resuspended in TE (pH 8.0), the concentration of the
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double-stranded oligonucleotide solution was measured spectrophotometrically and 
diluted with TE buffer to give a final concentration of 0.1 mg/ml. Oligonucleotide solutions
were stored at -20 °C. Annealing oligonucleotide concentration was determined as 
described in section 2.3.4.
2.5.3.3 End labelling o f double-stranded oligonucleotides
A typical 5'-kinase labelling reaction included the DNA to be labelled, [y32-P] dATP 
(Amersham), T4 polynucleotide kinase, and buffer (Promega). The components of the 
labelling reaction were added in the order listed:
Sterile d H2O 5 Ml
10X kinase buffer 1 Ml
DNA or oligonucleotide (50 pm) 2 Ml
[y32-P] dATP (10 mCi/ml) 1 Ml
T4 polynucleotide kinase (3 U/ul) 1 Ml
Total volume 10 Ml
After incubation at 37 °C, reactions were heat inactivated by incubation at 80 °C for 15 
minutes. Portions of the reactions were mixed with gel loading dye and loaded into a well 
of 6% non-denaturing polyacrylamide gel [15%(v/v) 40%(w/v) acrylamide: 2.1%(w/v) 
bisacrylamide, 0.5 X TBE (89 mM Tris base, 89 mM orthoboric acid, 2 mM EDTA, pH 
8.0), 0.07% APS, 0.08% TEMED] and electrophoresed for 60 minutes at 150 volts.
The position of each radiolabelled oligonucleotide was determined by exposing the gel, 
covered with cling film, to a sheet of Kodak XAR-5 film for 1-2 minutes. Using the X-ray 
film as a guide, the band containing the labelled probe was excised from the gel using a 
clean scalpel blade, The gel slice was transferred to a clean eppendorf tube and TE 
buffer was added to the tube sufficient to cover the gel slice. The tube was placed in a 
lead pot, sealed and left at room temperature overnight during which time the 
oligonucleotide eluted from the gel slice into the TE buffer. The polyacrylamide gel slice
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was removed from the solution using QIAquick spin columns (QIAGEN). The radioactive
oligonucleotide solution was quantified and stored at -20 °C.
2.5.3.4 EMSA, competition and supershift assay
5.5 pg HeLa nuclear extract protein was incubated in 15 pi of reaction containing 4% 
glycerol, 1 mM M gC^ 0.5 mM dithiothreitol (DTT), 0.5 mM EDTA, 50 mM NaCI, 10 mM
Tris-HCI, pH7.5 and 2.0 pg poly(dl-dC) with or without excess moles of unlabelled DNA 
competitors on ice for 10 min, followed by addition of 5,000-10,000 cpm of the probe.
For competition experiments, non-radioactive double-stranded oligodeoxynucleotides 
were added in 100-fold molar excess prior to addition of the probe. For supershift assays, 
1 or 2 pi of antibodies specific against Sp1, Sp3, Rb, Ap-2, c/EBP, c-Ets-2, NF-1, CBF 
(Santa Cruz Biotechnology), or NF-YA and NF-YB (PharMingen and Dr Mantoviani) were 
added to the reaction mixtures 25 minutes prior to the addition of the probe, then reaction 
mixture were incubated at room temperature for 1 hour or 4 °C overnight. All DNA-protein 
complexes were resolved on 5% native polyacrylamide gels running in 22.3 mM Tris, 22.3
mM boric acid, and 0.5 mM EDTA. Samples were electrophoresed at 150 volts at 4°C 
until the blue dye front in the tracking wells was about 3cm from the end of the gel. The 
gel was transferred onto Whatman 3MM filter paper and dried down on a Biorad 583 gel 
drier at 80 °C for 45 minutes using a slow rise in temperature. Visualisation of the dried 
gel was performed using both a computing Phosphorlmager with ImageQuant software 
analysis (BioRad) and autoradiography on Kodak XAR-5 films.
2.6 Computer Program Analysis
Homology searches were carried out using BLAST (Basic Local Alignment Search Tool), 
National Centre for Biotechnology Information (NCBI): http://www.ncbi.nlm.nih.gov/ (see 
appendix V). Nucleotide sequences were analysed by using programs devised by the
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University of Wisconsin Genetics Computer Group (UWGCG). Sequence comparisons 
were used the COMPARE program and were graphically displayed using the DOTPLOT 
program in the UWGCG package. Sequences were analysed for potential transcription 
factor binding sites by TESS: Transcription Element Search Software on the WWW, 
Jonathan Schug and G Christian Overton, Technical Report CBIL-TR-1997-1001-vO.O, of 
the Computational Biology and Informatics Laboratory, School of Medicine, University of 
Pennsylvania, 1997. Identification of CpG islands was carried out using GRAIL: Gene 
Recognition and Assembly Internet Link, http://compbio.ornl.gov/ Grail-1.3/.
Sequence alignment and phylogenetic comparative analysis of 5' flanking transcription 
region of the 21 mammalian TERC genes were manually aligned using Vector NTI Suite 
program (InforMax). The sequences of closest relatives were aligned first on the basis of 
primary sequence similarity, The comparison of hTERC with other TERC gene promoter 
sequence were also used Gap or Fasta program in GCG package (UWGCG) to help align 
divergent regions. Each of aligned sequences was then aligned against each of the other 
groups. Sets of highly conserved nucleotides were identified and used as markers for 
aligning the more variable regions. The full sequences identified in present study have 
been submitted to GenBank, accession numbers AF047386, AF047387 and AF176663 
(see appendixes I II and VI).
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Chapter 3 Cloning of the h TERC and mTerc promoter 
regions
The regulation of telomerase is a complex issue and has been reviewed in previous 
chapter. The results presented in this chapter begin to address the biological question as 
to whether telomerase RNA gene expression involves transcriptional control. In order to 
examine the transcriptional regulation of the TERC genes, genomic clones encompassing 
the TERC genes were identified and characterised (strategy shown in Figure 3.1).
3.1 Introduction
Telomeres are found at the end of linear chromosomes and consist of short repetitive 
sequences essential for the maintenance of normal chromosome structure and function 
(Wellinger and Sen, 1997). With each cell division, telomeres shorten due to the inability 
of DNA polymerases to replicate the ends of linear DNA molecules. However, telomere 
erosion is counteracted by the activity of the enzyme telomerase, a ribonuclear protein 
with reverse transcriptase activity, which adds telomeric repeats to the chromosomal 
termini (Morin, 1997; Nakamura et al., 1997). The genes for the human, (hTERC), and 
mouse, (mTerc), RNA components have been cloned, as has the human protein 
component; (hTERT) (Blasco et al., 1995; Feng et al., 1995; Nakamura et al., 1997; 
Soder et al., 1997a,b). Whilst telomerase expression is detectable in normal embryonic 
tissues and germ line stem cells, telomerase expression is repressed in most normal 
postnatal somatic cells (Blasco et al., 1995; Feng et al., 1995; Prowse and Greider, 1995; 
Soder et al., 1998; Wright et al., 1996a). The lack of telomerase expression may be the 
major reason for the progressive loss of telomeric sequences in somatic cells, which is 
considered to be one regulatory mechanism which monitors the number of times a cell 
divides before entering replicative senescence (Campisi, 1997). However, although 
telomerase appears to be stringently repressed in normal somatic tissues, there is 
substantial evidence to suggest that telomerase is expressed in the majority of human
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cancers and contributes to the immortal phenotype through the maintenance of telomere 
integrity (Holt et al., 1997; Kim, 1997; Shay and Bacchetti, 1997).
The regulation of telomerase activity is likely to be a complex issue including control of the 
transcriptional activity of the telomerase RNA and protein component genes, interaction of 
telomerase with other telomere associated proteins and post-translational modification of 
the enzyme complex. Identification of the regulatory regions of the h TERC promoter 
sequence will be essential in understanding the molecular mechanisms of positive and 
negative regulation of telomerase RNA gene expression. There are few studies that 
directly address the mechanisms regulating telomerase expression in normal and cancer 
cells (Bodnar et al., 1996; Broccoli et al., 1997a; Li et al., 1997; Mandal and Kumar, 1997; 
Morin, 1997; Nakamura et al., 1997; Soder et al., 1998). In this chapter, genomic DNA 
sequences encompassing both the human and mouse telomerase RNA genes have been 
cloned in order to identify the functional promoter regions.
3.2 Cloning genomic sequences of the h TERC and m Terc genes
Our group have previously reported the identification of P1 genomic clones for the 
human, (hTERC), and mouse, (mTerc), telomerase RNA genes (Soder et al., 1997a,b). In 
order to obtain sequences flanking the genes, the P1 genomic clones were digested with 
EcoR I and Hind III, subcloned into the plasmid vector, pPCR script (+SK), and colonies 
containing hTERC or mTerc sequences identified by hybridisation to PCR generated 
probes specific for the genes. A 1.3 kb genomic clone encompassing hTERC was isolated 
as was a 4 kb genomic clone encompassing mTerc (Figure 3.2).
A BLAST search using the 1.3 kb human sequence identified three high-scoring segment 
pairs: HSU85256, HSU86046 and MMU33831. HSU85256 (598 bp of sequence) and 
HSU86046, (545 bp of sequence), are published sequences for the transcribed region of 
the human telomerase RNA gene and confirmed that we had cloned genomic sequences 
encompassing hTERC (Bryan et al., 1997; Feng et al., 1995). MMU33831 is the
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sequence of the transcribed region of the mouse telomerase RNA gene that has 
previously been shown to have homology to the human gene (Blasco et al., 1995). In 
addition to the BLAST search, a text search for telomerase sequences carried out on the 
NCBI database revealed a 2.4 kb sequence, (131750), from US patent number 5583016, 
(Inventors: Ville-ponteau B, Feng J, Funk W and Andrews WH, assigned to the Geron 
Corporation), which aligned with the Hind III site at the 3’-end of our genomic clone and 
extended 5’ to the EcoR I site in our clone and thus completely overlapped the sequence 
of our 1.3 kb clone with only minor base differences. The sequence of P1 clone 5’ to the 
EcoR I site was extended by designing a PCR primer, hProm867 from the patent 
sequence and cloning and sequencing the PCR product using the P1 clone as a template. 
In total 1765 bp of sequence information encompassing the human telomerase RNA gene 
has been generated and a schematic representation of this is shown in Figure 3.2a. Thus 
the sequences in both the 3' and 5' flanking regions of h TERC have been extended and 
have confirmed the unpublished patent sequence.
_D N A  (ragmen!
j j  "U , y* (> Hum an or m ouse
genom ic cDNA 
library
Human and mouse 
genom ic P1 clones
1 Clone DNA fragm ents conta in ing  h TERC 
or m Terc sequences
2 Hybrid ization and sequencing ana lysis to 
confirm  hum an or m ouse TERC gene
3 C om puter program  ana lys is  predicts 
potentia l p rom oter region and potentia l 
transcription facto r b ind ing sites
4 Define the tem plate  region and 
transcrip tion  start site
5 Design PCR prim ers for 5' and 3' flanking 
end deletion
6 PCR am plifica tion
7 C lon ing the PCR fragm ent into a reporter 
vecto r (GFP o r Luciferase gene)
tem plaie
8 Functional assays for the characte risa tion  
of d istant contro l regions by transient 
transfection ana lysis
9 Define the m inim um  prom oter region
•Successful development of promoter activity in 
human and mouse cell lines 
•Demonstration of involvement of transcriptional 
mechanism in hTERC and mTerc gene regulation
Figure 3.1 Strategy for characterising the 
functional prom oter region
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a) Human telomerase RNA gene, h TERC, genomic structure, 1765bp.
hProm341 (-272) hProm176 (-107)
hProm505(-436) 
hProm540(-473) \
hProm697(-625)
hProm867(- 798] ■+¥
hProm120(-57) 
|hProm(+69) 
template  
^TERC
Pst 1 (1513)
{ r H i n d  I I I  (1 7 6 1 )
(601 CpG island (1 3 3 3 )
b )  Mouse telomerase RNA gene, m Terc, genomic structure, 4044bp.
m Prom 208('-/29) 
m Prom 267(-788) 
mProm418(-339) 
mProm458('-379) 
mProm628 (-519)
Pst 1 (2 8 )
H ind  I I I  (2 ) ~jj j
m P r o m 1 3 6 ( -5 7 )
template
mProm (+30) 
mTerc^'
Pst I (1660) 
Pst I (1988) 
Pst I (2555)
Hand I I ( 3449)
, EcoR  I (4040)
(1 4 6 6 )  (2 1 2 4 )
CpG island
Figure 3. 2 Restriction enzyme map of the h TERC and mTerc genom ic 
clones
Restriction enzyme map of the genomic clones encompassing the human, (a), and 
mouse, (b), telomerase RNA genes. The transcribed regions of h TERC and m Terc are 
depicted as red boxes within the central regions of the genomic sequences. The site of 
the template sequence within the telomerase RNA genes is indicated. The positions of the 
CpG islands are shown as a blue box beneath the genomic sequence. Numbers in 
brackets refer to the nucleotide position within the sequence. All the human promoter 
fragments are shown as hProm at the 3'-ends and fragments extend 5-prime to; 
hProm867, hProm697, hProm540, hProm505, hProm341, hProm176 and hProm120. All 
the mouse promoter fragments are shown as mProm at the 3'-end and fragments extend 
5-prime to; mProm628, mProm458, mProm418, mProm267, mProm208 and mProm136. 
The numbers after the prefix hProm or mProm refer to the number of nucleotides of 
genomic sequence contained in the promoter fragment, and numbers in brackets refer to 
distance from TSS. The 5’-end deletion constructs are listed in Table 3.1.
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DOTPLOT OF: m T e r c /h T E R C ,pnt Density: 3371.67 
COMPARE window: 18 Stringency: 12 Points: 3,075
A
mTerc.Seq c k :  1 , 2 7 7 .  1 t o  4 ,0 4 4
B
hTERC ck: XI6io 1231
Figure 3.3 Genomic sequences comparison between hTERCand m Terc
(A) An overview comparing h TERC  (vertical) and mTerc (horizontal) 5’ and 3' flanking 
region sequence is shown where each dot represents significant nucleic acid sequence 
sim ilarity of two genes. The genomic sequence was compared using the COMPARE 
program (window 18, stringency 14) and graphically displayed using the DOTPLOT 
program in the UWGCG package. The zoom-up window for the boxed area in (B) is 
shown with comparison between nucleotides 816 to 1231 bp of hTERC and 1534 to 1943 
bp of mTerc in the transcribed region: this region indicates 70.4% sequence identity.
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A BLAST search using the 4 kb mouse sequence identified both the published human 
gene sequences, (HSU85256, HSU86046) and the published sequence for the 
transcribed region of the mouse gene, MMU33831, (590 bp of sequence) (Blasco et al., 
1995; Bryan et al., 1997; Feng et al., 1995). In order to confirm that the genomic 
sequence obtained from the P1 subclone was genuine, 5’-flanking sequences were 
cloned using genomic DNA from Balb/c mice in PCR reactions. Sequence analysis of the 
Balb/c clones was identical to the P1 sequence except for minor polymorphisms. Thus the 
published sequence for the coding region of the mouse telomerase RNA gene have been 
extended in both the 3’ and 5’ flanking regions of mTerc. A schematic representation of 
the 4 kb of sequence information encompassing the mouse telomerase RNA gene is 
shown in Figure 3.2b.
3.3 Analysis of nucleotide sequence
3.3.1 Genomic cloning sequences of hTERC and mTerc
The nucleotide sequences of the human and mouse telomerase RNA genes were 
determined from cloning obtained using PCR products. The human telomerase RNA gene 
clone is 1765 nucleotides in length and has a base composition of 22.9% A, 26% C, 
27.1% G and 24% T. The 450 bp of published hTERC RNA sequence (Feng et al., 1995) 
was found to start at 799 and end at 1248 bp within this 1.7 kb clone. The template 
sequence of RNA, CTAACCCTAAC, is located between nucleotide 844 and 854 bp. The 
mouse telomerase RNA gene genomic clone is 4044 nucleotides in length and has a 
base composition of 25.3% A, 23% C, 24% G and 27.7% T. The 429 base pair of 
published mTerc RNA sequence (Blasco et al., 1995) was found to start at 1524 bp and 
end at 1952 bp. The template sequence, CTAACCCTG, is located between nucleotide 
1560 and 1568 bp. The full sequences have been submitted to GenBank, accession 
numbers AF047386, AF047387 (See appendix I and II). Thus nucleotide sequences are 
now available for investigation of the function of the human and mouse telomerase RNA 
gene promoters to determine the fine mechanisms of transcriptional regulation.
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3.3.2 Comparison of hTERC and mTerc gene sequences
To investigate the similarity of the human and mouse genomic clones, sequence 
comparisons were carried out. The transcribed regions of the two genes showed 67% 
identity in keeping with the published estimate (Feng et al., 1995). However, no significant 
sequence identity could be identified in either the 5’- or 3’-regions flanking the transcribed 
sequences as shown in Figure 3.3A. The comparisons described here highlight the 
conserved transcribed regions of two RNA genes as shown in Figure 3.3B
Both the human and mouse sequences were analysed for CpG islands by GRAIL. CpG 
islands were defined as regions larger than 200 bp, with an average GC content greater 
than 50% and the ratio of observed versus expected CpGs greater than 0.6 (Gardiner- 
Garden and Frommer, 1987). Interestingly, both the human and mouse genes lie within 
CpG islands, (see Figure 3.2). The human gene is covered by a CpG island 733 bp in 
length, with a GC content of 6 6 % and a ratio of observed versus expected CpGs of 0.89. 
A CpG island of 659 bp in length, with a GC content of 64%, covers the mouse gene and 
a ratio of observed versus expected CpGs of 0.81.
3.4 Detection of the hTERC and mTerc promoter region
3.4.1 Search for the potential transcription factors
The 5’-flanking regions of the human and mouse telomerase RNA genes were analysed 
for potential transcription factor recognition sites by using computer software described in 
section 2.6. As shown in Figures 3.4a and b, a number of potential binding sites were 
identified, including consensus sequences for glucocorticoid/progesterone/androgen 
receptor binding, AP1 and Ets family members. TATA and CCAAT boxes are found in 
both genes close to the published transcriptional start sites (Feng et al., 1995; Hinkley et 
al; 1998).
Analysis of the sequence around the transcriptional start site (TSS) region revealed that 
the hTERC gene promoter consists of a G+C-rich sequence extending from -107 to +69
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bp (GC content, 64.7%). This region contains a TATA-box at position -28 to -25 bp, one 
CCAAT-box at position -58 to -54 bp, three putative Sp1 binding sites and two Ap1 
binding sites at position -93 to -83 and -70 to -64 bp (Figure 3.4a). The G+C-rich region of 
the hTERC gene promoter is shorter and its GC content is higher than that of the mTerc 
gene promoter (-129 to +80, 58.2%).
The mTerc gene potential promoter also consists of a G+C-rich sequence extending from 
-129 to +80 bp (GC content, 58.2%) but differs from the h TERC promoter in that it lacks a 
sequence between TSS and template region (Hinkley et al., 1998; Figure 3.4b).A TATA- 
box is present at -30 to -25 bp, with one inverted Sp1 binding site at position -17 to -12 
bp ( 8  of 10 matching the Sp1 consensus) and one CCAAT-box located at position -53 to - 
49 bp. Three Ap2 sites are present, two of these overlap with two c-ETS-2 sites. These 
are clustered between -110 to -79 upstream of the transcription start site. One putative 
Sp1 binding site is present downstream of TSS. The mouse promoter region also 
contains a run of CpA dinucleotide repeats that may be of use in developing microsatellite 
genetic markers for this gene.
3.4.2 Series deletion mutants for the potential promoter
To identify whether the 5’-flanking region of the telomerase RNA genes exhibits promoter 
activity, sequences were fused to a firefly luciferase reporter gene, (pGL3-Basic). The 
transcriptional start sites for both the human and mouse telomerase RNA genes have 
been established (Feng et al., 1995; Hinkley et al., 1998). Various promoter constructs 
containing the transcriptional start site were therefore generated (Figures 3.2, 3.4 and 
Table 3.1).
hProm867 contains the hTERC promoter from -798 to +69 bp upstream of the luciferase 
gene of pGL3 basic (Promega). The shortest h TERC promoter hProm120 was created by 
using an oligonucleotide corresponding to the hTERC sequence from -51 to +69 bp 
relative to the transcriptional start site (Feng et al., 1995). Similar luciferase reporter
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constructs were created from h TERC regions -628/+69, -471/+69, -436/+69, -272/+69 
and -107/+69 (Figure 3,2a, Table 3.1). To clone the largest h TERC 5’-flanking promoter 
region (pLhK26, -5.0 Kb/+69), 0.6 Kb Xho I/Not I fragment of hProm(-798/+69) was 
replaced by about 4.4Kb of Xho I/Not I fragment from Dr Karen Steeghs, (Beatson 
Institute). pLhE26(-2.5 Kb/+69) was constructed by deletion of EcoR V fragment from 
pLhK26.
Table 3.1 The 5’ end deletion constructs of hTERC and mTerc
hTERC deletion constructs mTerc deletion constructs
Name Other name Position Name Other name Position
pLhK26 None -~5.0kb to +69 pL1658 None -1693 to +80
pLhE26 None -~2.5kb to +69 pL2730 mProm628 -549 to +80
pLh2023 hProm867 -798 to +69 pL2930 mProm458 -379 to +80
pLh2123* hProm697 -628 to +69 pL2830 mProm418 -339 to +80
pLh5F23 hProm540 -471 to +69 pL2530* mProm267 -188 to +80
pLh1417 hProm505 -436 to +69 pL2630 mProm208 -129 to +80
pLh2223* hProm341 -272 to +69 PL3630 mProm136 -57 to +80
pLh2923 hProm176 -107 to +69 pL2534 mProm 196 -188 to -8
pLh26n23 hProm 120 -51 to +69 pL2537 mProm154 -188 t o -34
* These constructs were used for DNase I footprinting analysis. Position refers to the 
transcriptional start site.
The mProm628 reporter construct containing -549 to +80 bp of mTerc gene promoter was 
inserted into a pGL3 Basic vector as described above. The shortest mTerc promoter 
mProm 136 was created by using an oligonucleotide corresponding to the mTerc 
sequence from -57 to +80 bp relative to the transcriptional start (Hinkley et al., 1998). 
Similar luciferase reporter constructs were created from mTerc regions -379/+80, - 
339/+80, -188/+80 and -129/-80 (Figure 3.2b, Table 3.1).
76
(Zhao, JQ., Sept. 2000) Chapter 3. Cloning h TERC & m Terc Promoter
A)
-465  -106 -58 -39 +12 +21Sp1.5 Spl 2 CCAAT Spi t .Sp13Sp14
6^ 9
.Sitkh EcoR V EcoR I Psll—-—IH-il—-—‘--- *-
0  CCAAT-box 
0  Sp1 
J  TATA-box
d l p L h K 2 6  
pLhE26 
|1 f| pLh2023 
I T U  pLh2123
- i n  PLh5F23
-ma pLhi4i?
- m  pLh2223
- m  pLh2923
- i 1 !  pLh26n23
W U uOU t
Relative Luciferase A ctivity (% )
29 49 60 89 100, 12q
GM847
HeLa
B)
Figure 3.5 Detection of promoter activities in the 5’ flanking regions of 
h TERC and m Terc genes
Detection of promoter activities in the 5'-flanking regions of human, (A), and mouse, (B), 
telomerase RNA genes. For each construct having endpoints from -5.0 Kb to -55 bp of 
h TERC gene or having endpoints extending from -549 to -57 bp of m Terc gene, the length 
of sequence upstream from the transcriptional start site is shown to the left and the 
luciferase activity to the right. pGL3 Basic luciferase vector is shown as negative control.
A) Diagram comparing luciferase activity from the human promoter constructs in 
GM847 and HeLa cells. The predicted promoter structure is shown at the top. The 
various colours symbols or circles represent the different transcription factor binding 
sites. The numbers indicate the position of the DNA-binding sites in relation to the 
TSS. Data for each construct is plotted as a percentage of the hProm505 luciferase 
activity as this construct consistently gave the highest activity in human cells. 
Transfection experiment of constructs pLhk26 and pLhE26 in GM847 cell lines did not 
performed.
B) Diagram comparing luciferase activity from mouse deletion constructs in 
Swiss3T3 and A9 cells. Data for each construct is plotted as a percentage of the 
mProm458 luciferase activity as this construct consistently gave the highest activity in 
mouse cells. The name of the deletion constructs is indicated in the centre column and 
these are also listed in Table 3.1. For each construct the mean and standard deviation 
for duplicate transfected wells are shown.
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3.4.3 Transfection assays detect the promoter activity
3.4.3.1 The h TERC Luc-reporter construct activity
The human promoter constructs containing truncated portions of the 5'-flanking region 
from -5.0 kb to -55 bp were transiently transfected into HeLa and GM847 cells (Figure 
3.5A). HeLa is a telomerase positive cervical carcinoma cell line, GM847 is a SV40- 
immortalized skin fibroblast cell line that expresses the telomerase RNA component but is 
telomerase-negative (Bryan et al., 1997). As shown in Figure 3.5A, promoter activity was 
observed in both cell lines with fragments containing 176 bp or more (from position - 
107/+69, see Figures 3.2a and 3.4a). The highest luciferase activity was observed with 
construct hProm505(-436/+69) that contains a 505 bp fragment. Construct, hProm120, 
which contains only 120 bp of 5'-flanking sequence (position -51/+69, see Figures 3.2a 
and 3.4a), produced a dramatically reduced level of luciferase activity (Figure 3.5A), and 
is not sufficient on its own for promoter activity. Thus, a minimal promoter sequence can 
be defined as extending 107 bp upstream of the transcription start site, and that elements 
responsible for promoter activity may be contained in a 176 bp region.
3A.3.2 The mTerc Luc-reporter construct activity
Various regions of the mouse promoter (from -549 to +80 bp) were tested for their ability 
to drive expression of the luciferase reporter gene in transiently transfected Swiss3T3 and 
A9 cells (Figure 3.5B). Swiss3T3 cells are an embryo derived line and A9 cells are of 
areolar and adipose origin. Both cell lines are telomerase positive. Results demonstrated 
that -129, -188 and -379 bp construct showed promoter activity that was significantly 
higher than the negative control construct (8 -fold). As shown in Figure 3.5B, promoter 
activity was observed in both cell lines with fragments containing from 208 bp or more 
(from position -129/+80, see Figure 3.2b and 3.4b). Construct mProm136, which contains 
only 136 bp of 5'-flanking sequence (position -57/+80, see Figure 3.4b), produced low 
levels of luciferase activity (Figure 3.5B). The promoter activity of mProm 196(-188/-8) or 
mProm154(-188/-34) was completely abolished when sequences between -7 and +80 or -
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33 and +80 have been deleted in construct mProm267 (-188/+80, Figure 3.5B), 
suggesting that this region is necessary for mTerc transcription. Thus, a minimal promoter 
sequence can be defined as extending 57 bp upstream of the transcription start site, and 
that elements responsible for promoter activity must be contained in a 136 bp region 
(Figures 3.2b and 3.4b). A 208 bp fragment located at -129 to +80 bp was sufficient for 
promoter activity, which directs the expression of the reporter gene in vitro.
Thus the ability of the upstream DNA to stimulate transcription of a reporter gene in 
several cell types was demonstrated. Transfection of the human promoter construct 
hProm867(pl_h2023) into mouse cells gave very strong promoter activity, with up to twice 
that of the strongest mouse construct, and transfection of the mouse promoter construct, 
mProm628(pL2730) into the human cells also showed luciferase activity at around 25% of 
the strongest human construct.
3.5 Discussion
The levels of telomerase RNA gene expression vary during normal development and 
between normal and cancerous cells and tissues (Avilion et al., 1996; Bestilny et al., 
1996; Blasco et al., 1995, 1996; Bodnar et al., 1996; Broccoli et al., 1996; Feng et al., 
1995; Kuniyasu et al., 1997; Soder et al., 1997a). Knowledge of telomerase RNA gene 
expression should therefore aid our understanding of the signal transduction pathways 
linking telomere attrition to proliferation, cellular senescence, differentiation and 
oncogenesis. As a first step towards this goal, the promoter regions of the human 
(hTERC) and mouse (mTerc), telomerase RNA genes have been cloned in order to 
identify the regulatory elements controlling telomerase RNA gene transcription.
79
(Zhao, JQ., Sept. 2000) Chapter 3. Cloning hTERC and m Terc Promoter Regions
3.5.1 Sequence similarity between the hTERC and m7erc
In general, there are no significant sequence homologies between the promoter regions 
of the human and mouse telomerase RNA genes. Indeed, there is considerable debate as 
to whether telomere length is regulated in a similar fashion in humans and mouse (Blasco 
et al., 1997; Kipling, 1997a,b; Zakian, 1997). However, mouse models represent a 
valuable resource with which to study the role of telomerase in cellular senescence and 
tumour progression and mouse models are likely to be required to investigate new 
therapies based on telomerase inhibition. In addition, the developmental regulation of 
telomerase will be more easily approached in mice (Bestilny et al., 1996; Blasco et al., 
1995, 1996, 1997; Broccoli et al., 1996; Prowse and Greider, 1995). Thus, knowledge of 
any differences between the two species may in fact aid our understanding of the function 
of telomerase in maintaining genome stability and may be important in developing good 
murine models for human disease or developmental processes. Whether the sequence 
divergence between the human and mouse gene promoters has any functional 
consequences can now be studied.
The human and mouse telomerase RNA genes do share an interesting similarity, in that 
they both lie in CpG islands, and thus their expression may be regulated by methylation. 
DNA methylation is thought to be important for gene regulation during normal 
development and cellular senescence, and abnormal methylation patterns may be a 
fundamental change in tumour progression (Baylin et al., 1991; Bird, 1996; Laird and 
Jaenisch, 1996; Vertino et al., 1994; Wilson and Jones, 1983). Thus it has been 
suggested that aberrant CpG island methylation during normal ageing process, could 
contribute to immortalisation by interfering with expression of 'mortality' genes, of which 
hTERC and mTerc can be included (Vertino et al., 1994; Wilson and Jones, 1983).
3.5.2 hTERC promoter shares high homology element with bTERC
The bovine TERC, {bTERC) has recently been cloned, (Tsao et al., 1998). This allows us 
to carry out a comparative study of the potential promoter functions of these three genes.
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The 351 bp of the bTERC promoter region has been cloned and sequence in our Lab. But 
our bTERC promoter has additional sequence that was not reported in the previously 
published sequence (Tsao et al., 1998). There is a sequence GGGTTGCG downstream 
of TSS (For sequence see appendix VI). Examination of the alignment of hTERC and 
bTERC 5’ flanking region sequences shows that certain regions are well conserved, 
particularly between two potential proximal promoter regions. The five potential binding 
sites were conserved between the hTERC and bTERC 5’-flanking sequence: a TATA-box 
element, a CCAAT-box, two GGGTGG motifs (GC-box) and the template region. Despite 
the lack of sequence similarity between the human and mouse telomerase RNA gene 
promoter region, hTERC, bTERC and m7erc genes have consensus binding sites such 
as TATA-box, CCAAT-box and Sp1. Presumably these conserved regions may be of 
functional significance to the promoter activity. Comparison of proximal promoter from 
species and the functional divergence will be further discussed in Chapter 5.
3.5.3 hTERC minimal promoter is 176 bp in length
Turning to the functional analysis of the cloned sequences, the minimal promoter for 
h TERC resides within a region of 107 bp upstream of the published transcriptional start 
site (Feng et al., 1995) (Figures 3.2a and 3.4a). There are a number of potential 
transcription factor binding sites in this region including consensus sequences for AP1, 
Sp1, PEA2/PEBP2, TATA-box and CCAAT-box. Interestingly, the expression of the 
fos/jun family of proteins, which determine AP1 activity, are suppressed during the onset 
of senescence and would be predicted to lead to a reduction in AP1 activity in senescent 
cells (Campisi, 1997; Irving et al., 1992; Riabowol et al., 1992; Seshadri and Campisi, 
1990). AP1 also responds to protein kinase C, and it has recently been demonstrated that 
hTERC expression is induced by protein kinase C during T-cell activation (Bodnar et al., 
1996). Extending the promoter region to 436 bp upstream of the transcriptional start site, 
increases the luciferase activity to its maximum level (Figure 3.5A). This region contains 
several consensus-binding sites for glucocorticoid/progesterone/androgen receptor 
binding, which may contribute to the maximal activity demonstrated by hProm505
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(pLh1417). Deletion of the sequence from -107 to -51 bp in construct hProm176(-107/69) 
abolishes the basal promoter activity suggesting requirement of this region for hTERC 
transcription, therefore a minimal functional promoter region is defined in 176 bp fragment 
at position -107 to +69 bp.
3.5.4 mTerc minimal promoter is contained within 136 bp of sequence
The promoter for mTerc resides in a 129 bp region upstream of the published 
transcriptional start site (Hinkley et al., 1998), (Figures 3.2b and 3.4b). A striking feature 
of this region is the presence of three AP-2 consensus sites, two of which are coupled to 
c-Ets-2 sites and all these elements are contained in the 73 bp region required for 
promoter activity (Figure 3.5B). Oncogenic Ras gene signalling has been shown to 
operate through c-Ets-2 binding sites, thus there is a testable relationship between 
oncogene activation during tumour progression and telomerase RNA gene transcriptional 
activity (Galang et al., 1994; Wasylyk et al., 1994). A reduction in promoter activity is 
observed on extending the promoter fragments to include more 5'-sequence, (Figure 
3.5B, mProm628), suggesting that sequences towards the 5'-end of the clone may 
influence promoter activity in a negative fashion. The shortest construct mProm136(- 
57/+80) showed a low promoter activity, this minimal promoter region contains a CCAAT- 
box, TATA-motif and two Sp1 binding sites. Deletion of the sequence from - 8  to +80 bp in 
construct pL2530 (-188/+80) abolishes the mTerc promoter activity indicating that this 
region may be required for mTerc gene transcription.
3.5.5 Implications for the study of TERC regulation and gene therapeutics
These studies have a number of implications for the development of new transcription- 
based therapies for cancer (Cai et al., 1996; Connors, 1995; Miller and Whelan, 1997; 
Peterson and Baichwal, 1993). Directly down-regulating expression of the telomerase 
RNA gene through manipulation of transcription factors may be an effective anticancer
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therapy and the cloning of the hTERC gene promoter will allow the analysis of therapeutic 
molecules which modulate hTERC promoter activity (Cai et al., 1996; Peterson and 
Baichwal, 1993; Sharma et al., 1997a). Indeed, by using a human cell line which has 
telomerase activity (HeLa) and one that expresses the hTERC gene but is telomerase 
negative (GM847) (Bryan et al., 1997), a system has been established in which the 
specificity of transcriptional manipulation of hTERC can be examined. In comparison to 
HeLa, the growth of GM847 does not appear to be dependant on telomerase expression, 
thus transcriptional targeting of h TERC in GM847 should have no cellular effects, 
whereas HeLa should be sensitive to the predicted anti-proliferative effects of the 
transcriptional targeting. In addition, it has recently been shown that there are tumour- 
specific patterns of hTERC gene expression with clear differentials in expression between 
cancerous and adjacent normal tissue (Soder et al., 1997a,b). Therefore, the hTERC 
gene promoter may be of considerable use in genetic therapies allowing selective 
expression of therapeutic genes in cancer cells expressing high levels of h TERC 
(Connors, 1995; Miller and Whelan, 1997; Soder et al., 1998).
3.6 Conclusion
These studies have identified potential regions involved in the transcriptional regulation of 
the human and mouse TERC genes. By defining the hTERC and mTerc gene promoters 
it will now be possible to identify the transcription factors which repress or activate these 
genes transcription. The constructs described in the present study will be ideal for more 
focused gene therapy studies and the development of transcription based therapeutics. In 
next chapter, studies that address how the telomerase RNA gene is regulated and which 
transcriptional regulators are involved in this modulation will be described
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Chapter 4 Identification and Mutagenesis of the hTERC 
transcriptional elements
As described in the previous chapter, functional promoter regions have been identified in 
the 5' flanking sequences of the hTERC and mTerc genes, and several potential binding 
sites for transcription factors have been predicted. These studies have provided evidence 
that both the hTERC and mTerc gene promoters are regulated at the transcriptional level. 
The present study focuses on the regulation of the hTERC promoter in 5637 and HeLa 
cell lines and identifies the major sequence elements of the promoter and transcription 
factors involved in hTERC gene expression. The strategy for characterising proteins that 
bind to a defined control element is summarised in Figure 4.1.
4.1 Introduction
Human telomerase activity can be reconstituted in vitro by the essential hTERC and 
hTERT genes (Tesmer et al., 1999; Yi et al., 1999; Autexier et al., 1996), and it is likely 
that there is a co-ordinated program for the de-repression of telomerase component 
genes during tumour formation. The complexity of gene regulation in eukaryotes has 
been well studied in recent years, and it has been shown that transcription, being the first 
step in the expression of genetic information, is one level at which gene activity is 
controlled. Transcription is regulated by promoter and enhancer elements recognised by 
gene-specific DNA-binding proteins, by general transcription factors, and at a higher level, 
by chromatin structures (Workman & Kingston, 1998). The 5’-flanking regulatory regions 
of the hTERC, hTERT (Zhao et al., 1998; Cong et al., 1999; Horikawa et al., 1999; Oh et 
al., 1999; Wick et al., 1999; Takakura et al., 1999) and the mouse (Zhao et al., 1998, 
1999; Hinkley et al., 1998) telomerase RNA genes have been partially characterised. 
Studies of the 5' flanking region of hTERC and mTerc have identified the minimal 
promoter regions for these genes (Zhao et al., 1998; Chapter 3), however the specific 
transcriptional elements and molecular basis for this regulation has not yet been defined.
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Transient expression of 5’-end truncated hTERC promoter-reporter constructs identified 
the elements responsible for proximal promoter activity are contained in -107 to 69 bp 
region relative to the transcriptional start site (TSS). In this study, I showed that mutation 
or deletion of the hTERC CCAAT-box abolishes the proximal promoter activity completely, 
whereas mutation of the h9 region of sequence from GCTC to ATAG (-36/-33 bp) results 
in an increased Luc-reporter activity.
4.2 Results
4.2.1 DNase I Footprinting to detect DNA regions bound by nuclear proteins
To investigate trans-acting factors that bind to the hTERC promoter in the -628 to +69 bp 
region, HeLa nuclear extracts were allowed to bind to 312 bp (-628/-306) and 375 bp (- 
306/+69) DNA fragments which were then used for DNase I footprinting analysis (see 
Figure 2.2 for strategy). DNase I footprinting of this region revealed 7 protected regions 
designated H2 (-545 GATTAATAA -537 bp), H3 (-155 CTTCCTC -149 bp), H4 (-110 
ACCAGCCCGCCCGAGAGAGT -95 bp), H5 (-467 AAGGGGCAGGGTTGGAAC -450 
bp), H9 (-40 GGCCGCTCCCTTTATAA -24 bp), H10 (-60 GGCCAATCCG -50 bp) and 
H11 ( + 6  CGGAGGGTGGGCCTGGGAGGGGTGGTGG +34 bp). Only the H2, h5 and h11 
protection regions were shown in Figure 4.2. The 3' end of the promoter was not well 
defined because of its proximity to the labelled end of the probe, and the presence of 
proteins that bind non-specifically to the ends of DNA. Although several DNA elements 
were protected, the three regions shown in Figure 4.2 (H2, H5 and H11) were the most 
strongly protected sequences. In following section, regions H4, H9, H10 and H11 were 
investigated further using the electrophoretic mobility shift assay (EMSA) as they lie in the 
minimum h TERC promoter region as identified in chapter 3.
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Figure 4.2 DNase I footprinting analysis of hTERC promoter region
The strategy for DNase I footprinting analysis is shown in Figure 2.2. The antisense (A) 
and the sense (B, C) DNA fragments were labelled by °P-ATP at e ither end and 
incubated with 50 ug of HeLa nuclear extract in a footprinting reaction. DNAse I footprint 
analysis reveals protein binding regions in the hTERC promoter (from -628 to -306 bp, or 
-7 to +45 bp) which are indicated by yellow rectangles. Maxam-Gilbert G+A sequence 
results from the probe are shown in lane 1. BSA control is shown in lane 2. Footprints 
were produced with increasing quantities of DNase I (A; lanes 3 to 7, B; lanes 3 to 5, C; 
lanes 4 to 7). DNA protection region indicated as H2, H5 and H11 correspond to the 
promoter sequence.
Figure 4.3A hTERC proximal promoter sequence and identified transcription 
factor binding sites
176 bp of hTERC proximal promoter sequence (-107/+69) is shown. The transcriptional 
start site (TSS) is marked as “+1” . The numbers at either end of the sequence relate to 
the TSS. The four red boxes indicated are protein protected regions detected by DNase I 
footprinting analysis. Four identified Sp1 binding sites are underlined and termed Sp1.1 to 
Sp1 .4. Sp1 .4 contains two overlapping Sp1 binding sites. The promoter structure is also 
depicted at the top of diagram. Lines marked h4, h9, h10 and h11 indicate 
oligonucleotides used for EMSA.
Figure 4.3B Oligonucleotides used in EMSA and mutagenesis studies of the 
hTERC promoter.
The sequence of the wild type oligonucleotides covering potential transcription factor 
recognition sites are shown. Oligonucleotide h9 covers Sp1.1 and the adjacent TATA-box, 
h10 covers the CCAAT-box, h4 covers Sp1.2 and h11 covers the overlapping Sp1.3 and 
Sp1.4 sites. Mutations, h1 0 m1 and h1 0 m2 , were introduced into the wild type 
oligonucleotides for use in EMSA and the construction of mutant reporter constructs. 
Oligonucleotide mutations are shown below wild type sequences. Regulatory motifs 
underlined on the wild type sequence are determined by mutation analysis or previously 
reported (Kim et al., 1992; Thiesen et al., 1990). These oligonucleotides are also listed in 
Table 2.4
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A)
h4 h10 h9 h11
_ 1 0 7  Sp1.2 CCAAT-Box - 4 9
AGCCCGCCCGAG* G AG TG AC TC TC ACG AG AG CC G C G A G A G TCAG CT1G G CC AATCCG IG
- 4 8  Sp1.1 +1 + 1 0
CG G TCGGCGGCCGCTCCCTTTATAftGCCGACTCGCCCGGCAGCGCACC G G TTG CGGA
+ 1 1  + 6 9
GGGTGGGC C TGGGAGGGGTGGTG G C C A TTTTTTG TC TA A C C C TA A C TG A G A A G G G C G TA
Sp1.3 Sp1.4
B)
Sp1.1
Sp1.2
Sp1.3/4
h9(wt:-44/-17) 
h9ml (-43/-40) 
h9mll(-39/-36) 
h9m2 (-36/-33) 
h9m21(-32/-29) 
h9m3 (-2 8/-2 5)
h 4 (wt:-110/-91) 
h41m(-101/-100)
hll(wt:-2/+36) 
hill (+11/+13) 
hll2 (+24/ + 2 6) 
hll3 
hll2c
CGGCGGCQ 3C T C C C T TT A T A A G C C G A C T  
: T T A C : : : : : : : : : : : : : : : : : : : : : : :  
: : : : : T A A A : : : : : : : : : : : : : : : : : : :  
::::::::ATAG:::::::::::::::: 
: : : : : : : : : : : : A T G C : : : : : : : : : : : :  
: : : : : : : : : : : : : : : : C G A C : : : : : : : :
AC  C A3CC C GC C C GAG AG AG T  
: : : : : : : : : A A : : : : : : : : :
C C G G G TTG G3GAGGGTGGQCC T GGGAGGGGTGGTGGCC  
A A A
A A A
T A A : :
T A A : : 
T A A : : T A A
CCAAT hlO ( w t : -63 /  -42 ) 
Box hlOml ( — 58/ — 55) 
hl0m2 ( - 5 1 / - 4 8 )
C TTG G EC A A TC C G TG C G G TC G G  
: : : : : A G T C : : : : : : : : : : : : :  
: : : : : : : : : : : : T G A T : : : : : :
Figure 4.3A 
Figure 4.3B
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4.2.2 Potential binding sites in the proximal promoter
Eukaryotic gene expression is controlled by a combination of effects from various cis- 
acting elements present in the promoter and enhancer regions. In general basal 
transcription is regulated by binding sites located in the proximal region of promoters 
close to the transcriptional start site.
As described in section 3.4.1 and 3.5.3, minimum hTERC promoter has been narrowed 
down to 176 bp in length. Using the Transcription Element Search Software (TESS) (web 
address see appendix V) to examine this region (+107/+69 bp, Figure 3.3a) several 
potential transcription factor binding sites were identified. These include one CCAAT-box 
and TATA-box element, three Sp1 sites, two GAGA and Ap1 sites, one PEA2/PEBP2 
binding motif and 90.5% identity for a YY1 site. Four regions, H4, H9, H10 and H11 
indicated by the red box in Figure 4.3A, detected by DNase I footprinting match the Sp1, 
GAGA/TATA-box, CCAAT-box, and GAGA-1/Sp1 potential site, respectively.
4.2.3 Sp factors bind to the hTERC promoter at multiple sites
4.2.3.1 Sp1 binds to the h9 region
To identify the factors binding to the H9 region, oligonucleotides containing binding sites 
for Sp1, TFIID, Ap2 and Ets2 were tested as competitors for h9 (-44/-17, for sequence 
see Table 2.2 and Figure 4.3B) binding in an electrophoresis mobility shift assay (EMSA). 
The results of the EMSA are shown in Figure 4.4A. In all but two instances the complexes 
remained unchanged. The exceptions were competition with oligonucleotides 
corresponding to Sp1 and h9 itself (Figure 4.4A, lanes 2 and 4). The Sp1 consensus 
oligonucleotide competed with the three slowest migrating complexes (Sp1 and Sp3) 
suggesting that Sp1 or related factors together with one or more unknown proteins are 
responsible for the h9 binding characteristics (Figure 4.4A, lane 2). In contrast, a 
consensus TFIID oligonucleotide did not compete for h9 binding activity (Lane 3). Ap2, a 
transcription factor that binds to the consensus GCGGGGGCG, may compete with some
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of the slowest migrating complexes suggesting an association with Ap2. Indeed the core 
h9 sequence shows a 6/10 match with the Sp1 consensus and 7/9 matches with Ap2 
consensus (Figure 4.4B).
As shown in Figure 4.5A, an antibody against the Sp1 protein causes a super-shift of the 
upper band, indicating that Sp1 is part of this protein complex (Figure 4.5A, lane 9). The 
second and third lower bands were super-shifted by antibodies against Sp3 (lane 10). 
Antibodies against Ap2 or Ets2 failed to interact with any of the protein complexes binding 
to h9 (lanes 11 and 12). Depending on antibodies being effective in this assay, these 
studies demonstrate that transcription factors Sp1 and Sp3 specifically bind to the hTERC 
h9 region (termed Sp1.1)
4.2.3.2 Mutation o f the h9 sequence prevents Sp1 binding
Since the h9 region (-44/-17 bp) containing the Sp1-binding site was present in the critical 
promoter region, additional studies were carried out using site-directed mutagenesis to 
clarify the specific nucleotides responsible for Sp1 binding activity. Mutations were 
created that spanned the h9 region with 4 sequential nucleotide substitutions (mutants 
from h9m1 to h9m3) as shown in Figure 4.3A. EMSA was performed and results are 
shown in Figure 4.5A, lanes 3-7. The three major DNA-protein binding complexes were 
disrupted by a 100-fold molar excess of unlabelled h9 oligo itself (lane 2). Mutants h9m1, 
h9m11 and h9m3 each retained the ability to displace nuclear protein binding (lanes 3, 4 
and 7), suggesting that regions -43 to -36 bp and -28 to -25 bp were not critical for the 
DNA-protein interaction. Mutants’ h9m2 and h9m21 did not compete for Sp1 binding 
activity suggesting (lanes 5 and 6 ) that the region -36 to -29 bp is important for h9 binding 
to protein. To demonstrate that this sequence change did not introduce a new protein 
binding site, EMSA was performed using labelled h9m2a oligonucleotide as a probe, as 
shown in Figure 4.4A. The results show that no specific complexes can be formed with 
h9m2 oligonucleotide and FleLa nuclear extract protein (Figure 4.4A, lanes 7 to 12).
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These data clearly indicate that the specific binding of Sp1 and Sp3 nuclear proteins to 
the h TERC promoter primarily involves nucleotides -39 to -29 bp and that each of the 
residues -36 to -29 bp (5'-GCTCCCTT-3') are essential. The TATAA sequence (-28/-24 
bp) does not appear to be responsible for protein binding under these experimental 
conditions.
4.2.3.3 Two Sp1 binding sites in h11 region
The two putative binding sites for GAGA-1 and Sp1, at positions +9 to +18 bp and +23 to 
+32 bp within the H11 region, have 96% and 100% identity with the Sp1 binding sites 
described by Kim (1992) and Thiesen (1990). Interestingly, this sequence region, +1 5'- 
GGGTTGCGGAGGGTGGGCCTGGGAGGGGTGGTGGCC-3, +36, also contains two 
copies of GGGTGG motif (also called retinoblastoma control element, termed RCE) 
identified in the promoter of the c-fos proto-oncogene (5'-CCCGCGCGCCACCCC-3'. core 
element underlined)(Pai & Bird, 1997; Felzien et al., 1997; Udvadia et al., 1992 and 
1993). This motif in the c-fos gene has recently been shown to bind both Sp1 and Sp3 
(Adnane et al., 1999; Udvadia et al., 1993 and 1995; Kennett et al., 1997). It would 
therefore be interesting to test whether the Sp-family of factors bind to these elements 
and whether pRb is involved in the regulation of hTERC transcription. These issues will 
be discussed further in section 5.2.3.
To clarify which specific transcription factors target this region, an EMSA was performed 
with a 32P-labelled h11 oligonucleotide corresponding to the -2/+36 bp region (see 
sequence in Figure 4.3B). As shown in Figure 4.5C, EMSA revealed the formation of 
several specific DNA-protein complexes (lanes 1 and 12). The combination of Sp1 and 
Sp3 antibodies caused a super-shift of almost all of the DNA-protein complexes (lane 15), 
whereas antibodies against Ets2 did not cause any super-shifts (lane 16). These 
experiments identify Sp1 and Sp3 transcription factors as binding to the hi 1 region.
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To further map the exact position of these Sp1 binding sites in h11 region several 
oligonucleotides containing different site-directed mutations spanning the h1 1  region 
(termed hi 11, hi 12 and hi 13, Figure 4.3B) were tested for their ability to compete with 
32P-labeled h11 for protein binding. As shown in Figure 4.5C, the oligonucleotides hi 11 
and hi 12 (lanes 3-8) competed as effectively as the unlabeled h11 oligonucleotide itself 
(lane 2), whereas oligonucleotide hi 13 (lanes 9-11) was a less effective competitor than 
unlabeled h11. These results indicate that both the GGG(+11/+13) and the 
AGG(+24/+26) within the Sp1 elements are necessary for the formation of DNA-protein 
complexes. The oligonucleotide hi 13 shows weak competition that may be due to the 
remaining GGTGG motif (+27/+31 bp), and may therefore bind Sp1 protein (Sabath et al., 
1998). This was proved by mutation of the GG to AA at position +30/+31 in 
oligonucleotide h112c (for sequences see Table 2.3 and Figure 4.3B) that totally 
abolishes the ability to bind Sp1.
To summarise, these results show that at least two distinct Sp1 elements termed Sp1.3 
and Sp1.4 are present between the TSS and the RNA template region. Mutations in either 
one of these sites (oligo’s hi 11 and hi 12) reduce the affinity of the binding to Sp1 
proteins; and mutations in both sites (mutant hi 13) causes a decrease in binding ability, 
however it is still not totally abolished, suggesting the presence of an other potential 
binding sequence in this region, possibly the GGTGG motif at +27 to +31.
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Probes: h9 h9m2
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B
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B)
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| | | | | |  | ( M a t c h  1 / 9 )
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S p l c o n s 3 ' - G G G G C G G G G C - 5 ' ( M a t c h  6 / 1 0 )
Figure 4.4 Sp1 Protein binding to h TERC  h9 region (-44/-17)
A) Protein binding to h TERC  h9 region (-44/-17) EMSA was performed using HeLa 
nuclear extract and the radiolabelled double-stranded oligonucleotides h9 or h9m2. 
Competition was performed in the presence of 100-fold molar excess of h9 (lane 2), or 
consensus DNA-binding oligonucleotides (lanes 3-6). Specific and unspecific DNA- 
protein complexes are indicated with arrows corresponding to Sp1/Sp3, Sp3 and N, 
respectively. F is free probe. Double-stranded mutant oligonucleotide h9m2 probe was 
used in EMSA analysis as shown on the right hand side. Competition was performed 
in the presence of 100-fold molar excess of the non-radioactive h9m2 oligonucleotide 
(lane 8), h9 oligonucleotide (lane 9), consensus Sp 1 binding-site sequence (lane 10), 
Ap2 (lane 11), or 5 ug poly(dl-dC) (lane 12). C1 and C2 are indicated by arrows as 
unspecific DNA-binding complexes.
B) h9 region sequence An alignment of the h9 sequence with Sp1 and Ap2 consensus 
sequence. The h9 sequence shows a 6 to 10 bp match with the Sp 1 consensus and 7 
to 9 bp match with Ap2 consensus sequence. The core sequence responsible for h9 
DNA binding activity is underlined.
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Figure 4.5 Identification of Sp-family factors binding to the hTERC promoter
HeLa nuclear extract was mixed with radiolabelled oligonucleotide probes and analysed 
by EMSA. Specific DNA/protein complexes are indicated by arrows on the left.
Competition was performed in the presence of 100-fold molar excess of the cold-probe
alone (lane 2), or site-replaced mutation oligonucleotides (Figure A: lanes 3-7; Figure B: 
lane 4), or increasing concentrations of mutant oligonucleotides (25, 50 and 100-fold 
molar excess, Figure C: lanes 3-11). In Figure 4.5C, complexes supershifted by 
preincubation with antibodies are shown on the right by arrows marked ‘ss\ The 
oligouncleotides used as probes are indicated at the top of each figure.
A) Protein complex formation at the Sp1.1 site in h9 region.
B) Protein complex formation at the Sp1.2 site in h4 region.
C) Protein complex formation at the Sp1.3/Sp1.4 sites in h11 region. Sequences of all 
oligonucleotides are shown in Figure 4.2B and Table 2.4.
CCAAl
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Figure 4.6 Differential Sp1 binding affinity
A) Consensus Sp1 oligonucleotide (Promega) was radiolabelled by kinase treatment 
using [y-32P] dATP. 5.5 ug of HeLa nuclear extract was incubated with increasing 
concentration of each unlabelled oligonucleotide for 1 0  minutes followed by incubation 
with the Sp1 probe and electrophoresed on a 5% polyacrylamide gel. Molar excess 
(increasing from 0, 2.5, 6.25, 12.5, 25 to 75 pMol present in lanes 2-6 or lanes 7-11) of 
unlabelled h4 (Sp1.2), h9(Sp1.1), h11c(Sp1.3), h11d(Sp1.4) and h5(Sp1.5) 
oligonucleotides are indicated. Lane 1 without competitors was used as a control. 
Three major DNA-protein complexes are indicated with arrows.
B) Diagram shows the affinity of each Sp1 element to the Sp1 protein. Quantitative 
analysis of the dried gel was performed using both a computing Phosphorlmager with 
ImageQuant software (Molecular Dynamics) and autoradiography on Kodak XAR-5 
films.
C) Alignment of identified GC box in hTERC. The numbers indicate the sequence position 
in the promoter region. The core Sp1 binding sequences are underlined in bold and 
differential Sp1 affinity is shown at the bottom.
S p l ATTCGATCGGGGCGGGGCGAGC Consensus Sp1 binding sequence
h5 -471 GAAAAAGGGGCAGGGTTGGA -452 Sp 1.5 in this study
h4 -91 ACTCTCTCGGGCGGGCTGGT -110 Sp1.2 in this study
h9 -17 AGTCGGCTTATAAAQQGAGCGGCGGCCG -45 Sp 1.1 in this Study 
h l l c  -2 CCGGGTTGCGGAGGGTGGGCCTGGG +23 Sp1 3containing RCE (Kim, 1992)
h l l d  + 14 GCCTGGGAGGGGTGGTGGCC +3 6 Sp1 4 containing 12t (Thiesen, 1990)
A ffin ity  of Sp1: h5 > h i 1 d > h11c > h4 > h9
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-107 -55
pLh2 923 (-107 +69) AGCCCGCCCGAGAGAGTGACTCTCACGAGAGCCGCGAGAGTCAGCTTGGCCAA
pLh29m223 (ASpl.2)  AA-------------------------------------------------
pLhlOll(ACCAAT)  AGTC
pLh29m292(ASpl.1+2) ------ AA-------------------------------------------------
-54 -1
pLh.2 92 3 ( -107 +69) TCCGTGCGGTCGGCGGCCGCTCCCTTTATAAGCCGACTCGCCCGGCAGCGCACC
pLhl02 -- TGAT----------------------------------------------------
pLh910--------------  TTAC-------------------------------------------
pLh911  TAAA--------------------------------------
pLh92 (ASpl.l)------  ATAG-----------------------------------
pLh29m2 92 (ASpl. 1 + 2 )------------------- ATAG----------------------------------
pLh921 (ASpl.l)  ATGC-------------------------------
pLh93 0 (ATATA) ---------------------------- CGAC--------------------------
pLh2 6n2 3 (-51 +69)---- ---------------------------------------------------------
+ 1 +53
pLh2 6n23(-51 +69) GGGTTGCGGAGGGTGGGCCTGGGAGGGGTGGTGGCCATTTTTTGTCTAACC
pLh29111(ASpl.3)  AAA------------------------------------------
pLh29112(ASpl.4) -------------------------TAA---------------------------
pLhlll* — *-------AAA------------------------------------------
pLhll2 * *----------------------TAA---------------------------
pLhll3* — *-------AAA---------- TAA---------------------------
pLhll4* — *--------AAA---------- TAA---AA---------------------
+54 +69
CTAACTGAGAAGGGCGTA
* Double mutagenesis by using pl_h29m292 as template which contains mutations in Sp1.1 and Sp1.2.
Figure 4.7 Scanning m utation analysis of h TERC prom oter (-107/+69).
The sequence of the wild-type hTERC  proximal promoter is shown at the top, and 
identified regulatory motifs are underlined. The name of each mutant construct with 
mutation site is indicated on the left hand side. The number on either side of the 
sequence is related to the transcriptional start site. Dashes indicate an identical sequence 
to the wild type, mutated nucleotides are shown below the wild type sequence. The 
multiple site-replaced mutations were created by using construct pLh29m292 (ASp1.1/A 
Sp1.2) as template and indicated as **’. Each mutant was confirmed by sequencing.
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Figure 4.8 Promoter activities of the site-replaced mutant constructs
The predicted promoter structure is shown at the top. The various colours symbols or 
circles represent the different transcription factor binding sites. The numbers indicate the 
position of DNA-binding sites related to the transcriptional start site. The constructs are 
shown with red circles indicating a site-replaced mutation in one or more positions. The 
names of the Luc-reporter constructs are shown in the middle column. The result of the 
promoter activity is shown on the right hand side. Three micrograms of each plasmid were 
used for transfection analysis in 5637 cells. (For DNA quantitation, transfection and 
luciferase assays see section 2.3.4 or 2.4.4). Promoter activities of the mutant constructs 
were assayed by transfection and compared to the wild-type promoter (pLh2923). For 
each transfection the mean and standard error for duplicate samples are shown. Flatched 
bars show relative luciferase activities, error bars show standard deviations. The pSEAP2 
Control plasmid was used as an internal control to normalise the transfection efficiency.
A) Promoter activities of single site-replaced mutant constructs
B) Promoter activities of double or multiple site-replaced mutant constructs
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4.2.3.4 h4 region is recognised by Sp1
EMSAs were also performed with DNA probe spanning footprint H4 region, containing 
potential Sp1 site termed Sp1.2. HeLa nuclear extract formed three major complexes on 
the hTERC DNA probe h4 (Figure 4.5B, lane 1). These three complexes were competed 
by the Sp1 consensus oligonucleotide (lane 3) and cold h4 oligonucleotide itself (h4, lane 
2). These complexes were not competed when the oligo's contained the double-point 
mutation in the potential Sp1 site (h41m, lane 4, for sequence see Figure 4.3B). After 
incubation with antibodies to Sp1 or Sp3, the number of complexes formed with the 
nuclear extract was reduced (Figure 4.5B, lanes 6  and 7) respectively. Antibodies against 
Ap2 failed to interact with any of the protein complexes binding h4. The faster migrating 
minor complex formed by nuclear proteins with h4 oligo’s appears to be non-specific. 
These experiments therefore demonstrate that Sp1 and Sp3 are two of the proteins that 
bind to motifs within the h4 regions in the hTERC promoter. An Sp1 site was also 
predicted in H5 footprint region; this region was also investigated by EMSA even though it 
lies upstream of the proximal promoter region. The result was identical to those for h4.
4.2.3.5 Sp1 sites show different affinities to Sp1 protein
As shown in the preceding section, five different Sp1 binding sites were identified each 
with different sequences, it seemed interesting to determine if there were any differences 
in their binding affinities for Sp1. To approach this question, an end-labelled Sp1 
consensus sequence oligonucleotide probe was utilised in competition EMSAs with 
excess unlabelled hTERC Sp1 element oligonucleotides. As shown in Figure 4.6A and B, 
the Sp1.5 (h5) oligonucleotide was able to efficiently compete the labelled Sp1 probe at a 
low level molar excess concentration, whereas the Sp1.1(h9) and Sp1.2(h4) 
oligonucleotides required at least 1 0 0 - to 1 0 0 0 - fold excess concentrations, respectively, 
for efficient competition (Figure 4.6B). The two cold oligonucleotides, h11c and hi 1 d, 
designed separately from h1 1  sequence, competed well with a radio-labelled commercial 
Sp1 consensus oligonucleotide binding activity as shown in Figure 4.6A. Since h11 
contains the elements that show similarity to Sp1 sites, the ability of a consensus Sp1
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(CGGGGCGGGG) oligonucleotide to compete with h11 oligonucleotide for binding to 
nuclear proteins was assessed. These data indicate that the relative affinities of the 
hTERC GC-box elements as determined by EMSA are Sp1.5(h5) > Sp1.3(h11c) > 
Sp1.4(h11d) > Sp1.2(h41) > Sp1.1(h9) (Figure 4.6C). In conclusion, at least five Sp1 
binding sites have been identified in the hTERC promoter region and those sites show a 
differential binding affinity to Sp1 family of transcription factors.
4.2.4 Refining the functional regions in the hTERC promoter
A number of putative sequence elements were identified in the hTERC proximal promoter 
(Figure 4.3A, -107/+69 bp) described above. These motifs were subsequently focused on 
as the promoter elements most likely to be supporting hTERC transcription and for further 
analysis by site-directed mutation. To examine the involvement of each of these elements 
in the hTERC gene transcription, a series of single site-directed mutant Luc-reporter 
constructs were created and their corresponding luciferase activities were monitored in 
5637 cells. The mutant sequences of each construct were shown in Figure 4.7.
A comparison of promoter activities between this series of mutant constructs is shown in 
Figure 4.8A. The wild-type (pLh2923, -107/+69) and neutral mutant constructs (pl_h102, 
pLh910, pLh911, pLh921 and pLh29111) show similar promoter activities. Mutation or 
deletion of the CCAAT-box sequence element [constructs pLh1011 (ACCAAT-box), and 
pLh26n23(del-CCAAT-box, -51/+69) respectively] completely abolishes the hTERC 
promoter activity suggesting that this element is the site of action for an activator for the 
hTERC promoter and central to hTERC transcriptional efficiency. By comparison, 
mutation of the TATA-box had no effect on reporter gene activity (construct pLh930, A 
TATA).
Turning to the Sp1 sites, mutation of the Sp1.1 site (pLh92 ASp1.1) significantly increases 
basal promoter activity by 3-4 fold, suggesting that this element is the site of action for a 
repressor of h TERC promoter activity. A similar up-regulation is shown by the single-site
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mutant construct, pLh29112(ASp1.4), which showed about a 2-fold increase of basal 
promoter activity. Mutation of Sp1.2 (construct pL29m223, ASp1.2) did not significantly 
alter promoter activity.
To further determine how these Sp1 elements interact or relate to each other, double and 
multiple site-directed mutant constructs were created. As shown in Figure 4.8B, the 
stimulation of promoter activity by mutation of site Sp1.1 was still observed upon mutation 
other Sp1 sites within the promoter constructs pl_h29m292 (ASp1.1+ASp1.2) and pLh112 
(ASp1.1+ASp1.2+ASp1.4). However, combination of mutation of Sp1.1 with mutation of 
Sp1.3 reduces promoter activity back to control levels in construct pLh111 (ASp1.1+A 
Sp1.2+ASp1.3). Thus it is possible that site Sp1.3 is a positive regulatory element of 
hTERC promoter where activation is revealed by mutation of Sp1.1 site. However 
mutation of all four Sp1 sties in construct pLh114 (ASp1.1+ASp1.2+ASp1.3+ASp1.4) did 
not abolish promoter activity completely suggesting another unknown transcriptional 
mechanisms. The same results of constructs pLh92, pLh1011, pLh26n23 and pLh114 
were obtained by transient transfection analysis in HeLa cells. These results demonstrate 
that the Sp1 family of transcription factors, through its differential interactions with 
different regions of the hTERC promoter, play an important part in the hTERC gene 
regulation. Thus several regulatory elements involved in either the activation or repression 
of the hTERC promoter have been identified. The major conclusions of this part of the 
study are the CCAAT-box is essential for h TERC promoter activity; Sp1.1 acts as 
negative regulatory element and Sp1.3 as positive regulatory element.
4.3 Discussion
In the present study, the hTERC promoter was investigated by DNase I footprinting,
EMSA, site-directed mutagenesis and transient transfection experiments to identify
regulatory elements. The major findings are as follows: (i) at least five discrete sequence
elements were identified, namely one CCAAT-box and four Sp1 elements. These
elements constitute the 176 bp proximal promoter of the h TERC gene; (ii) the CCAAT-box
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element was found to be essential for hTERC gene transcription; (iii) an unusual Sp1 site 
was found overlapping with the TATA-box which appears to inhibit hTERC promoter 
activity.
4.3.1 Regulation of hTERC through Sp1 sites
The 176 bp of the hTERC proximal promoter was able to drive promoter activity in 5637 
and HeLa cells. Transient transfections with a series of progressive site-directed mutants 
of the h TERC proximal promoter fused to the Luc-reporter gene implicated a sequence 
element between -40 to -17 bp region, which harbours a TATAA motif closely linked to an 
Sp1.1 binding site. Interestingly, Sp1.1 may be a negative regulatory element of h TERC 
activity. Evidence to support this conclusion involves mutation of the Sp1.1 sequence 
from GCTC to ATAG, (-36/-33 bp), in different constructs, pLh92, pLh112 and 
pLh29m292 (Figure 4.8B). Whereas, mutation of the nearby TATA sequence to CGAT, (- 
28/-25 bp), did not affect the DNA-binding complex or Luc-reporter activity. Therefore 
Sp1.1 motif is perhaps the target for the transcriptional repressor Sp3.
It is noteworthy that Sp1.1 shows low-affinity for Sp1 binding and this may be due to 
differences in the hTERC Sp1.1 sequence to the consensus Sp1 sequence. In addition 
the spatial alignment of the multiple Sp1 sites along the hTERC promoter may be 
important. Sp1.1 is only 49 bp 5’ to Sp1.3 and 67 bp 3’ to Sp1.2 . Sp1.1 also overlaps with 
a TATA-box consensus sequence and only 19 bp 3’ to CCAAT-box. Several studies have 
shown that small changes in the separation of Sp1 binding sites can have significant 
effects. For example, movement of an Sp1 binding site from 8  bp downstream of a TATA 
box in the adenovirus E1B early region to 30 bp upstream of the box was sufficient to 
abolish its transcriptional function (Wu & Berk, 1988). Other studies with the E1B early 
region showed that separation of two Sp1 binding sites by <30 bp did not alter expression 
levels, but these levels dropped when the separation was = 40 bp (Segal & Berk, 1991). It 
has also been shown that bending of DNA induced by Sp1 binding relative to a TATA box 
can be influenced by an insertion as small as 5 bp (Sjottem et al., 1997).
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Multiple site-directed mutation analysis releases a positive regulatory element Sp1.3 
although reduction is not observed in single mutation of Sp1.3. Evidence to support this 
conclusion involves different constructs pLh92, pLh112 and pl_h29m292 (Figure 4.8B). 
This is probably due to the removal of the nearby negative regulatory Sp1.1 sites which 
may renders up Sp1.3 for Sp1 activation. It was found in this study that the affinity of Sp1 
protein binding to Sp1.3 site is higher than Sp1.1. Presumably protein binding to Sp1.1 
will be more active to repress Sp1.3 activation. However it is unclear how the bTERC 
promoter is organised and selectively recognised by Sp3 (causing repression) and Sp1 
(which might cause activation) and whether the negative/positive regulation is dependent 
on either the precise sequence element or the critical position of the Sp1 site.
While the presence of Sp1 binding site in a promoter region is a good indication that they 
play a role in regulating gene transcription, mutation of the Sp1 sites can up- or down- 
regulate gene promoter activity (Conn et al., 1996; Peters et al., 1997; She and Taylor, 
1995). It was reported that mutation of RCE site (A typical Sp1 site) results in an up- 
regulation of elastin promoter activity of about 2-3 fold (Conn et al., 1996). Perhaps more 
relevant to the current study is work by She and Taylor (1995) which showed that the 
three Sp1 binding sites found in the hamster aprt promoter region are not required for 
expression, though all three sites can bind Sp1 protein in vitro. These studies 
demonstrated that mutation of Sp1 sites in a promoter sometimes do not correlate with 
transfection analysis in vitro and it is unclear how those genes are regulated when Sp1 
sites are destroyed. It may suggest the presence of other unknown transcriptional 
mechanisms. However, it seems that multiple transcriptional elements form the minimal 
hTERC promoter by directing Sp-family factors to up- or down-regulate hTERC gene. 
Thus hTERC gene expression may be due to a combination of Sp-family and CCAAT- 
binding factors.
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4.3.2 hTERC transcription requires the CCAAT-box
The regulation of the hTERC gene through the CCAAT-box is discussed in full in the next 
chapter. Deletion of the sequence from -107 to -51 bp in construct pLh2923(-107/69) 
abolishes the basal promoter activity suggesting requirement of this region for h TERC 
transcription. The mutation sequence from CCAA to AGTC at position -58 to -55 bp of 
CCAAT-box disrupts the h TERC transcription therefore demonstrating that CCAAT-box is 
a key controlling element. The data discussed above suggests that the h TERC gene 
contains multiple transcriptional elements and the CCAAT-box may be essential for 
promoter activity. The CCAAT-box motif is recognised by a variety of CCAAT-binding 
transcription factors (for example; NF-Y/CBP, c/EBP, CTF, NF-1). The selective binding 
mechanism by which multiple factors bind to the same target sequence in different genes 
is not clear. It may involve competition among the factors, influenced by sequences 
flanking the consensus motif, or interactions with other proteins binding to adjacent sites. 
Identification of the specific CCAAT-binding factors will be an important issue for 
understanding regulatory mechanism of the hTERC gene transcription.
4.4 Conclusions and Implications
In conclusion, the hTERC promoter posesses sequence elements that allow interactions 
with several different transcription factors. The interplay between CCAAT-binding factor, 
Sp1 and Sp3 within the architecture of the hTERC promoter may combine to enable a 
wide variety of cell types from mortal to immortal to regulate hTERC expression through 
transcriptional control, and the protein binding to CCAAT-box element is essential. Use of 
different types of promoters to drive synthesis of telomerase RNA genes between species 
could reflect distinct pathways of telomerase RNA gene regulation. It is interesting to 
know which protein binds to the CCAAT-box in h TERC and how those regulators act on 
hTERC promoter, and that will be discussed in chapter 5.
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Chapter 5 Identification of Transcriptional Complexes 
Regulating the hTERC Gene Promoter
The previous chapter identified several transcription factor binding sites in the hTERC 
proximal promoter region. This chapter will discuss the identification of NF-Y as the 
hTERC CCAAT-box binding complex. In addition, the role of NF-Y, Sp1, Sp3, pRb and 
E1A proteins in hTERC promoter regulation will be demonstrated (see Figure 5.1 for 
overview). Functional divergence of TERC gene regulation between species will also be 
discussed.
5.1 Introduction
Reconstitution of telomerase activity in vitro by the essential h TERC and hTERT gene has 
been reported, although it is likely these core subunits are augmented by additional 
factors to function optimally (Holt & Shay 1999; O’Reilly et al., 1999). hTERC gene 
expression is regulated during normal human development, with the high levels of 
expression found during embryogenesis decreasing as tissue differentiation occurs. By 
the 10th postnatal week the adult pattern of hTERC expression is evident with only primary 
spermatocytes retaining high levels of expression (Yashima et al., 1998). Although 
hTERC expression is down-regulated from most adult somatic cells, low hTERC 
expression can be detected in some cells such as the regenerative regions of epithelium 
and activated lymphocytes (Weng et al., 1997; Ogoshi et al., 1998; Yashima et al., 1998). 
However, during carcinogenesis the repression of hTERC in the cancer cell is lost or 
deregulated, thus contributing to the almost universal reactivation of telomerase in cancer 
cells (Holt and Shay 1999; Sarvesvaran et al., 1999). Recent studies have indicated that 
transcriptional regulation may have a role to play in the control of hTERC gene expression 
(Zhao et al., 1998; Yi et al., 1999). It is important to identify the molecular basis for the 
transcriptional regulation.
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Figure 5.1 Model illus tra ting  the hTERC proxim al prom oter contro l elem ents 
and the functiona lly  relevant transcrip tiona l regulators.
hTERC proximal promoter structure with identified transcription factor binding site is 
shown. NF-Y complexes are indicated as grey, yellow and red ellipsoid shapes joined 
together, and Sp1/Sp3 is illustrated as green ellipsoid shapes. E1A and pRb as activators 
are shown at the top of diagram.
Studies on hTERC regulation suggest that two mechanisms determine the steady-state 
level of h TERC in cells; the rate of synthesis (the transcription rate) and the rate of 
degradation (the half-life). Elevated h TERC  levels in tumour cells might be due to an 
increased transcription rate, an increased half-life as a result of the association of h TERC  
with the hTERT or other regulatory modifications, or a combination of these factors (Yi et 
al., 1999). The promoter of the h TERC has been cloned and partially characterised (Zhao 
et al., 1998; Chapter 3 and 4) and several transcriptional elements have been identified. 
These studies provide some evidence to suggest that the 5’-flanking sequence region 
plays a role in the hTERC transcriptional control.
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The RNA component of telomerase has been characterized in a variety of species, 
including ciliates, yeast, and mammals (Greider, 1995). Ciliate telomerase RNAs are RNA 
polymerase III (Pol III) transcripts of -160 to -190 nucleotides. The studies of these 
genes demonstrate a well-conserved secondary RNA structure although the primary 
sequence appears to be poorly conserved (Lingner et al., 1994; Romero & Blackburn, 
1991). A conserved proximal sequence element (PSE) located at the proximal promoter 
region of ciliates telomerase RNA has also been identified suggesting transcriptional 
regulation (Hargrove et al., 1999). Telomerase RNAs from the budding yeasts are much 
larger than their ciliate counterparts, they are transcribed by Pol II and processed at their 
3' ends from polyadenylated precursor forms (Chapon et al., 1997). To the date, 35 
telomerase RNA genes have been cloned and sequenced from a variety of vertebrate 
species including 21 mammals, 2 birds, 1 reptile, 7 amphibians, and 4 fishes. Biochemical 
evidence suggests that the vertebrate telomerase RNA gene is transcribed by RNA 
polymerase II (Avilion, 1995 ; Feng et al., 1995; Chen et al., 2000; Zhao et al. 1998; 
Hinkley et al., 1998) and contains potential promoter regions at the 5’ end. However, 
transcriptional regulation has yet to be fully investigated.
Telomerase function is conserved across species and is involved in telomere 
maintenance. Interestingly, the regulation of telomerase expression may differ between 
species. Telomerase activity is low or negative expression in the normal human somatic 
tissue but is readily detectable in the mouse. This suggests that telomerase is regulated 
in different ways in human and mouse (Broccoli et al., 1995, 1996; Zhao et al., 1998). 
Knowledge of the genomic organisation of the telomerase RNA gene and isolation of 
upstream regulatory sequence would be valuable in understanding species differences in 
expression of TERC. Differential expression between different species could reflect 
distinct pathways of telomerase gene regulation. It is important to identify whether 
different pathways of telomerase gene regulation exist because this has significant 
implication for generation of animal models for human disease.
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In this chapter, I describe the identification and partial characterisation of the promoter- 
regulatory region of the human, bovine and mouse TERC gene and compare the 
sequence of 18 other mammalian TERC genes. Functional comparison of the human, 
bovine and mouse TERC promoters demonstrate that TERC genes are indeed 
differentially regulated in different species.
5.2 Results
5.2.1 NF-Y activation of the hTERC gene transcription
5.2.1.1 NF-Y factor binds to the hTERC CCAAT-box
As described previously (section 4.2.2), a CCAAT-box is found upstream of the 
transcriptional start site for hTERC (Figure 4.3A), and corresponds to the protected H10 
region identified by DNase I footprinting (see section 4.2.1). In order to identify which 
cellular proteins interact with this motif, protein extracts from the HeLa cell line were used 
in an electrophoretic mobility shift assay (EMSA) with an oligonucleotide corresponding to 
the wt hTERC sequence (termed h10, Figure 5.2B). Figure 5.3A shows that the h10 
oligonucleotide binds proteins in a specific fashion as competition for binding with the h1 0  
oligonucleotide itself abolishes the complex, as does an oligonucleotide with mutations 
outside the CCAAT-box region (sequence h10m2 see Figure 5.2B). Addition of 
oligonucleotide with mutation introduced into the CCAAT site does not compete for 
protein binding (Figure 5.3A, lane 3; see h10m1 sequence in Figure 5.2B). This suggests 
that the CCAAT-box is the functional region for DNA-binding proteins that might regulate 
the h TERC promoter.
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A)
C “ 7> \
“107 Sp1.2 CCAAT-Box "49
AGCCCGCCCGAGAGAGTGACTCTCACGAGAGCCGCGAGAGTCAGCTTGGCCAATCCGTG
-48 Sp1.1 +1 +10
CGGTCGGCGGCCGCTCCCTTTATAAGCCGACTCGCCCGGCAGCGCACC GGTTGCGGA
+11 +69
GGGTGGGCCTGGGAGGGGTGGTGGCCATTTTTTGTCTAACCCTAACTGAGAAGGGCGTA
Sp1.4
B)
hlO(wt s-63/-42) CTTGGCCAATCCGTGCGGTCGG 
hi0ml (-58/-55) :::::AGTC:::::::::::::
hl0m2 (-51/-48) ::::::::::::TGAT::::::
CBFcons AGACCGTAGGTGATTGGTTAATCTCTT 
NF-YCons ATTTTTCTGATTGGTTAAAAGT
C/EBP cons TGCAGATTGCGCAATCTGCA
NF-1 cons TTTTGGATTGAAGCCAATATGATAA
Figure 5.2 hTERC proximal promoter sequence and identified transcription factor 
binding sites
176 bp of h TERC proximal promoter sequence (-107/+69) is shown in (A), and identified 
regulatory motifs are underlined. The transcriptional start site is marked as “+1”. Four Sp1 
sites are shown and termed Sp 1.1 to Sp1.4. Sp1.4 contains two overlapping Sp1 binding 
sites. The promoter structure is also depicted at the top of diagram. Lines with h4, h9, h 10 
and h i 1 indicate oligonucleotides used for EMSA.
Consensus oligonucleotides for definition of CCAAT binding protein (B). Oligonucleotide 
sequences used in EMSA competition experiments to define h TERC  CCAAT-binding 
complexes. The c/EBP, CBF and NF-1 oligonucleotides were obtained from Santa Cruz, 
and the NF-Y oligonucleotide was from Geneka Biotechnology Inc. These sequences are 
also listed in Table 2.2. Forward or inverted CCAAT-boxes are shaded in light purple.
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Figure 5.3 hTERC CCAAT-box binding to NF-Y factor
A) DNA-binding complexes in HeLa cells 5.5 pg of HeLa cells nuclear extracts were 
mixed with radiolabelled h 10 oligonucleotide probe and analysed by EMSA. Specific 
DNA-protein complexes are indicated by arrows on the left. Competition was 
performed in the presence of 100-fold molar excess of the cold h 10 oligonucleotide 
alone (lane 2), or site-replaced mutation oligonucleotides (lanes 3 and 4), or 
consensus CCAAT-binding sequence (lanes 5 to 8) as indicated. Complexes 
supershifted by preincubation with antibodies are shown on the right by arrows 
marked lss’ (lanes 10-14). Sequences of all oliqonucleotides are shown in Fiqure 5.2B 
and Table 2.4.
B) DNA-binding complexes in 5637, SUSM-1 and Swiss3T3 cell lines Nuclear extracts 
from 5637, SUSM-1 and Swiss 3T3 cell lines were mixed with radiolabelled h 10 or 
CBF consensus olioonucleotide nrobe and analysed bv EMSA as described above.
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Figure 5.4A Inhibition of h TERC promoter activity by expression of the dominant- 
negative-mutant protein NF-YA
5637 cells were co-transfected with 3.0 pg of the pLh2923(-107/+69) construct and 
increasing concentrations of the NF-YAm29 dominant-negative expression vector (red 
bars) or wt NF-YA expression vector (green bars). For each transfection the mean and 
standard deviation for duplicate samples is shown. Hatched bars show relative luciferase 
activities, error bars show standard deviations. The pSEAP2 Control plasmid was used as 
an internal control to normalise the transfection efficiency.
Figure 5.4B Mutation or deletion of CCAAT-box inhibits hTERC promoter activity
The predicted promoter structure is shown at the top. The various colours symbols or 
circles represent the different transcription factor binding sites. The numbers indicate the 
DNA-binding sites related to the transcriptional start site. The constructs are shown with 
red circles indicating a site-replaced mutation in one or more positions. The names of the 
Luc-reporter constructs are shown in the middle column. Three micrograms of each 
plasmid were used for transfection analysis in 5637 cells. The result of the promoter 
activity is shown on the right hand side. Promoter activities of the mutant constructs were 
assayed by transfection and compared to the wild-type promoter (pLh2923). For each 
transfection the mean and standard deviation for duplicate samples are shown. Hatched 
bars show relative luciferase activities, error bars show standard deviations. The 
pSEAP2-Control expression system and PCR semi-quantitation were used to normalise 
transfection efficiency.
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CCAAT-binding proteins encompass a heterogeneous group of transcriptional regulators 
that differ in their sequence requirements and fulfil distinct biological roles (Maity & de 
Crombrugghe, 1998). It was therefore important to ascertain the likely components of the 
hTERC CCAAT-box binding complex. Three candidate CCAAT-binding complexes were 
investigated: NF-Y, (also called CBF or CP1), c/EBP, and NF-1 (consensus binding 
sequences are shown in Figure 5.2B and Table 2.2). As shown in Figure 5.3A, two 
consensus oligonucleotides for NF-Y (termed NF-Y and CBF), compete for hTERC 
CCAAT-binding activity whereas consensus oligonucleotides for c/EBP and NF-1 do not 
(lanes 5-8). Also, antibody supershift analysis revealed that the hTERC CCAAT-binding 
complexes contain two subunits of the NF-Y protein complex, NF-YA and NF-YB (lanes 
10 and 11), but not the distinct CCAAT-binding factors NF-1 or c/EBP (lanes 13-14). As 
shown by others, antibodies to the NF-YC subunit of NF-Y did not disrupt the complex, 
possibly due to inaccessibility on complex formation (Faniello et al., 1999).
To clarify whether hTERC CCAAT-box binds to NF-Y protein from other cell lines, EMSAs 
were also performed using 5637, Swiss 3T3, and Susm-1 cell nuclear extracts as shown 
in Figure 5.3B. The radiolabelled consensus CBF probe was used as a control 
oligonucleotide and the CCAAT-box/NF-Y binding complexes detected in these cell lines. 
The antibody supershift also detected NF-YA and B complexes in 5637 cells as described 
above in HeLa cells. Taken together, these data indicate that the hTERC CCAAT-box is 
recognised by the NF-Y complex.
5.2.1.2 Inhibition o f NF-Y abrogates hTERC promoter activity
As previously described in section 4.3.2, mutation or deletion of the CCAAT-box element 
abolishes the hTERC promoter activity completely, suggesting that this element is the site 
of action for an activator of the h TERC promoter. Furthermore, a mutation of CCAAT-box 
in the large version of hTERC construct, pLh471(ACCAAT, -272/+69, Table 2.5.), lead to 
dicrease wt promoter activity about 8 8 %. In order to evaluate the functional significance 
of NF-Y-CCAAT complex formation on the hTERC promoter, the dominant-negative NF-Y
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vector (NF-YA13m29) developed by Mantovani (1994) was used. Upon transfection into 
mammalian cells, it expresses a mutant protein containing a triple amino acid substitution 
in the NF-YA DNA-binding subdomain that still enables the subunit to interact with the NF- 
YB-NF-YC dimer, but renders the resulting trimer inactive in terms of CCAAT recognition. 
This vector is highly diagnostic, as it has been tested in many different systems and has 
been shown to be specific for NF-Y-dependent promoters (Mantovani, 1994). 5637 cells 
were co-transfected with the hTERC Luc-reporter constructs (pLh2923, -107/+69) and 
increasing amounts of the dominant-negative NF-YA construct or wild-type NF-YA. Figure 
5.4A shows that the dominant-negative vector is indeed inhibitory to hTERC promoter 
activity starting at 60 ng . At higher concentration, hTERC-Luc transcription is decreased 
by 5-7-fold, a level that corresponds to the relative contribution of NF-Y binding to the 
CCAAT-box, as tested in transfections with CCAAT element mutants (Figure 5.4B, 
constructs pLh1011 and pLh26n23). Co-transfection of the wt h TERC Luc-reporter 
construct with wt NF-YA expression vector had no effect on promoter activity. Similar 
experiments were also performed to verify the specificity of the dominant-negative mutant 
by using a larger h TERC promoter construct, pLh2023 (-798/+69)(Figure 5.8). These 
results confirm that NF-Y is the hTERC-dependent factor that transactivates the hTERC 
promoter via the CCAAT-box.
5.2.2 h TERC promoter is activated by Sp1 and repressed by Sp3
The identification of Sp1 sites in the hTERC promoter (Chapter 4) suggests the 
involvement of the Sp1 family of transcription factors in the regulation of the hTERC. In 
order to investigate this further expression vectors for candidate regulators were co­
transfected into the bladder carcinoma cell line 5637 (which is functionally negative for 
pRb) along with the hTERC Luc-reporter constructs. Fluctuations in reporter activity due 
to expression of the candidate proteins were then monitored.
As shown in Figure 5.5A, Sp1 is an activator of the hTERC promoter. Interestingly, Sp1- 
mediated induction of hTERC transcription was abrogated by combined mutation of all
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identified Sp1 sites in construct pLh114 (Figure 5.5A). In contrast, Sp3 is an efficient 
repressor of hTERC promoter activity, even having small effect on construct pLh114 
(Figure 5.5B). As shown in Figure 5.5A and B, constructs pLh1011 (ACCAAT-box) and 
pLh26n23(-51/+69) were not stimulated by expression of the Sp1 protein, the interaction 
of these constructs with Sp3 could not be tested due to the very low basal activity. These 
studies suggest that Sp3 is repressor and Sp1 is activator of the hTERC promoter, and 
Sp1 activation requires functional Sp1 binding sites and a functional CCAAT-box for their 
effect.
To further analyse the functional combination of Sp-family transcription factors in h TERC 
promoter regulation, constant amount of the pLh2023, pLh29m292 or pLh2923 Luc- 
reporter constructs, containing the different versions of the hTERC promoter context (see 
Table 3.1 and Figure 4.7), was co-transfected with 3.0 pg of expression construct for Sp1 
and varying amounts of the Sp3 expression construct in 5637 cells. As shown in Figure 
5.5C and consistent with the above findings, expression of Sp1 alone increased the 
activity of constructs pLh2023 and pLh2923 about 2-fold, but construct pLh29m292 with 
two mutated Sp1 sites (ASp1.1 and ASp1.2) did not show clear stimulation. Co­
expression of Sp3 caused a dose-dependent decrease in luciferase activity. Furthermore, 
repression of the promoter activity was seen in all three constructs when the Sp3 
expression vector was transfected at quantities as low as 0.25 pg, with a plateau of 
repression (-10 fold) being reached at 2.0 pg. These results demonstrate that Sp3 
repression appears to override Sp1 activation of the h TERC promoter.
A combination of the Sp-family of factors and NF-Y would appear to play an important 
role in the control of hTERC gene transcription. Co-transfection experiments were also 
performed with several different hTERC Luc-reporter constructs and the dominant- 
negative NF-YA expression vector and with Sp1/Sp3 expression vectors. The results 
indicate that hTERC transcription was almost totally repressed by expression of 
dominant-negative NF-YA, the resulting level of transcription being approximately the 
same as the shortest deletion construct, pLh26n23 (-55/+69). Taken together, these 
studies suggest that Sp-family of transcription factors activate or repress the hTERC gene
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transcription, and this interaction depends on NF-Y binding to CCAAT-box as no Sp1 
activation was seen when the CCAAT-box was mutated.
5.2.3 pRb regulates the hTERC transcription
The retinoblastoma protein (pRb) is considered to have important roles in normal 
transcriptional regulation and in the progression of a normal mortal cell to an immortal 
cancer cell (Seller and Kaelin 1996; Holt and Shay 1999). It has also been suggested that 
Sp1-mediated transcription can be stimulated by pRb (Kim et al., 1992b; Udvadia et al., 
1993; Chen et al., 1994a). The hTERC gene promoter contains cis-acting elements for 
the transcription factor Sp1, therefore, the ability of pRb to modulate the h TERC promoter 
was assessed in the pRb/p53 null bladder cell line, 5637.
To test whether the hTERC promoter is regulated by the tumour suppresser protein pRb, 
an 867 bp fragment of the hTERC promoter construct pl_h2023 (-798/+69) was used. 
Transient expression of pRb from a CMV-pRb expression vector induced hTERC 
promoter activity as shown in Figure 5.6A. This activation was dose dependent ranging 
from 1.5 fold induction when 62.5 ng CMV-pRb vector was introduced up to 4-7 fold 
induction with 250 ng. As CMV is a strong promoter and hTERC activation is very 
sensitive to the dose of CMV-pRb vector used, a SV40 promoter-driven pRb expression 
vector was also tested. When 0.5 to 1.0 pg of the SV40-Rb expression vector were co­
transfected with the hTERC Luc-reporter, very similar results were obtained.
To determine whether pRb activation is specific to the h TERC promoter, a mTerc Luc- 
reporter construct, pL2730 (-549/+80), was also used. The mTerc promoter shows no 
significant sequence homology to the hTERC promoter (Zhao et al., 1998; section 3.3.2) 
although 3 potential Sp1 sites are detected in the mTerc promoter region. As shown in 
Figure 5.6A, the mTerc promoter was not activated by pRb under the same experimental 
conditions as the human promoter, thus demonstrating a functional difference between 
the human and mouse telomerase RNA gene promoters in terms of their response to 
pRb. This study demonstrates for the first time that pRb specifically stimulates hTERC 
promoter activity.
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It has been reported that pRb can transactivate a number of gene promoters by 
interaction with a variety of transcriptional complexes including MyoD, c/EBP, NF-IL6 , 
YY1 and Sp1 (Sellers et al., 1998; Chen et al, 1996a,b; Kim et al., 1992b; Udvadia et al., 
1993; Petkova et al., 2000). There are two Sp1 sites (Sp1.3 and Sp1.4) which contain 
GGGTGG elements, which has be reported as an indicator of a pRb responsive gene 
(Kim et al., 1992b; Udvadia et al., 1993), located at position +11 to +16 and +26 to +31 bp 
within the h TERC proximal promoter. To determine whether these or other transcriptional 
elements are involved in pRb-mediated induction of hTERC, co-transfection experiments 
were performed using 0.5 pg of SV40-Rb expression vector with 3.0 pg of the hTERC 
proximal promoter (pLh2923 -107/+69) or the shortest deletion promoter (pLh26n23 - 
51/+69) which still retains Sp1.3 and Sp1.4 sites but lacks the CCAAT-box. As shown in 
Figure 5.6B, pRb activates transcription of 176 bp of the hTERC proximal promoter by 4- 
fold but is unable to activate the 1 2 0  bp minimal promoter.
Next hTERC Luc-reporter constructs with mutations of the four Sp1 sites (construct 
pLh114; ASp1.1, ASp1.2, ASp1.3 and ASp1.4) or with mutation of the CCAAT-box 
(construct pLh1101 ACCAAT) were used. In co-transfection experiments, pRb is able to 
increase pLh114 promoter activity by 2-fold, but it is unable to activate pL1101 promoter 
activity. As described previously (section 4.2.4), the promoter activity was not fully 
abolished in construct pLh114 despite multiple mutations. To further confirm that pRb was 
still able to activate this construct, the sequence of this individual plasmid preparation was 
verified by restriction enzyme mapping and DNA sequencing, and the experiments were 
repeated with separately prepared preparations of plasmid DNA. The same result was 
obtained in each case. Thus, mutation of all four Sp1 sites including GGGTGG motifs in 
the hTERC proximal promoter region did not abolish pRb transactivation.
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Figure 5.5 Sp1/Sp3 factors regulate hTERC gene transcription
The predicted promoter structure is shown at the top. The various colours symbols or 
circles represent the different transcription factor binding sites. The numbers indicate the 
DNA-binding sites related to the transcriptional start site. The constructs are shown with 
red circles indicating a site-replaced mutation in one or more positions. The names of the 
Luc-reporter constructs are shown in the middle column. The result of the promoter 
activity is shown on the right hand side. Three micrograms of each plasmid were used for 
transfection or co-transfection with the Sp1/Sp3 expression vector in 5637 cells. Promoter 
activities of the mutant constructs were assayed by transfection and compared to the 
wild-type promoter (pLh2923). For each transfection the mean and standard deviation for 
duplicate samples are shown. Flatched bars show relative luciferase activities, error bars 
show standard deviations. The pSEAP2  Control plasmid was used as an internal control 
to normalise the transfection efficiency.
A) The Sp1 transcription factor activates the hTERC promoter.
B) The Sp3 transcription factor represses the hTERC promoter.
C) Suppression of Sp1-induced hTERC transcription by Sp3 Indicated amounts of 
pCMVSp3 were transfected into 5637 cells along with a constant amount (3.0 pg) of 
pCMVSpI, in addition to either pLh2023 (-798/+69, 1.0 pg), pLh29m292 (ASp1.1/A 
Sp1 .2 , 3.0 pg) or pLh2923 (-107/+69, 3.0 pg) luciferase reporter constructs. The 
results are expressed as relative luciferase activity from one of three independent 
experiments.
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Figure 5.6 pRb transactivates hTERC gene transcription
A) pRb activates h TERC  promoter activities The pRb/p53 negative cell line 5637 was 
transfected with a fixed amount of the pLh2023 (-798/+69, 1.5 pg) construct and 
increasing concentrations of CMV-Rb expression vector. In the control experiment, the 
mouse telomerase (mTerc) promoter-luciferase construct pL2730 (-549/+80, 1.5 pg) 
was analysed for its response to pRb. This experiment has been performed at least 
three times. For each transfection the mean and standard deviation for duplicate 
samples is shown.
B) Mutation or deletion of the CCAAT-box blocks the pRb activation of hTERC gene 
transcription The predicted promoter structure is shown at the top. The various 
colours symbols or circles represent the different transcription factor binding sites. The 
numbers indicate the DNA-binding sites related to the transcriptional start site. The 
constructs are shown with red circles indicating site-replaced mutations in one or more 
positions. The names of the Luc-reporter constructs are shown in the middle column. 
The result of the promoter activity is shown on the right hand side. Three micrograms 
of each plasmid were used for transfection or co-transfection with 0.5 pg pSV40-Rb 
vector in 5637 cells. The result of the promoter activity is shown on the right hand side. 
Promoter activities of the mutant constructs were assayed by transfection and 
compared to the wild-type promoter (pLh2923). For each transfection the mean and 
standard deviation for duplicate samples are shown. The Luciferase activity was 
normalised by co-transfection with the pSEAP control vector. Hatched bars show 
relative luciferase activities, error bars show standard deviations.
119
(Zhao, JQ., Sept. 2000) Chapter 5. Regulation of the hTERC Promoter
As described above, pRb activation could not be observed in mutation construct pLh1101 
(ACCAAT), or deletion construct, pLh26n23 (-51/+69). Removal of the hTERC CCAAT- 
box from the proximal promoter region abolishes the promoter activity totally and this can 
not be rescued by pRb. These studies suggest that the hTERC promoter can be positively 
regulated by pRb, a functional CCAAT-box is necessary for this activation, but Sp1 sites 
including the GGGTGG motif are not essential, at least in 5637 cells.
5.2.4 The hTERC and hTERT promoter activity in mortal and immortal cells
To investigate the regulation of the human telomerase genes (hTERC and hTERT) 
transcriptional regulation in mortal and immortal cells, 3.0 pig of Luc-reporter constructs, 
h TERC and hTERT, were transfected into the mortal or immortal cells and the promoter 
activities were monitored. 5637 cells are a pRb/p53 null immortal cell line that is 
telomerase-positive, whereas WI38 and IMR90 are telomerase-negative mortal cell lines 
(Meyerson et al., 1997). As shown in Figure 5.7A, WI38 and IMR90 cells have very low 
hTERC and hTERT promoter activity. In contrast, high levels of reporter gene expression 
were detected in 5637 cells with the h TERC exhibiting a 3-fold higher activity than the 
hTERT promoter. In this experiment, pSEAP2-Control vector (Clontech) was used as 
internal control for transfection efficiency within cell line. But in across cell lines, the 
transfected plasmid DNAs were measured by PCR semi-quantitation, identical amount of 
luciferase gene PCR products were detected in all transfected cells after luciferase assay 
(for methods described in section 2.4.5). These results show that low telomerase gene 
promoter activity in two mortal cells is not due to low transfection efficiency.
5.2.5 E1A induces the h TERC and hTERT promoter activity
The Adenovirus 5 early region 1A (E1A) oncogene induces progression through the cell 
cycle by binding to the products of the p300/CBP and retinoblastoma gene families.
120
(Zhao, JQ., Sept. 2000) Chapter 5. Regulation of the h TERC  Promoter
To test whether the oncoprotein E1A affects the transcriptional regulation of the human 
telomerase genes, the two constructs, hTERC (pLh2923, -107/+69) and hTERT 
(phTERT19, -526/+9), were used in co-transfection experiments with wild-type E1A. As 
shown in the Figure 5.7B, transient expression of wild-type E1A could efficiently increase 
both h TERC  and hTERT  promoter activity. The activities of the hTERT and h TERC  
promoters were increased about 5- and 2.5-fold respectively by E1A. These prelim inary 
results suggest for the first time that the adenovirus protein E1A can induce both the RNA 
and protein components of telomerase transcription. To summarise, human telom erase 
genes show high promoter activity in immortal cells but not in mortal cells, and the hTERT 
and hTERC  promoters are capable of up-regulation by E1A in 5637 cells.
hTERThTERT
IM R90 W I38
Figure 5.7 Comparing regulation of hTERC and hTERT promoter transcription
Three micrograms of the luciferase reporter constructs; h TERC, (pLh2923, -107/+69, red 
bars), and hTERT, (phTERT19, -526/+9, yellow bars) were transfected by using 
SuperFect reagents with or without the E1A expression vector (for hTERT promoter 
sequence see Appendix III). Related luciferase activity was detected 48 hours post­
transfection. For each transfection the mean and standard deviation for duplicate samples 
are shown.
A) hTERC and hTERT promoter activity in mortal and immortal cells. Two mortal cell 
lines (IMR90 and WI38) and one immortal cell line (5637) were used for the 
transfection assay. Luciferase activity was normalised to the SEAP activity of a co­
transfected internal control plasmid, pSEAP-control( 1.5 pg) (Clonetech). In this study, 
the semi-quantitation PCR system (see section 2.4.4) was used to detect the 
transfected plasmid DNA in tested cells to normalise the transfection efficiency.
B) E1A induction of hTERC/hTERT gene transcription in 5637 cells
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5.2.6 Functional divergence in the transcriptional regulation of the TERC gene 
between species
Despite conservation in telomerase enzyme function across species, there may be 
fundamental differences in telomerase gene regulation between mouse and human (Zhao 
et al., 1998; Blasco et al., 1997). In order to gain a clearer insight into the regulation of 
telomerase RNA genes, and to understand TERC transcriptional mechanisms whether 
different exist in differences species, the human, mouse and bovine TERC gene 
promoters cloned in our Lab were analysed for comparative transcription. The response 
of these three TERC gene promoters to the transcriptional regulators pRb, NF-Y, Sp1 and 
Sp3 were compared in transient co-transfection experiments in 5637 cells. The bovine 
telomerase RNA gene promoter was included in this study as it is more closely related to 
the human gene in terms of sequence and may be of value in dissecting promoter 
function (Tsao et al., 1998). As shown in Figure 5.8, the human and bovine promoters 
were activated by pRb whereas the mouse promoter was not; the result from mTerc is 
consistent with an observation described in section 5.2.3. Transcription factor Sp1 
activates and Sp3 represses all three promoters. The dominant negative NF-YA mutant, 
NF-YAm29, is diagnostic for NF-Y-dependent gene transcription. Transient expression of 
NF-YAm29 repressed promoter activities of the hTERC but not bTERC and mTerc 
suggesting NF-Y regulation appears to be essential to human gene promoter. Titration 
experiments have been performed in each individual promoter construct to further prove 
this point. These studies demonstrate that the TERC genes are differentially regulated at 
the transcription level in different species.
5.2.7 Comparison of different mammalian TERC promoter region
A recent study of the vertebrate TERC genes (Chen et al., 2000) allows comparison of 
the proximal promoter regions. This may provide insight into the transcription regulation of 
different species. As shown in Figure 5.9, alignment analysis of the mammalian TERC 
gene proximal promoter sequence realised a phylogenic tree indicating the bovine and pig 
sequences are closely related to the human. Since the hTERC proximal promoter has
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been detected within 107 bp upstream of the TSS, a sequence comparison of 176 bp of 
the hTERC and bTERC promoter was performed. As shown in Figure 5.10, an alignment 
of the hTERC proximal promoter region sequence shares 70.5% identity with the bTERC. 
The sequence element between TSS and the template region of h TERC and bTERC is 
not found in the mTerc proximal promoter. Among promoter elements thought to be 
important for the regulation and expression of hTERC, the CCAAT-box and Sp1.3 binding 
sites, were also found in the bTERC potential promoter region. A YY1 site, and the TATA- 
box are also conserved between the hTERC and bTERC proximal promoter region.
The sequence analysis of the three TERC promoters revealed an interesting divergence 
between the human and mouse. It was therefore of interest to analyse the promoter 
sequence relationship of a larger group of mammalian TERC genes. In order to identify 
potential clusters of related sequences, by using the human TERC proximal promoter as 
the control sequence, the 5' flanking region sequences of 21 mammalian TERC genes 
spanning -106 to +63 bp region were aligned by using the Vector NTI Suite program 
(InforMax) to detect conserved promoter elements. As shown in Figure 5.11, from this 
study, the mammalian TERC proximal promoter sequence was predicted. The following 
major points were found; the mammalian TERC promoters contain (i) a single forward 
CCAAT-box element which is located between -40 bp and - 6 6  bp relative to the TSS; (ii) a 
TATA-box is located about 25 bp up-stream of the TSS; (iii) a conserved template 
sequence downstream of the TSS from 2 to 51 bp away. The mouse, hamster, rat and 
vole TERC genes appear to lack a typical sequence region between TSS and template 
region (termed 5'-FTR). The results of sequencing studies demonstrate that the TATA 
box, an upstream forward CCAAT-box and template region are conserved in all species, 
and a conserved promoter structure for rodent TERC genes can be predicted as shown in 
Figure 5.12.
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Basic alone 
+ Rb 
+ Sp1 
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pLh2023 
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pLb410 
(b TERC)
Figure 5.8 Functional divergence in the transcrip tiona l regulation of TERC 
genes between species
Promoter-luciferase constructs for the human, mouse and bovine TERC genes were 
compared to assess their regulation by NF-YAm29, Sp1, Sp3 and pRb. The human 
promoter (hTERC) construct shown is the full-length 867 bp plasmid (pl_h2023, -798/+69 
bp). The mouse telomerase (mTerc) promoter-luciferase construct used was pL2730 (- 
514/+114 bp), and the luciferase-reporter construct containing the bovine telomerase 
RNA gene promoter (bTEHC) was pl_b410 (-274/+69 bp; for sequence see Appendix VI). 
The activity of the promoters in response to co-transfection with the transcriptional 
regulation is shown as fold inductions relative to the promoters alone. For each 
transfection the mean and standard deviation for duplicate samples are shown.
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Figure 5.9 TERC prom oter 
phylogentic tree
Phylogenetic analysis using 
proximal promoter sequence in 
the 5'-flanking transcriptional 
regulatory region from 21 
mammalian TERC genes. The 
phylogenetic tree is derived 
from minimum-evolution using 
the vector NTI Suite program 
(InforMax).
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5.3 Discussion
Reactivation of telomerase is an almost universal event in carcinogenesis. Though other 
proteins are involved in optimal function of the telomerase enzyme, the RNA subunit 
(TERC) and the catalytic protein components (TERT) are sufficient to reconstitute this 
enzyme activity. Consistent with telomerase activity, both components are expressed at 
high levels in the majority of cancers. The general goal of this study is to define candidate 
molecules that regulate the hTERC gene expression and to further understand 
mechanisms of transcriptional regulation. Several factors capable of modulating hTERC 
promoter activity in cell culture have been identified (overview in Figure 5.1). (i) hTERC 
transcription requires binding of nuclear factor NF-Y to the CCAAT-box. (ii) The promoter 
is activated by Sp1, and repressed by Sp3. (iii) The tumour suppressor protein pRb 
stimulates hTERC transcription, (iv) The transcriptional regulation of telomerase RNA 
gene appears to exhibit divergence between species.
5.3.1 NF-Y is essential for the hTERC expression
The sequences that control basal transcription are common to many genes and include 
the TATA-box, the CCAAT-box and the initiator sequence. Mutation of TATA-box did not 
affect promoter activity, however mutation of the CCAAT-box abolished hTERC 
transcription suggesting that this CCAAT motif is an essential element. Several pieces of 
evidence provided in this study indicate that the CCAAT-box bound by NF-Y plays a 
significant role in the transcriptional regulation of the hTERC gene.
In higher eukaryotic promoters the CCAAT-box is most usually found between 60 and 100 
bp upstream of the transcriptional start site (TSS) of a gene (Maity & Crombrugghe, 1998; 
Mantovani, 1998). The hTERC CCAAT-box is located -58 to -54 bp upstream of the TSS, 
within the minimal promoter region that was narrowed down to 176 bp (ranging from 
position -107 to +69 bp) with the aid of 5'-deletion constructs (section 3.5.3). Secondly, in 
vitro DNase I footprinting analysis revealed that there were proteins binding to the region 
centred around the CCAAT-box from -60 to -50 bp (designated the H10 region). Thirdly,
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in EMSAs, similar CCAAT-binding complexes were detected from four different immortal 
cell lines (HeLa, 5637, Swiss 3T3 and Susm-1; Figure 5.3B). These complexes could be 
supershifted by NF-Y antibodies or disrupted by mutation the CCAAT-box. These results 
indicate that the major retarded band was due to the binding of NF-Y to the CCAAT 
element in the promoter. Fourthly, deletion and site-directed mutagenesis of the CCAAT- 
box drastically reduced the Luc-reporter activity. Furthermore, inhibition of NF-Y by 
transient expression of a dominant-negative mutant NF-YA protein also specifically 
reduced Luc-reporter activity. In summary, NF-Y appears to be the major transcription 
factor that binds to hTERC CCAAT-box, and regulates the h TERC transcription.
NF-Y is a heterotrimeric transcription factor composed of three subunits (NF-YA, B, and
C), which complexes with DNA (Maity & Crombrugghe, 1998; Mantovani, 1998). NF-Y 
subunit sequences are highly conserved among eukaryotes, and the yeast homologue 
heme-activated proteins can form heterotrimeric complexes with the corresponding 
mammalian subunits (Chodosh et al., 1988). Both NF-YB and NF-YC contain conserved 
putative histone fold motifs (HFM)( Baxevanis et al.,1995). This motif shows most 
similarity to histones H2B and H2A (Motta et al., 1999), and is responsible for the 
formation of the histone octamer. NF-YB and NF-YC form a tight association that is a 
prerequisite for NF-YA binding and sequence-specific DNA interactions (Sinha et al.,
1995). Therefore, NF-Y may be important for organising promoter architecture leading to 
gene expression.
Recent studies from several laboratories have suggested that NF-Y interacts, either 
functionally or physically, with other transcription factors or regulatory proteins both in 
vitro and in vivo (Framson & Bornstein, 1993; Ericsson et al., 1996; van Ginkel et al., 
1997; Wright et al., 1995a; Zwicker et al., 1995). Mutation of the CCAAT motifs of 
promoters, including that of the mouse 1 collagen gene, the mouse albumin gene, the 
human multidrug resistance gene, and the human blood coagulation factor X gene, 
decreases the basal promoter activity (Maity & de Crombrugghe, 1998) suggesting 
important role of NF-Y regulation in those genes. As discussed by Fucharoen studies 
(1990), removal of Y-box from the MHC class II Ea promoter dramatically decreases
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transcription, altering start site selection (Fucharoen et al., 1990). NF-Y might have 
distinct roles depending on the promoter context; in Ea it could directly participate in the 
formation of a pre-initiation complex and ultimately help in selection of the TSS, in 
conjunction with an Initiator element (Mantovani et al., 1992; Bellorini et al., 1996,1997a; 
Caretti et al., 2000). In the globin promoter it might help build the overall architecture and 
allow the proper interactions of additional DNA binding activators (Liberati et al., 1998). 
Mutation in the NF-Y-binding site of the mouse a2(1) collagen promoter abolished the NF- 
Y -dependent transcriptional activation (Coustry et al., 1996). Studies by Hu et al (2000) 
reported that stable expression of a dominant negative NF-Y mutant protein in the mouse 
fibroblast cells inhibit expression of the E2F1, topo Hoc, and a2(1) collagen genes, thus 
indicating that NF-Y directly in the regulation of these genes in vivo (Hu & Maity, 2000).
NF-Y specifically bound to the hTERC CCAAT-box, whereas other proteins which have 
been reported to bind CCAAT-boxes such as c/EBP, CTF and NF-1 did not bind to the 
h TERC CCAAT-box, suggesting that in addition to the CCAAT sequence other specific 
nucleotides are also required for NF-Y binding. Inhibition of NF-Y binding to CCAAT-box 
abrogates the h TERC transcription. Thus, the results presented so far strongly suggest 
that NF-Y is the hTERC-dependent CCAAT-box activator.
In general the vast majority of the CCAAT boxes have been shown to significantly 
contribute to overall promoter strength and, indeed, sometimes to be strictly required for 
activity (Mantovani, 1998). The hTERC gene promoter contains a TATA sequence which 
is not required for hTERC gene expression in the tested cells, others have also 
demonstrated that other promoters containing a TATA-like sequence might actually work 
without it (for review see Mantovani, 1998). In the case of the Ea promoter, for example, a 
TATA-like sequence binding TBP and TFIID is present at -25 bp (same as hTERC), but is 
functionally irrelevant (Viville et al., 1991; Bellorini et al., 1996). A direct interaction of NF- 
YB and NF-YC with TBP has recently been demonstrated in vitro (Bellorini et al., 1997a). 
NF-Y can serve a structural role by recruiting TBP and/or TAFIIs to connect upstream 
activators with the general polymerase II transcription machinery (Coustry et al., 1998; 
Matuoka & Chen, 1999). It has also been reported that NF-Y can interact with the
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nucleosome. NF-Y, itself not posessing very strong transcriptional activation domains, 
play a dominant role in determining gene promoter architecture (Motta et al., 1999). 
Therefore, NF-Y might play an important role in hTERC gene transcription by organising 
promoter architecture. The significance of the architectural factor, NF-Y, in the differential 
expression of mortal and immortal cells should be considered and further elucidated.
Primary human cells have a limited life span in culture and undergo replicative 
senescence after a certain number of divisions. CBP/tk (equivalent to NF-Y) protein 
binding to the inverted CCAAT-box in the thymidine kinase gene is detected in serum- 
stimulated young (low PDL) IMR-90 cells, but not in senescent cells (Good & ChenA
1996), this indicates that the expression of CBP/tk protein is cell cycle- and age- 
dependent. Both NF-YA and NF-YB are constitutively expressed at the mRNA level in 
IMR-90 cells, however, expression of NF-YA and NF-YB at the protein level are clearly 
age-dependent (Good & Chen, 1996). NF-Y may also have a rule in cell senescence 
(Matuoka & Chen, 2000).
NF-Y also binds to and controls a number of cell cycle regulated promoters and may be 
directly involved in oncogenesis (Pang et al., 1996; Maity & Crombrugghe, 1998; Gu et 
al., 1999). NF-Y activity is found to change during senescence and in response to 
inducing agents (Good & Chen 1996; Farina et al., 1999; Marziali et al., 1999; Maity & 
Crombrugghe, 1998). It has been discussed that the reactivation or expression of 
telomerase may be a major mechanism by which cancer cells overcome normal cellular 
senescence (Bodnar et al., 1998; Holt & Shay, 1999; Parkinson et al., 1997). Therefore, 
NF-Y may be part of the molecular mechanism linkage cell senescence and telomerase 
expression.
5.3.2 Sp-family factors regulate telomerase gene transcription
The Sp1 binding sites within the hTERC promoter appears to be two distinct functions, 
one to weakly promote transcription and other to strongly repress telomerase RNA gene
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activation. Competitive binding between different trans-factors at the same or nearby 
promoter elements, often having opposing effects, is a mechanism of transcriptional 
regulation seen in many promoters. This type of regulation may be a particularly important 
mode for the hTERC promoter. Sp1 and Sp3 represent just two members of a growing 
family of mammalian Kruppel-like transcription factors which bind GC-rich sequence 
elements, and are involved in the regulation of tissue specific and housekeeping genes. 
These factors have been shown to compete with similar affinities for binding at the same 
GC-box elements (Kingsley & Winoto, 1992; Hagen et al., 1992, 1994). Although Sp1 has 
long been known to function as an activating transcription factor, in many instances over­
expression of Sp3 has indicated that Sp3 may serve as an inhibitory member of the Sp 
family, causing repression of Sp1-mediated promoter activation (Hagen et al., 1994; 
Majello et al., 1994, 1995; Kumar & Butler, 1997). Therefore, the relative levels of Sp1 
and Sp3 proteins in a given cell are likely to be important determinants of the 
transcriptional activity of a target promoter (Kubo et al., 1995; Apt et al., 1996).
The multiple Sp1 elements found within the hTERC promoter suggest a complex 
interactions between Sp1 and Sp3. It has been demonstrated that the repression of 
promoter activity by Sp3 is strictly dependent on the promoter context of the DNA-binding 
sites and the number of Sp1 sites. It was discussed that Sp3 is functional when targeted 
to a promoter-proximal-RNA sequence and Sp3 may serve as important regulatory 
targets in setting the mRNA expression levels in various cell types (De Luca et al., 1996; 
Majello et al., 1997). Sp3-mediated repression may act directly on the general 
transcription machinery. Removal of the all identified Sp1 sites in the hTERC promoter 
abolished the Sp1 activation but did not abolish Sp3 repression (Figure 5.5B) suggesting 
other unknown mechanism. That may act through another as yet unidentified 
mechanisms (for example; a potential Sp1 site close to the 3'-end of proximal promoter 
region, Figure 3.4a).
Recent studies identified a 181 bp proximal promoter region of hTERT around the 
transcription start site which contains five Sp1 sites. Each of the five Sp1 sites co­
operatively functioned as a c/s-acting element and abrogation of all Sp1 sites resulted in
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almost complete loss of transcriptional activity. In addition, Sp1 function was required for 
Myc-mediated transactivation of hTERT (Kyo et al., 2000). As described in section 5.2.2, 
removal of all four Sp1 sites in the h TERC proximal promoter region abolishes the Sp1 
transactivation. These findings suggest a central role for Sp1 in activation of hTERC and 
hTERT transcription in an overlapping, though not necessarily co-ordinated control 
mechanism. Sp1 knockouts show that Sp1 is required for early mouse development 
(Lania et al., 1997 ). Sp1 is considered to be a ubiquitous factor, however greater than 
1 0 0 -fold differences in its expression level have been found between different cell types 
(Saffer et al., 1991), It has been demonstrated that levels of Sp1 expression were much 
higher in cancer than normal cells, correlating with telomerase activity (Kyo et al., 2000). 
Thus, despite its widespread expression, the level of Sp1 expression may be a critical 
determinant of telomerase activity not only in cancer but also in normal cells.
Co-operation between NF-Y and Sp1 has been demonstrated in the regulation of several 
genes including the MHC class ll-associated invariant chain (Wright et al., 1995a), the 
p27KIP1 gene (Inoue et al., 1999), the hamster thymidine kinase gene (Sorensen & 
Wintersberger, 1999), and the rat fatty acid synthase gene (Roder et al., 1997). The 
promoters of these genes all have in common one or several Sp1 binding sites located in 
close proximity (20 to 30 nucleotides) with an inverted CCAAT motif. Cooperation 
between these two transcription factors is involved in the insulin response of the fatty acid 
synthase gene, the vitamin D3 response of the p27KIP1 promoter, and the serum response 
of the thymidine kinase promoter. The molecular mechanism responsible for this 
cooperative activity has been recently partially elucidated by the demonstration of the 
cooperative DNA binding of NF-YA and Sp1 and the presence of specific protein-protein 
interaction domains in NF-YA and Sp1 (Roder et al, 1997, 1999). A physical interaction 
between NF-YA and Sp1/Sp3 has been demonstrated (Yamada et al., 2000; Roder et al., 
1999). In the hTERC promoter, there are multiple Sp1 binding sites, one Sp1 site located 
38 nucleotides upstream, three Sp1 sites located 17, 35 and 48 nucleotides downstream 
of the NF-Y binding site, respectively. These Sp1 sites alone did not mediate hTERC 
transcription with a mutated CCAAT motif suggesting that Sp1 family factors modulation
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of hTERC transcription is subject to a functional NF-Y binding CCAAT-box. Thus the 
functional co-operation between NF-Y and Sp1 remains to be tested. A proximal promoter 
structure is now emerging composed of a functional CCAAT-box, four Sp1 sites and 
template region (Figure 5.1).
5.3.3 pRb activates the hTERC transcription
Our finding that pRb is an activator of the h TERC promoter was somewhat surprising 
given its well-known function as a tumour suppresser. pRb negatively regulates 
transcription of a number of genes that play a role in cell cycle progression by forming 
complexes with members of the E2F transcription family. However, pRb also has an 
ability to co-activate a number of genes including TGF-p2, the retinoblastoma gene itself, 
cyclin D1, YY1 and the Werner helicase gene is well described (Kim et al., 1992a; Muller 
et al., 1994; Yamabe et al., 1998; Chen et al., 1994a: Petkova et al., 2000). Rb can also 
stimulate the c-fos, c-Myc, TGF-(31 (Kim et al., 1991; Udvadia et al., 1993) promoters 
through stimulation of Sp1-mediated transcription.
As described in previous sections, hTERC regulation involves Sp1-mediated transcription. 
Promoters with Sp1 sites containing GGGTGG sequence have been shown to be 
positively regulated in a cell type-specific manner by the retinoblastoma gene product 
(Kim et al., 1992b; Udvadia et al., 1992; Yamabe et al., 1998; Seller et al., 1996). The 
GGGTGG motif may therefore be an indicator for gene transactivation by pRb. In 
agreement with this, both the hTERC and bTERC promoters which contain these motifs 
(Figure 5.10) are stimulated by pRb, whilst mTerc dose not contain this motif and fails to 
respond to pRb activation. A study by Noe et al. provided evidence that Sp1 can be 
physically associated with pRb (Noe et al., 1998). Recombinant pRb protein enhances the 
DNA-binding activity of Sp1 (Kim et al., 1992b; Udvadia et al., 1993; Chen et al., 1994a) 
thus stimulating Sp1 -mediated transcription. pRb might also act by liberating Sp1 from a 
negative regulator (Chen et al., 1994a). However, these mechanisms may not be acting in 
the case of h TERC regulation since pRb still activates promoter activity when all four Sp1
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sites have been mutated. This is consistent with the fundings of others (Udvadia et al., 
1992, 1995) and suggests that pRb regulation in the context may not involve DNA 
binding.
pRb has been shown to enhance the binding activity of both c/EBP (Chen et al, 1996a) 
and NF-IL6  (Chen et al, 1996b), members of the c/EBP family of transcription factors, to 
their cognate DNA sequences in vitro, and to transactivate c/EBPp- and NF-IL6 - 
responsive promoters in cells. It has been reported that Rb inhibits YY1 binding to DNA 
and blocks YY1-dependent transcription in vitro. YY1-Rb interaction causes the activation 
of genes that free YY1 repress and repression where free YY1 functions as an activator 
(Petkova et al., 2000).The present study suggests that pRb transactivation of the hTERC 
promoter requires a functional CCAAT-box. However, since the hTERC CCAAT-box has 
been shown to be recognised by NF-Y rather than c/EBP, it is unlikely that pRb activation 
of the hTERC transcription is through interaction with the CCAAT-binding factor c/EBP. It 
has been reported that over-expression of pRB alone in RB/p53-defective tumor cells 
causes cell senescence decrease in telomerase activity (Xu et al., 1997), and Nguyen et 
al., also demonstrated that functionally intact Rb was required for cell cycle-dependent 
downregulation of telomerase activity in SCC lines (Nguyen et al, 1999). Here transient 
expression pRb has been shown to transactivate hTERC promoter but to have no effect 
on the hTERT promoter (data not shown) suggesting differential regulatory mechanisms 
may be involved in transcriptional control between hTERC and hTERT gene expression. 
In recent years growing evidence has been accumulating for a more general function of 
pRb at both the transcriptional level and the cellular level. pRb not only regulates the 
activity of certain protein-encoding genes but also the activity of RNA polymerase pol II 
and pol III transcription (Herwig & Strauss, 1997). How pRb activates transcription is not 
fully understood but in keeping with the results of Sellers (1998) the ability of pRb to 
activate the hTERC promoter is independent of its ability to bind E2F (unpublished data 
generated in our Lab). It is unknown whether pRb can activate endogenous hTERC gene 
expression in cells, or whether pRb acts through an interaction with NF-Y and further 
research is clearly required to answer this question.
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To summarise, the hTERC promoter is responsive to transactivation by pRb, which is not 
mediated through identified Sp1 sites. By analogy with other studies pRb possibly 
activates h TERC transcription by interaction with other nuclear proteins rather than 
directly binding to the DNA sequence. The present findings provide evidence for a 
functional link between pRb and the hTERC gene, and the identification of hTERC as 
another gene that is activated by pRb may contribute to the investigation of this aspect of 
pRb function.
5.3.4 E1A activates telomerase genes transcription
Since active telomerase requires the presence of both the protein and RNA components, 
it is intuitive to expect that the synthesis of the components may be co-ordinated. 
Transcriptional up-regulation of h TERC is observed in immortalised cell types that 
express endogenous hTERT (Yi et al., 1999). In addition, I have shown that activity of 
both the h TERC and hTERT promoters is higher in immortal cells than in two mortal cell 
strains. This observation is consistent with other studies (Cong et al., 1999) showing that 
transcription-rate of the telomerase genes is different between normal and tumour cells 
and that these parallel telomerase enzyme activity (Yi et al., 1999).
Expression of telomerase has been reported to be regulated at the transcription level 
(Zhao et al., 1998; Hinkley et al., 1998; Fujimoto et al., 2000; Kyo et al., 1999, 2000; Wick 
et al., 1999; Cong et al., 1999; Horikawa et al., 1999; Hargrove et al., 1999). A variety of 
molecules may potentially be involved in telomerase regulation (section 1.5.2, and 1.5.4). 
In this study, transcriptional regulation of the hTERC promoter was further investigated by 
introducing a viral transforming protein E1A. The E1A proteins of small DNA tumour 
viruses are able to disrupt normal cell growth control leading to uncontrolled cell 
proliferation by their abilities to associate with a number of cellular growth regulatory 
proteins through multiple domains. The E1A proteins alter the cell growth regulation 
through at least two independent protein binding domains; one domain binds members of 
the pocket-containing protein family, the most characterised of which is the Rb tumour
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suppresser protein. The second domain binds members of the CBP/p300 family of co­
activators (Jones, 1995; Moran, 1993). It has also been reported that E1A protein induces 
the expression and assembly of a heteromeric complex consisting of the 110-kDa protein 
CBF/NF-Y, and mediates optimal transactivation of the human cdc2 promoter by 
promoting interaction of NF-Y with the two CCAAT motifs of the cdc2 promoter (Kao et 
al., 1999; Tanimoto et al., 1998J. The adenovirus E1A protein is also be able to alter YY1 
function from a repressor to a trans-activator (Shi et al., 1991) and trans-activates gene 
promoters through induction of c-MYC (Jayachandra et al., 1999). Since the oncoprotein 
c-Myc up-regulates telomerase activity by targeting hTERT promoter E-box and NF-Y is a 
major activator of h TERC transcription by binding hTERC promoter Y-box, these could 
provide the mechanisms of activation of both telomerase components by E1A. Further 
investigation using E1A mutants will be useful in dissecting the mechanism of E1A 
activation of telomerase.
Taken all together, transcriptional regulation of the hTERC promoter involves NF-Y and 
Sp1 family factors. This promoter architecture also allows other onco- or cellular-proteins 
(such as E1A and pRb) to transactivate the h TERC promoter activity in certain 
circumstances. The data for NF-Y, Sp1 factors, pRb and E1A suggest a possible role of 
chromatin in the hTERC regulation.
5.3.5 Chromatin modification and the hTERC gene regulation
Transcription factors not only bind to the cognate DNA sequences, but also interact with 
one another to regulate gene transcription. In addition, these factors interact with non 
DNA-binding proteins, such as co-activators and co-repressors. They, in turn, form a 
ternary complex, interact with basic transcription machinery, and confer 3-dimensional 
structure which results in stimulation or repression of the gene promoter. Information 
accumulated over the past several years has demonstrated that transcription is the first 
step in eukaryotic gene expression and that chromatin structure plays a vital role in the 
regulation of transcription. Chromatin structure can restrict the access of transcription-
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associated proteins to promoters and histone acetylation is a major mechanism for 
antagonism of chromatin-mediated repression.
A number of transcription factors can associate with histone acetyltrasferases (HAT) 
which stimulate transcription by acetylating histones and disrupting nucleosome structure. 
Conversely, several other factors have been shown to interact with histone deacetylases 
(HDAC) whose activity leads to nucleosome formation and promoter repression (Owen et 
al., 1998; Motta et al., 1999; Faniello et al., 1999; Jin & Scotto, 1998; Currie, 1998). Sp1 
interacts with p300/ CBP which has HAT activity (Owen et al., 1998). The activities of Sp1 
and NF-Y are altered by the treatment of cells with an inhibitor of HDAC, trichostatin A 
(Jin & Scotto, 1998; Sowa et al., 1997). NF-Y has been demonstrated to associate with 
nucleosomes (Motta et al., 1999) and to exert its effect through alterations in promoter 
architecture. It can also interact with HAT, p300, P/CAF and GCN5 (Faniello et al., 1999; 
Jin & Scotto, 1998; Currie, 1998). These studies demonstrate that Sp1 and NF-Y may 
regulate gene transcription by chromatin modification. It would be of interest to examine 
whether the regulation of telomerase RNA gene in development and in mortal and 
immortal cells is related to chromatin structure and if so, whether this is mediated by NF- 
Y.
5.3.6 Regulation of mammalian TERC promoter
The major transcriptional regulatory elements are usually present in the proximal 
promoter region. Comparative studies have demonstrated that the conserved 5'-flanking 
sequences often constitute c/'s-acting elements that are involved in the regulation of gene 
expression (Thacker et al; 1999), and that important regulatory regions can be discovered 
by comparison of the human and rodent sequences (Fickett & Wasserman, 2000). As 
more data accumulates, it will be valuable to examine the extent of the conservation 
within evolutionary tree of mammalian telomerase RNA gene proximal promoter 
sequences looking, firstly, at a particular sequence element, secondly, the proteins 
binding that element, and finally, a possibly correlated phenotype. I have identified several 
elements conserved across mammals in the hTERC promoter (Figure 5.11).
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Figure 5.12 Speculative model of mammalian TERC proximal promoter 
structure
The highly conserved CCAAT-box, TATA-box and TERC template regions are indicated. 
Sp1 motifs are indicated in the 5'-flanking transcriptional region (5'-FTR) between the 
transcriptional start site and template regions of the human and bovine TERC gene 
promoters. The 5'-FTR absent in the m Terc gene promoter is indicated as a broken line.
Table 5.1 The list of CCAAT-box elements in mammalian TERC
Class Gene CCAAT-box MAT POS TATA DIS REF
Consensus Y Y R R C C A A T (c/g)(A/g)G C hen 1997  
Matuoka, 1999
NF-Y T T A A C C A A T C A G 12/12 Vourio et al 1990
CBF T T A A C C A A T C A C 11/12 Lum et al . 1990
Mammalian Bovine T C G G C C A A T C A G 12/12 -58/-54 a 24 A F221936
(21) Pig T C G G C C A A T C G G 12/12 -58/-54 a 24 AF221920
Plorse T C G G C C A A T G G G 12/12 -57/-53 a 23 A F221925
Ferret C C G G C C A A TC G G 12/12 -58/-54 a 24 AF221931
Racoon C C G G C C A A TC G G 12/12 -58/-54 a 24 AF221917
Mouse T C G A C C A A T C A G 12/12 -53/-49 b 18 AF221922
Rat T C A G C C A A T C A G 12/12 -53/-49 b 18 AF221916
Flamster C C G G C C A A T C A G 12/12 -55/-51 b 20 AF221928
Vole C C G A C C A A T C A G 12/12 -57/-53 b 22 AF221909
Fluman T T G G C C A A T C C G 11/12 -58/-54 a 24 AF221907
Rabbit T C G G C C A A T C C G 11/12 -57/-53 a 23 AF221918
Elephant T T G G C C A A T C C G 11/12 -56/-52 a 23 AF221932
Arm adillo T C G G C C A A T C C G 11/12 -56/-52 a 22 AF221906
Chinchilla T C A G C C A A T C C G 11/12 -58/-54 a 24 AF221937
GuineaPig T C A G C C A A T C C G 11/12 -57/-53 a 23 A F221929
M anatee T T G G C C A A T C C G 11/12 -44/-40 -16/-11 24 AF221923
Cat T A A G C C A A T C G G 11/12 -58/-54 a 24 AF221939
Shrew T C A G C C A A T C A G 12/12 -57/-53 b 22 AF221921
Gopher T C A G C T A A T A C G 9/12 -57/-53 b 22 A F221930
TreeShrew T C G T C C A A T C C G 10/12 -57/-53 a 23 A F221912
Quoll G C G A C C A A T G A G 11/12 -66/-62 a 32 AF221919
The name of the gene is indicated as is the CCAAT sequence in the promoter. The 
CCAAT-box consensus sequence (Matuoka & Chen, 1999; Chen et al., 1997; Pang et al., 
1993) is shown (Y=pyrimidines and R=purines). Bold sequence indicates a proven binding 
site for transcription factor NF-Y. MAT is the number of base pairs matching the 
consensus CCAAT-box sequence and the pink colour shows a mismatch. POS is the 
position of the CCAAT motif with respect to the +1 transcriptional start site (TSS). TATA 
indicates whether the promoter has a consensus TATA signal in the -30/-25 bp region 
shown as "a" or in the -31/-26 bp region shown as "b". DIS indicates the distance between 
the CCAAT and the TATA signals. REF is the reference or GeneBank accession number.
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The distances between TSS and template region vary from 2 to 51 bp in mammalian 
TERC genes. The hTERC TSS lies 45 bp upstream of the template, whereas the mouse 
appears only 2 bp upstream of the template (Feng et al., 1995; Hindely et al., 1998; Chen 
et al., 2000). The mouse, rat, hamster and vole TERC genes lack this sequence region 
suggesting that it is not essential for telomerase function. This region is part of TERC 
gene promoter defined as the 5' flanking transcriptional regulatory region (5'-FTR). 
Comparison 5'-FTR sequence (+1 to +45 bp) of the human with other species shows that, 
the ferret has the highest identity of 93%, the racoon, pig and bovine have 91%, 87% and 
76% respectively. Phylogenetic analyses of proximal promoter (Figure 5.9) demonstrate 
that the bovine and pig TERC gene are more similar to the human. Depending on 
whether they contain the 5'-FTR, mammalian TERC gene promoters can be divided into 
two groups, the mTerc promoter is amongst those which lack this feature. Presence of 
the Sp1 site with GGGTGG sequence element in the TERC 5'-FTR region indicates pRb 
activates gene transcription. The GGGTGG motif in hTERC 5'-FTR region is also present 
at the same position in 1 1  of 2 1  mammalian genes including the bovine, pig, cat, ferret, 
racoon, treeshrew, rabbit and possible horse (see Figure 5.11). We hypothesise that the 
5 '-FTR regions of TERC gene may be responsible for differential transcriptional 
mechanisms which may alternatively explain the different phenotype. Therefore, this is 
important as the divergence in the regulation of telomerase RNA genes between different 
species needs to be taken into account when studying telomerase in animal models of 
development and disease states (Blasco et al., 1997).
TATA-box and CCAAT-box binding site and the template sequence in the proximal region 
are highly conserved across mammalian species even though considerable variation is 
tolerated in other potential transcription factor binding sites. A typical TERC promoter 
structure is predicted (Figure 5.12). The alignments demonstrate constraints on sequence 
that are not explained by simple binding of the known factors. The TATA box, although it 
was shown to be non-functional in hTERC, is fixed at position -30 to -25 bp, but shows a 
varying distance to the template. The CCAAT-box is located position at -58 to -49 bp in 19 
of 21 genes, with the exception of two genes (manatee is in -44/-40 and quoll is in -6 6 /-
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62, Table 5.1). Interestingly, hTERC NF-Y binding sequence, 5'-TTGGCCAATCCG-3', is 
also found in elephant and manatee genes. It has been reported that NF-Y binding motif 
in a promoter of the same gene from different species is strictly conserved. In all cases so 
far reported [MFIC class II, y-globin, a1 (I) collagen, albumin, MDR1, topoisomerase II a] 
this has been formally proven (Matovani, 1998). Statistical analysis of the binding 
sequence around NF-Y revealed a consensus YYRRCCAAT(C/G)(A/G)G (Matuoka & 
Chen, 1999; Pang et al., 1993; Bucher et al., 1990), which it seems to fit well with the 
mammalian TERC gene CCAAT-boxes. Thus it would be of interest to examine the 
interaction of NF-Y with TERC CCAAT-box in more detail.
5.4 Summary
Taking these findings collectively, a model for hTERC gene regulation can be developed 
(Figure 5.1). In this model, direct DNA-protein interaction is shown for NF-Y, Sp1 and 
Sp3. These and other factors may then be modulated by transcriptional regulators to 
interfere directly or indirectly with transactivation. Thus, permutations in signals including 
NF-Y, Sp1, Sp3, pRb and E1A are able to contribute to the regulation of hTERC gene 
expression. Alterations in the relative contributions of those factors in a cell may be 
relevant to hTERC gene expression. These data raise the possibility of cross-talk 
between the hTERC and hTERT gene expression at the transcriptional level as Sp1 is 
known to regulate hTERT. This is an important issue and mechanism of co-regulation 
should be a focus of future work. In particular, the study of NF-Y expression in mortal and 
immortal cells will be key issue for understanding hTERC regulation. This may perform an 
important biological function in vivo, which may link the global way of chromatin 
modification and telomerase regulation.
140
Chapter
Summary
•  Summary of results 
Discussion of results
•  Concluding remarks
•  Future study
(Zhao, JQ., Sept. 2000) Chapter 6. Summary
Chapter 6 Summary and Future Study
Over the past few years, the human telomerase RNA gene (hTERC) has been cloned and 
sequenced and the functional region for reconstitution of telomerase activity has been 
identified. In this study, the hTERC and mTerc gene promoters have been cloned and the 
transcriptional mechanism regulating hTERC gene expression has been investigated. 
Several regulators have been identified as being involved in this regulation (Figure 6.1). 
Analysis of promoter-reporter constructs has provided information concerning individual 
transcription factors, leading to the conclusion that Sp1, NF-Y and pRb activate, Sp3 
represses the hTERC promoter.
6.1 Summary of results
6.1.1 h TERC promoter analysis
About 5.9 kb of hTERC genomic sequence has been cloned and 1.76 kb encompassing 
the hTERC gene promoter region was sequenced. No significant sequence similarity 
could be detected in comparisons between human and mouse 5' and 3’ -flanking regions. 
Range between -5.0 kb and -51 bp in the hTERC gene is responsible for high promoter 
activity, the minimal promoter region has been defined as 176 bp of hTERC (-107 to +69 
bp). Four Sp1 binding sites termed Sp1.1(-29/-36), Sp1.2(-106/-97), Sp1.3(+8/+17) and 
Sp1.4(+21/+32) have been identified in the h TERC proximal promoter region and were 
found to have different affinities for the Sp1 protein. A TATA-box closely overlapping the 
Sp1.1 site was not shown to bind any protein. Mutation of the Sp1.1 site resulted in a 3-4- 
fold induction of promoter activity suggesting it to bind to a negative regulator. Single or 
multiple site-directed mutation analysis demonstrated that the Sp1.3 might interact with 
positive regulators of hTERC. Mutation of the TATA-box alone had no significant effect on 
reporter gene activity. Transient co-transfection analyses demonstrated that Sp1 
stimulates and Sp3 represses hTERC gene transcription. These data illustrate that Sp- 
family of factors involve in the regulation of h TERC transcription.
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Figure 6.1 Model illustrating the human telomerase RNA gene structure
A) The genomic DNA of the hTERC gene is indicated in middle of diagram. Previously 
identified regions of functional hTERC RNA are shown at the bottom, and the 5’- 
flanking transcriptional regulatory region (5‘-FTR) is shown at the top of diagram.
B) Schematic diagram of h TERC  promoter region The identified transcriptional elements 
between -5.0 kb and +69 bp in the full-length Y\TERC 5’-flanking transcription 
regulatory region are shown. The core promoter of h TERC  (-107/+69) are shown as 
yellow box. The various colours symbols or circles represent the different transcription 
factor binding sites and are indicated. The numbers indicate the position of DNA- 
binding sites related to the TSS.
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6.1.2 hTERC transcription depends on NF-Y binding to the CCAAT-box
A major finding in this study is the hTERC CCAAT-box that is bound by nuclear factor NF- 
Y. Deletion or mutation of the CCAAT-box in the proximal promoter abolished hTERC 
promoter activity therefore demonstrating that the CCAAT-box is a key controlling 
element. EMSA experiments further identified the CCAAT-box motif as being specifically 
recognised by the transcription factor NF-Y. Furthermore, NF-Y was demonstrated to be 
essential for the hTERC gene transcription by using a dominant-negative NF-YA vector. 
Thus a functional CCAAT-box residing at -58 to -54 bp and nuclear factor NF-Y binding to 
this element appear to be essential for the transcriptional activation of hTERC gene.
6.1.3 Further regulation of hTERC transcription
hTERC promoter activity was investigated in several cell lines including human and 
mouse, the results show high transcriptional activity in several immortal cell lines in 
comparison to two mortal cell lines (WI38 and IMR90). Furthermore, co-transfection of the 
hTERC promoter constructs with E1A or pRb expression vectors causes up-regulation of 
promoter activity in immortal cells. How these gene products activate hTERC transcription 
was not further investigated in this study.
6.1.4 Mammalian TERC gene promoter comparisons
Sequence analysis has identified three conserved transcriptional elements. A typical 
mammalian TERC promoter contains a TATA-box located at about -25 bp, a single 
sense-orientated Y-box located around 50 bp upstream of the TSS, and a template 
sequence (Figure 5.12). Of all 21 TERC genes, only the bovine and pig TERC gene 
promoters are significantly close to the human in terms of overall sequence. The 5’-FTR 
sequence varies between different species, although most (11 of 21) contain the Sp1 site 
identical to h TERC GGGTGG motif. Only the mouse, hamster, rat and vole TERC genes 
differ most significantly in the 5'-FTR region. Despite conservation of sequence elements
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within the promoter region, the regulation mechanism of TERC gene transcription may be 
different from different species. By using human, mouse and bovine promoter in transient 
co-transfection analyses, a functional divergence was observed; although Sp1 activates 
and Sp3 represses all three promoters, the human and bovine promoter are activated by 
pRb whereas the mouse promoter is not, and NF-Y regulation only appears to be 
important for the human promoter.
6.2 Final discussion
Regulation of gene expression by sequence-specific DNA binding proteins has emerged 
as one of the most important mechanisms governing cell differentiation, development, 
and homeostasis in metazoans. The population of transcription factors that are active in 
the cell nucleus largely dictates the transcriptional output and hence the proliferative or 
differentiated phenotype of the cell. Thus, it is not surprising that alteration of transcription 
factor function, as a result of either gain or loss of function mutations, are now been 
established as a frequent cause of neoplastic transformation and tumour progression in 
humans. Telomerase activity is easily detected in immortal cells but not in mortal cells 
suggesting that up-regulation of telomerase occurs in tumour progression. Recent studies 
have suggested that expression of telomerase is regulated at the transcription level (Zhao 
et al., 1998; Hinkley et al., 1998; Fujimoto et al., 2000; Kyo et al., 1999, 2000; Wick et al., 
1999; Cong et al., 1999; Horikawa et al., 1999; Hargrove et al., 1999; section 1.5.2). In 
this study, progress has been made in identifying molecules involved in binding to and 
regulating the hTERC promoter (Figure 5.1 and 6.1). Specifically, the transcription factor 
NF-Y has been shown to be a major transactivator that can influence hTERC 
transcription, possibly by maintenance of the telomerase RNA gene promoter architecture 
through its binding to the CCAAT-box. NF-Y in combination with other factors controls 
hTERC gene expression.
There is an abundance of cis-acting elements identified in the h TERC promoter. The 
presence of multiple Sp1 binding sites in a promoter region is a good indication that they
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play a role in regulating gene transcription. Sp1 is a member of a family of transcription 
factors consisting of Sp1, Sp2, Sp3 and Sp4. These proteins bind to GC-rich sequence 
(e.g. GGGCGG) found in the promoters of many cellular genes. Sp1 can activate 
transcription through a variety of mechanisms, functioning as a basal promoter element 
and as an upstream activator, depending on promoter context. In many instances over­
expression of Sp3 has indicated that it may serve as an inhibitory member of the Sp 
family, causing repression of Sp1-mediated promoter activation (Hagen et al., 1994; 
Majello et al., 1994, 1995; Kumar & Butler, 1997). As discussed in section 4.3.1, Sp1 
activates hTERC transcription through interaction with multiple Sp1 sites and Sp3 
represses transcription via these sites, in addition there are unknown ways in which these 
factors affect hTERC transcription. Sp1 elements in the hTERC promoter may therefore 
serve as bifunctional promoter elements, acting as either positive or negative regulatory 
elements depending upon the complement of trans-acting factors interacting at nearby 
elements. Based on the present results and the current scientific literature, Sp1-mediated 
hTERC transcription is stimulated by the retinoblastoma gene product. One could 
speculate that pRb may regulate hTERC transcription by interaction with other nuclear 
factors rather than by binding directly to the DNA (Kim et al., 1992b; Udvadia et al., 1992, 
1995), however this regulation appears to be subject to transcription factor binding to the 
CCAAT-element.
Mutation of all four Sp1 sites in the proximal promoter does not prevent efficient hTERC 
transcription, a clear indication that additional activators are indeed operating. Among 
upstream elements, the CCAAT-box is one of the most common, being found in 25% of 
eukaryotic promoters, with a strong position preference at -60 to -80 (Matovani, 1998). As 
described in section 5.3.1, NF-Y binding to the CCAAT-box plays a major role in 
transcriptional regulation of the hTERC gene. NF-Y is generally considered to function as 
a transcriptional activator and appears to increase the affinity of transcription factors for 
their target sequence (Kunzler et al., 1994; Muller-lmmergluck et al., 1990; Gerster et al., 
1990; Tanaka & Herr, 1990; Williams & Tjian, 1991; Arents & Moudrianakis, 1993; Reith 
et al., 1994). Cooperative interactions between NF-Y and different transcription factors
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have been described for several promoters (Mantovani, 1998; Maity & deCrombrugghe, 
1998). NF-Y may also be involved in the transcriptional initiation complex (Liberati et al., 
1999; Bellorini et al., 1996, 1997a). The CCAAT-box located within the hTERC promoter 
is required for NF-Y inducible transcription.
As discussed in section 5.3.1, NF-Y might represent a key component of the 
transcriptional machinery of the hTERC promoter. hTERC transcription depends on NF-Y 
possibly for both physical organisation and in functional regulation. This finding may point 
to a potential anti-cancer therapy. Thus a molecular approach has validated the NF- 
Y/hTERC CCAAT-box interaction as a possible drug target. If a specific molecule such as 
polyamides, sequence specific DNA-binding small molecule (Dickinson et al., 1999; 
Dervan & Burli, 1999), could be designed to target and disrupt NF-Y binding to the 
hTERC CCAAT-box, hTERC expression could be inhibited. On the other hand, NF-Y is a 
pharmacological target with three known but unrelated anticancer agents inhibiting NF-Y 
activity. These drugs are Genistein which may operate through phosphorylation (Zhou & 
Lee, 1998), HMN-154 which may inhibit NF-Y complex formation by interaction with NF- 
YB (Tanaka et al., 1999) and the alkaloid isolated from the marine ascidian, Ecteinascidia 
turbinata, ET-743, which may interfere with the interaction of NF-YA with DNA (Minuzzo 
et al., 2000; Jin et al., 2000; Bonfanti et al., 1999). Although it is likely that drugs such as 
ET-743 will still lack specificity and may target numerous NF-Y regulated promoters, an 
ideal situation is to develop DNA binding drugs that target specific sequences and alter 
the expression of individual genes. We speculate that stable inhibition of such NF-Y 
binding might consequently inhibit telomerase and/or telomere elongation in vivo by 
prevention of hTERC gene expression.
Many transcription factors have been shown to be important in the regulation of hTERT 
(section 1.5.2), NF-Y can now be added to this to make a list of known regulators of 
telomerase as a whole. A physical and functional interaction between c-Myc and the NF- 
YC subunit has been reported recently (Taira et al., 1999). Since NF-Y and c-Myc appear 
to be important regulators of hTERC and hTERT transactivation respectively, this might 
suggest a degree of cross-transcriptional regulatory control between the hTERC and
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hTERT. This speculation is consistent with the discussion reported by Stanta (1999) and 
Masutomi (2000). There may be a reciprocal control at the transcriptional level of the 
expression of hTERC and hTERT which in turn is associated with tumour progression 
(Stanta et al., 1999; Masutomi et al., 2000). Therefore, transcriptional regulation of the 
telomerase genes in certain cell-type seems to be complex issue including distinct 
mechanisms for each gene and possibly interactions between these.
In summary, the activity of the h TERC promoter was found to be controlled by a 
combination of the activities of the transcription factors Sp1, Sp3, and NF-Y. The interplay 
between Sp1, Sp3, and NF-Y within the architecture of the hTERC promoter, the 
ubiquitous nature of these trans-acting factors, and the action of tissue selective 
repressor element(s) may combine to enable a wide variety of cell types to differentially 
regulate hTERC expression through transcriptional control.
6.3 Concluding remarks
The present study has uncovered parts of the transcriptional machinery involved in the 
regulation of human telomerase RNA gene (hTERC) expression demonstrating that the 
Sp-family of factors, NF-Y and other regulators participate in this modulation through the 
hTERC natural promoter context. The hTERC promoter structure, in conjunction with the 
relative abundance and state of activity of the trans-acting factors, may provide the basis 
for selective cell-specific transcriptional regulation of the widely distributed telomerase 
RNA. Use of different context-dependent promoters to drive the synthesis of the 
telomerase RNA component in different species could reflect distinct pathways of 
telomerase gene regulation. Analyses of other cis-elements essential for promoter 
regulation as well as of proteins that interact with the NF-Y factor may provide further 
insights into the molecular mechanisms of telomerase RNA gene regulation in normal 
cells and during carcinogenesis. The understandings of telomerase regulation will not only 
satisfy the curiosity surrounding this complex and important enzyme but will also provide 
a foundation for the pursuit of telomerase-based therapeutic intervention.
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6.4 Future studies
1. Several steps can be taken to achieve a more thorough picture of h TERC promoter 
structure. Firstly, DNase I footprinting and EMSA analysis are required to investigate 
the 3’ end of hTERC promoter region. Mutation and deletion analysis of the hTERC 
proximal promoter region did not totally abolish the activity suggesting the involvement 
of other unknown machinery. Indeed, there is a potential YY1 site and another Sp1 
site present in the more 3’ end of promoter. It is also interesting to know whether the 
proteins binding to the template region regulate h TERC promoter activity. Secondly, 
further investigation of 5’-FTR function should be undertaken. It would be helpful to 
know whether the pRb activation effect is controlled through the 5’-FTR, and whether 
insertion of this region into the same position in mTerc would make the mTerc 
promoter responsible to pRb. This study could give an insight into the regulation 
mechanism for context-dependent TERC transcription. Further investigation of the 
upstream promoter region would also be important to identify further regulatory 
regions where positive or negative regulatory factors might bind and contribute to the 
overall regulation of hTERC.
2. In considering the regulation of telomerase genes, hTERC and hTERT, in normal 
development and during oncogensis, it is unclear how to hTERC and hTERT are co­
expressed during the passage from mortal normal cells to immortal cancer cells. As 
with studies on almost any biological molecule, analysis of h TERC transcriptional 
regulation raises more questions than it answers. Of immediate interest is defining the 
role of NF-Y in transcriptional modulation in normal cells and cancer cells. It would 
also be of help to understand how NF-Y regulates hTERC in vivo, possibly by 
establishing a stable cell line expressing a dominant negative NF-YA. Further studies 
are required to address the nature of this signaling and the biological relevance of the 
NF-Y regulation of telomerase function.
3. Information has accumulated during the past few years to suggest that transcription is 
the primary level at which eukaryotic gene activity is controlled and chromatin
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structure plays a vital role in this through acetylation and deacetylation of histones 
(Davie & Spencer, 2000). Therefore it would be interesting to investigate whether 
acetylation is important in the regulation of telomerase genes, and whether 
recruitment of chromatin remodelling proteins in general, and HAT and/or HDAC in 
particular, holds the key to activation or repression of telomerase gene expression. 
The reagents created in this study can be used to test this hypothesis.
We are like the seven blind men and the elephant in the Indian fable, each focusing on a 
very limited aspect of telomerase, awaiting the day when scientists can piece all the 
information into a complete picture.
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Appendix I: Homo sapiens telomerase RNA (TERC) gene, promoter and complete
sequence
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901 t c t c g c t g a c t t t c a g c g g g cggaaaagcc tc g g c c tg c c g c c t tc c a c c g t t c a t t c t a
961 g ag caaacaa a a a a t g tc a g c tg c tg g c c c g t t c g c c c c t cccggggacc tg c g g c g g g t
1021 c g c c tg c c c a gcccccgaac c cc g c c tg g a g g cc g cg g tc ggcccggggc t tc t c c g g a g
1081 g c a c c t a c tg ccaccgcgaa g a g t tg g c tc tg tc a g c c g c g g g t c t c t c g ggggcgaggg
1141 c g a g g t tc a g g c c t t t c a g g ccgcaggaag aggaacggag c g a g tc c c c g cgcgcggcgc
1201 g a t t c c c t g a g c tg tg g g a c g tg c a c c c a g g a c tc g g c tc a c a c a tg c a g t t c g c t t t c c
1261 t g t t g g t g g g gggaacgccg a tc g tg c g c a tc c g tc a c c c c tc g c c g g c a g tg g g g g c t t
1321 g tg a a c c c c c a a a c c tg a c t g ac tg g g c ca g t g t g c t g c a a a t tg g c a g g a g a cg tg aa g
1381 g c a c c tc c a a a g tc g g c c a a a a tg a a tg g g c ag tg a g c c g g g g ttg c ic tg g a g c c g t tc c
1441 t g c g t g g g t t c t c c c g t c t t c c g c t t t t t g t t g c c t t t t a t g g t t g t a t t a c a a c t t a g t
1501 t c c t g c t c t g c a g a t t t t g t t g a g g t t t t t g c t t c t c c c a a g g t a g a t c t c g a c c a g tc c
1561 c c tc a a c g g g g tg tg g g a g a a c a g t c a t t t t t t t t t g a g a g a t c a t t t a a c a t t t a a t g a
1621 a t a t t t a a t t a g a a g a tc ta a a t g a a c a t t g g a a a t t g t g t t c c t t t a a t g g t c a t c g g t
1681 t t a t g c c a g a g g t t a g a a g t t t c t t t t t t g a a a a a t t a g a c c t t g g c g a t g a c c t tg a g c
1741 a g t a g g a t a t  a a c cc cc ac a  a g c t t
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Sequence feature view of the RNA region: qi I 3005555:799-1248
LOCUS
D E F IN IT IO N
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
T ITLE
JOURNAL
MEDLINE
REFERENCE
AUTHORS
TIT L E
JOURNAL
FEATURES
gene
misc RNA
BASE COUNT 
ORIGIN
AF04 7 3 86 450 bp DNA PRI 02-A P R -1998
RNA from : Homo s a p ie n s  te lo m e r a s e  RNA (TR) gene,  
p ro m o te r  and c o m p le te  sequence .
AF04 73 86 
A F 0 4 7 3 8 6 .1
human.
Homo s ap ie n s
E u k a ry o ta ;  M e ta z o a ;  C h o r d a ta ;  C r a n i a t a ;  
V e r t e b r a t a ;  Mammalia; E u t h e r i a ;  P r im a te s ;  
C a t a r r h i n i ;  H o m in id a e ;  Homo.
1 (bases 799 t o  1248)
Z h a o ,J .Q . ,  H o a r e , S . F . , M c F a r la n e , R . ,  M u i r , S . ,  
P a r k in s o n ,E . K . , B la c k ,D .M .  and K e i th ,W .N .
C lo n in g  and c h a r a c t e r i z a t i o n  o f  human and mouse 
t e lo m e ra s e  RNA gene p ro m o te r  sequences  
Oncogene 16 (10) , 1 3 4 5 -1 3 5 0  (1998)
98206512
2 (bases 799 t o  1248)
Z h a o ,J .Q . ,  H o a r e , S . F . ,  M c F a r la n e , R . ,  M u i r , S . ,  
P a r k i n s o n , E . K . , B la c k ,D .M .  and K e i th ,W .N .
D i r e c t  S ubm iss ion
S u b m it te d  (0 9 -F E B -1 9 9 8 )  M e d ic a l  O n co lo gy , B eatson  
I n s t i t u t e ,  S w itc h b a c k  Rd, G lasgow G61 1BD, UK 
L o c a t i o n / Q u a l i f i e r s  
< 1 . . 4 5 0  
/gene="TR "
1 . . 4 5 0  
/ gene="TR"
/ p r o d u c t = " te lo m e r a s e  RNA"
65 a 147 c 155 g 83 t
1 g g g t tg c g g a  g g g tg g g c c t  gggaggggtg  
61 a ag g g cg tag  g c g c c g tg c t  t t t g c t c c c c  
121 ggcggaaaag c c tc g g c c tg  c c g c c t tc c a  
181 a g c tg c tg g c  c c g t tc g c c c  c tc cc g g g g a  
241 a c c c c g c c tg  gaggccgcgg tcg g cccg g g  
3 01 a a g a g t tg g c  t c t g t c a g c c  g c g g g t c t c t  
361 ggccgcagga agaggaacgg a g c g ag tcc c  
421 a c g tg c a c c c  agg actcg g c  tc a c a c a tg c
g t g g c c a t t t  t t t g t c t a a c  c c ta a c tg a g  
g c g c g c t g t t  t t t c t c g c t g  a c t t t c a g c g  
c c g t t c a t t c  ta g a g c a a a c  a a a a a a tg tc  
c c tg c g g c g g  g tc g c c tg c c  cagcccccga  
g c t t c t c c g g  a g g c a c c ta c  tg c c a c c g c g  
cg9999c9a9 g g c g a g g t tc  a g g c c t t t c a  
cgcgcgcggc g c g a t t c c c t  g a g c tg tg g g
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Appendix II: Mus musculus telomerase RNA (terc) gene, promoter and complete 
sequence
AF047387 . Mus musculus telom...[gi;3005556]
LOCUS
D E F IN IT IO N
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
T IT L E
JOURNAL
MEDLINE
REFERENCE
AUTHORS
T IT L E
JOURNAL
FEATURES
source
g e n e
p ro m o te r
m isc RNA
BASE COUNT 
ORIGIN
A F047387 4044 bp DNA ROD 02-A P R -1998
Mus musculus te lo m e r a s e  RNA ( t e r c )  gene , p ro m o te r  and 
co m p le te  sequence.
AF0473 87
AF0473 8 7 .1  G I :3 0 0 5 5 5 6
house mouse.
Mus musculus
E u k a ry o ta ;  M e tazo a ;  C h o rd a ta ;  C r a n i a t a ;  V e r t e b r a t a ;  
Mammalia; E u t h e r i a ;  R o d e n t ia ;  S c i u r o g n a t h i ; M u r id a e ;  
M u r in a e ; Mus.
1 (bases 1 t o  4044)
Z h a o ,J .Q . ,  H o a r e , S . F . ,  M c F a r la n e , R . ,  M u i r , S . ,  
P a r k i n s o n ,E . K . , B la c k ,D .M .  and K e i th ,W .N .
C lo n in g  and c h a r a c t e r i z a t i o n  o f  human and mouse 
t e lo m e ra s e  RNA gene p ro m o te r  sequences  
Oncogene 16 ( 1 0 ) ,  1 3 4 5 -1 3 5 0  (1998 )
98206512
2 (bases 1 t o  4044)
Z h a o ,J .Q . ,  H o a r e , S . F . ,  M c F a r la n e , R . ,  M u i r , S . ,  
P a r k in s o n ,E . K . , B la c k ,D .M .  and K e i th ,W .N .
D i r e c t  S ubm iss ion
S u b m it te d  (0 9 -F E B -1 9 9 8 )  M e d ic a l  O n co lo gy , B ea ts o n  
I n s t i t u t e ,  S w itc h b a c k  Rd, G lasgow G61 1BD, UK 
L o c a t i o n / Q u a l i f i e r s  
1. .4044
/o rg an ism = "M u s  m usculus"
/ d b _ x r e f = " t a x o n :100 90"
/chrom osom e="3"
1 . . 1 9 5 2  
/ g e n e = " t e r c "
1. .1523  
/ g e n e = " t e r c "
1524 . . 1952  
/ g e n e = " t e r c "
/p r o d u c t = " te lo m e r a s e  RNA"
1023 a 928 c 973 g 1120 t
1 a a g c t tg g a c  t tg a c a a a g a  a a c tg c a g a t  c a tc tg g a c c  c c c cc cc cc c  c c c a t t t a g g
61 t t t a a c a a t g  t a c c a g c t a t  c t g a c t t a a g  c a a a c t g t g t  t c c t c a t a g a  taag gcg g ga
121 c t g c t c a t g g  t c a t t g t g a a  g t t c a g t t g g  g a ta a a c a a a  t t t t a a g g t g  c a ta a c a a a a
181 a a c a c a a a a t  g t t g g t g t t t  g t t t a a a a a a  a a c ta a a g a a  t t t c t g g a g g  c a g g c a g t ta
241 c a g a a a a c a t  g c t g a t a t t c  t g a g t t g c c t  g c t a g t t g g t  g c c a t t c c a c  c ag ag tg aa c
301 a c a t c t c t g t  t g a c c c t g a t  t t t c t g t a g g  t c t g t c t g t g  t g t c t g t c c t  t t c t c c a g c a
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361 a gg g c tg acc c ta a tc g g g g tc c c a g g a c c c a a g c c t tg a g aa ag g c ag t a g t a t g t c a t
421 c t a g t t g a a a t g a c a c a t t c t c t a c a g t g t c c a a a tg a c a t c t t t g t g c t agacagaaca
481 t t t t a t t g g a t g g a c t a t g g c t g a c c a c t t g g c t tg g g g g gggggggaag gggccgccaa
541 gggcgggggt c c c t c a t t t g c t t g t t a t t a a c a c t t g c t t g t t t g t t t a c t t g t t a g t a g
601 g a a t c t g c t c ta c c a c g tg g g t t c t a c a t g g t tc c a c a g g g g tc a c c tg g t c c g t t t t t g
661 t t t t c t g g g a c a g t t t t c a c a a a t g t t g t c t a g a c t c c a c g t t g g c t t t g a a g c c ta c a g
721 c t a t g a g c c t c t g t g c c a g t t t a t g c a g t a g t a t c t c t c g g g t t g t c c t t c a c c g t t a g t
781 a g t g g tg c tc t ta g a a g g c a c c g t g a t t t t t t g c t t t c c a t c t c t t t c c c c tg c c a tg c c
841 t t c t g t g g t t c tc tg c c a g g c a c c a a a c tg t t c a g a a a c t c tc c a g c c c g g ta g a g a a c g
901 gtag g g gg aa a g a a c tg a c g tg tg g a a g g g atgg g cag gg agaagaggca c c g a a c tc g g
961 t c t t a a a c a a aaa aa aa aa a aaaaggagca t ta g a a a a a a a a a c a a a t t t g t g a c c t t g a
1021 a c ta c a g a c c t c c t g c c t c a g c c t c c ta c a a g c t g g g a t t a ta g g c tc g g g tc a g c ta c c
1081 c t t g a a a t c t t t t t c t t t c t g g a a c tc a g t a c c t g g t t g g c c a tg c a c tc a c a a g a g a tc
1141 c g c c t g c c t t c t g t c t c t c a a a t t c t g g a a t t a a a g a t t t g c g c c a c t t t t c c c c a c t t c
1201 cacccccggc tg tg g g a g tg g a c t g g g t tg a a g g tg g a a t t t t t t t t t t t t t t t t t t t t t
1261 t t t a g t g a a a aaagggggga t t g g a a a t a t c c c t a c t t t c a a c t c t a g t a t a t t t c a g a a
1321 a c c a a g c c tc a g a g a tg tg c g tg c g tg c g t g t g t g t g t g t g t a t g t g t g t g t g t c t c a c a
1381 g caagaaaca g a t t t t a t t a t t t a t t t t t t a t t t a t t t a t t t t t t g c a a g t g a c t g g c t a
1441 g g aagagtgg ggaagcggga g g a c a a a tg g ggaagaggga g c a t t t c c g c a a g tg c tg g g
1501 c tc g a c c a a t cagcgcgcgc c a t g g g g t a t t t a a g g t c g a g g g cg g ctag g c c tc g g c a c
1561 c ta a c c c tg a t t t t c a t t a g c t g t g g g t t c t g g t c t t t t g t t c t c c g c c c g c t g t t t t t c
1621 t c g c t g a c t t ccagcgggcc a g g a a a g tc c a g a c c tg c a g cgggccaccg c g c g t tc c c g
1681 a g c c tc a a a a a c a a a c g tc a gcgcaggagc t c c a g g t t c g c cg g g ag c tc cgcggcgccg
1741 ggccgcccag t c c c g t a c c c g c c ta c a g g c cgcggccggc c t g g g g t c t t a g g a c tc c g c
1801 tg c c g c cg c g a ag a g c tc g c c t c t g t c a g c cgcggggcgc cgggggctgg ggccaggccg
1861 ggcgagcgcc gcgaaggaca g g aa tg g a ac t g g t c c c c g t g t t c g g t g t c t t a c c t g a g c
1921 tg tg g g a a g t gcacccggaa c t c g g t t c t c a c a ac cc cc a t t c c c g c t g g g g a a a tg c c c
1981 c gc tgcag g g c g g g c cg c ta g a a c c tg c g a c t t c t g g g g a a a g g g g c t tc g g tg tg a g a c
2041 gg ta g cc ag c c a a a g g g ta t a t a t c g c c c t c a c g c c c c g t c c c c c tc c a c t t t t g t c t a a
2101 t a c t c c t g t t t c t g t t g t g c a g a t t t t g c a g g c g t t t c g c t g g c t c t g c c tg a a c g a g c t
2161 a tg c a g c c a t g t g g t c c t t g ggggtggggg tg g g g a tg g g a g g a c ta c a g g c g t a g a t c t
2221 t c a t a c t g g g t t t g t g t a g t g c t g g g a a t t g a a c c t a g t t t c c t a a g t t c t c t a t c a a c t
2281 g g t a t t c c c a t t g t a t g g g a g a t t t t t t t t t t c t t t t g t a ta tg g g g g c g t t g a a c a t t t
2341 t g t a a a c a a t t a g a a a a t c t a g t a g t t t t t t a a t g a a a a t g t t c a c t t t t c t t t g t c t t t
2401 g g g a tg ca aa a c a t t a c a t t g a a g c tg a g a a g t t t a a a g a t g c g t g t c t t c c c c t g c c ta
2461 c c t t c g c g t t cacacagaac c t g t t a t c t t t t c a g a a a a g a a a a tg a g a t agg cag g g tg
2521 g a t c tg g a g t t tc a a g g c c c t t g c c t g g t c tg c a g a g tg a g t ta g g c c a c accagaaaag
2581 t a t g t g t c a a a aacaaag aa g a a a g g c t t t g tg g g g g g tg g g g ta g c a a a c g a t c t t a a t
2641 c c c c t g t g c t tgggaggccc gcaaggggga t a t c t g t g a a ggagacaaac a a a g c ta c a c
2701 t g t g t g g t a a a caaaaaacg aggaggagga gcaagaagaa ta tg a g a g c c cacggaagga
2761 a g a g ta tc a g tc c c c a g g c c a c c a g t t c c t cag g g g ta ac t a t g t t t g t g a g t g t c t c g g
2821 t g c c t t g a c t t c c t c a g t a c t t t t c t g g g t t t t a g t c a t a a a a a a c a t t g a a g a g a tg a a
2881 g a a g t g t a t g t t t a g t a a g t a c a ta c c a a a a g t t t g t g a g c t a t a t g c a t a ta g c a a c tc
2941 a g tc a c c tg a aacaggcccc t t g c a g c t a a c a t a t t t c t t a g t a t t a c t a t t a t a a a g a c
3001 ta g g g g a g t t t c ta a g c c g g c a c t c c t t a c aagggacgaa g c c a t g t t c a g c t c c a g c t t
3061 g c c a a g a t tc tg a a a c c c a a c g tc a a g c c t g a c g a g t tc g a g c c tg g c a t c tc tc a g c c g
3121 c tg c tc g a g c tg g a g a tg a c c a c g g a tc tc aaggcacagc t g t g g g a a c t c a a c a tc a c c
3181 gaagccaagg a a a a t tg a a g t t g g t g g t g g tc a g a a g g c t g t t a t a a t t t t t g t a c c a g t
3241 t c c t c a g c t t a a a t c t t t c c a g a a a a tc c a a g t c t g g c t a g t t t g t g a a t tg g a g a a a a a
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3301 g t tc a g c g g a a a g c a c g tg t c t t c a t t g c t cagaagagga t c t g t c c a a g ccaaccagga
3361 a a a g c tg ta c g a a a a a ta a g ccaaagcacc c ta g a a g c tg c a c c c tg a c a g c a g tg c a tg
3421 t c t t c t c a a g t g a a a t t g t g ggaaagagga t c c a t c c g t g tg a a a c tg g a t g g c a a t c t g
3481 g a g c a g g t tc a t c t t c c t c t c t g g t a c a t c c c a t g t c t c c t c a t c t c c a t c c t c c c c t c t
3541 g c c t c t g t g t c t c a t c t c t a a a a c t c t c a g c c c a t c t t c c t t t a c c a c t g c c c a a tc a c a
3601 g g c tc ta g c c t t a c c t t t c a c c t g c c c t c a c c t g c t t a t a g a c a g c a a tc t a c a t t t c t c
3661 c c t t t t t g t c c a a t t a a a a g a c t c t t t t c t c t c g g a t a t a a a a tg a g c a c a a c t a t t a t t
3721 a c c a t t c t g t a a t t t a t a a a g t a t a g a t a g a c c ta a c a c c c a g t c t a t c a t t t t g a c a g t
3781 ta a a t a a a g c a t t c t g c a a t c c t a t c c t a a c t t t a a a a g g c t t a t a a t t c t a c a c t t g t t
3841 a t g t c c t g g t t c a g c t t g t a t a t t a g a a a a c c a t c t c a a a t t a t a t a t a t a t a t a t a t t a
3901 c a c ac ac ac a t a t g t a t a t a t a c a t a t a t a t g t a t a c a c a c a c a c a c a ta t a t a t a t g t a
3961
4021
t a t g t a t g t a
a c t a c t t c a a
t g t a t g t a t a
t c c tg c c a g a
t a t a t a t a c t
a t t c
t t t a a t g c t a a a ta g c c tg g g t t g g c t a a g
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Sequence feature view of the RNA region: qi|3005556:1524-1952
LOCUS
D E F IN IT IO N
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
T IT L E
JOURNAL
MEDLINE
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
gene
m isc RNA
BASE COUNT 
ORIGIN
AF04 7 3 87 429 bp DNA ROD 02-APR -1998
RNA fro m : Mus musculus te lo m e r a s e  RNA ( t e r c )  gene,  
p ro m o te r  and c o m p le te  sequence.
AF047387  
A F047387 .1
house mouse.
Mus musculus
E u k a r y o ta ;  M e tazo a ;  C h o r d a ta ;  C r a n i a t a ;  V e r t e b r a t a ;  
M ammalia; E u t h e r i a ;  R o d e n t ia ;  S c i u r o g n a t h i ;
M u r id a e ; M u r in a e ; M us.
1 (bases 1524 t o  1952)
Z h a o , J . Q . ,  H o a r e , S . F . ,  M c F a r la n e , R . ,  M u i r , S . ,  
P a r k i n s o n , E . K . , B la c k ,D .M .  and K e i th ,W .N .
C lo n in g  and c h a r a c t e r i z a t i o n  o f  human and mouse 
te lo m e r a s e  RNA gene p ro m o te r  sequences  
Oncogene 16 ( 1 0 ) ,  1 3 4 5 -1 3 5 0  (1998)
98206512
2 (bases 1524 t o  1952)
Z h a o ,J . Q . ,  H o a r e , S . F . ,  M c F a r la n e , R . ,  M u i r , S . ,  
P a r k i n s o n , E . K . , B la c k ,D .M .  and K e i th ,W .N .
D i r e c t  S ubm iss ion
S u b m it te d  (0 9 -F E B -1 9 9 8 )  M e d ic a l  O n co lo gy , B eatson  
I n s t i t u t e ,  S w itc h b a c k  Rd, G lasgow G61 1BD, UK 
L o c a t i o n / Q u a l i f i e r s  
< 1 . . 4 2 9  
/ g e n e = " t e r c "
1. .429
/g e n e = " t e r c "
/p r o d u c t = " t e lo m e r a s e  RNA"
63 a 141 c 145 g 80 t
1 g g g g t a t t t a  agg tcgaggg  c g g c ta g g cc  t c g g c a c c t a  a c c c t g a t t t  t c a t t a g c t g
61 t g g g t t c t g g  t c t t t t g t t c  t c c g c c c g c t  g t t t t t c t c g  c t g a c t t c c a  gcgggccagg
121 a a a g tc c a g a  c c tg ca g c g g  gccaccgcgc g t tc c c g a g c  c tc a a a a a c a  a a c g tc a g c g
181 c ag g ag c tc c  a g g t tc g c c g  g g a g c tc c g c  ggcgccgggc c g c c c a g tc c  c g ta c c c g c c
241 tac ag g cc g c  g g cc g g c c tg  g g g t c t t a g g  a c tc c g c tg c  cgccgcgaag a g c tc g c c tc
3 01 tg tc a g c c g c  ggggcgccgg gggctggggc  caggccgggc gagcgccgcg aaggacagga
361 a tg g a a c tg g  t c c c c g t g t t  c g g t g t c t t a  c c t g a g c t g t  g g g a a g tg c a  c c c g g a a c tc
421 g g t t c t c a c
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Appendix III: The human telomerase reverse transcriptase (hTERT) gene promoter 
sequence from -499 to + 8 6  bp
DEFINITION
SOURCE
ORGANISM
REFERENCE
FEATURES
BASE COUNT 
ORIGIN
439 ccggatcagg 
•379 atggcccctc 
319 cctcgctggc
Homo sapiens telomerase reverse transcriptase (TERT) 
gene, promoter, 
human.
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; 
Mammalia; Eutheria; Primates; Catarrhini; Hominidae;
Homo.
1 (bases 1 to 535)
Kyo et a l ., 2 00 0 ;
Takakura et al. , 1999;
Sequences of the hTERT core promoter and consensus 
motifs for factor binding sites. The start site of 
transcription is shown by an arrow (Kyo et a l . , 
2000; Takakura et a l ., 1999). The -1 indicates the
first nucleotide 5' to the start site of 
transcription, while 1 indicates the first 
nucleotide of the mRNA. The initiating ATG codon 
is shown in capital bold. The E-box is boxed and 
the Spl consensus motifs are underlined.
535
-449 ccctgggtct
ccagcggcca aagggtcgcc gcacgcacct gttcccaggg cctccacatc
cctcgggtta ccccacagcc taggccgatt cgacctctct ccgctggggc
gtccctgcac cctgggagcg cqagcgqcqc gcgggcgggg aagcgcggcc
WT1
-259 cagacccccg ggtccgcccg gagcagctgc gctgtcgggg ccaggccggg ctcccagtgg
-199 attcgcgggc acagacgccc aggaccgcgc ttcccacgtg gcggagggac tggggacccg
E -b o x
-139 ggcacccgtc ctgccccttc accttccagc tccgcctcct ccgcgcggac cccgccccgt
Spl
-79 cccgacccct cccgggtccc cggcccagcc ccctccgggc cctcccagcc cctccccttc 
S p l S p l S p l
+ 1
-19 ctttccgcgg ccccgccctC tcctcgcggc gcgagtttca ggcagcgctg cgtcctgctg
Spl
+42 cgcacgtggg aagccctggc cccggccacc cccgcgATGc cgcgc +86 
E -b o x
The hTERT promoter region used in this study is from -449 bp to 
+32 bp in length.
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Appendix IV: The bovine telomerase RNA gene (bTERC) promoter sequence 
Bos taurus telomerase RNA gene, promoter region and partial sequence
LOCUS
D E F IN IT IO N
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
AF176663 MAM 0 2 -N O V-1999320 bp DNA
Bos ta u r u s  te lo m e r a s e  RNA gen e , p ro m o te r  r e g io n  and  
p a r t i a l  sequence.
AF176663  
A F 1 7 6 6 6 3 .1 G I :6175865
REFERENCE
AUTHORS
T IT L E
JOURNAL
REFERENCE
AUTHORS
T IT L E
JOURNAL
FEATURES
sou rce
p ro m o te r
misc_RNA
BASE COUNT 
ORIGIN
cow.
Bos ta u r u s
E u k a ry o ta ;  M e tazo a ;  C h o rd a ta ;  C r a n i a t a ;  V e r t e b r a t a ;  
E u t e l e o s t o m i ; Mammalia; E u t h e r i a ;  C e t a r t i o d a c t y l a ;  
R u m in a n t ia ;  P e co ra ;  B o vo id e a ;
B o v id a e ;  B o v in a e ;  Bos.
1 (bases 1 t o  320)
Z h a o ,J .Q . ,  B i l s l a n d , A .  and K e i t h ,W .N .
B o v in e  te lo m e ra s e  RNA gene p ro m o te r  
N e o p la s ia ,  2 ( 6 ) ;  5 3 1 -5 3 9 .  (2000 )
2 (bases 1 to  320)
Z h a o ,J .Q . ,  B i l s l a n d , A .  and K e i t h ,W .N .
D i r e c t  Subm iss ion
S u b m it te d  (10 -A U G -1999)  M e d ic a l  O n c o lo g y , CRC B eatson  
Labs, S w itc h b a c k  Rd, Glasgow G61 1BD, UK
L o c a t i o n / Q u a l i f i e r s
1 . . 320
/o rg a n ism = "B o s  t a u r u s "
/ d b _ x r e f = " t a x o n :9913"
1 . . 281  
282 . . >320
/ p r o d u c t = " te lo m e r a s e  RNA"
86 a 72 c 98 g 64 t
1 c c g ta c c tg g c t t t t a a g a g g tg g a a a a c a g c g c tc a g a a g c a c t c a a g t t a a t t t t c a a
61 g tc a c a a g g t cag ac g tc g g a a g t a a a a ta t t c a a a t c t g c g g a ta a a a a a c g tg a g g ta
121 gggcggcgac t a t c c t t t t g gccggaaaca g a a c t t t t g a g aa aa a aa aa a a t tg c g a g a
181 c c g g t t a t c g cgagagccgc tg tg g a c a g g c tc g g c c a a t c ag cg tag g c g c c g g c tg c t
241 g c a t t c a t a a ggagacgcag ccagcggcgc qqccrcrcrttcrc qgagggtggg c c c c g g g ttg
301 g tg g c a g c c a t t t c t c a t c t
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Appendix V: The list of CCAAT-box in vertebrate TERC gene
Class Gene CCAAT-box MAT POS TATA DIS REF
Consensus YYRR CCA AT(C /gxa/g)G Chen, 1997  M aiuoka.1999
NF-Y TTAACCAATCAG 12/12 Vourio et al . 1990
CBF TTAACCAATCAC 11/12 lu m  et a l,, 1990
Mammalian Bovine T C G G C C A A T C A G 12/12 •58/-54 a 24 A F221936
(21) Pig TC G G C C A A T C G G 12/12 -58/-54 a 24 A F221920
Horse T C G G C C A A T G G G 12/12 -57/-53 a 23 A F221925
Ferret C C G G C C A A TC G G 12/12 -58/-54 a 24 A F221931
Racoon C C G G C C A A TC G G 12/12 -58Z-54 a 24 A F221917
M ouse T C G A C C A A T C A G 12/12 -53Z-49 b 18 A F221922
Rat T C A G C C A A T C A G 12/12 -53/-49 b 18 A F221916
Ham ster C C G G C C A A T C A G 12/12 -55/-51 b 20 AF221928
Vole C C G A C C A A T C A G 12/12 -57/-53 b 22 AF221909
Human TTGGCCAATCCG 11/12 -58/-54 a 24 AF221907
Rabbit T C G G C C A A T C C G 11/12 -57/-53 a 23 AF221918
Elephant TTGGCCAATCCG 11/12 -56/-52 a 23 A F221932
Arm adillo T C G G C C A A T C C G 11/12 -56/-52 a 22 A F221906
Chinch illa T C A G C C A A T C C G 11/12 -58/-54 a 24 A F221937
G uineaP ig T C A G C C A A T C C G 11/12 -57/-53 a 23 AF221929
M anatee TTGGCCAATCCG 11/12 -44/-40 -16/-11 24 A F221923
Cat T A A G C C A A T C G G 11/12 -58/-54 a 24 A F221939
Shrew T C A G C C A A T C A G 12/12 -57Z-53 b 22 AF221921
G opher T C A G C T A A T A C G 9/12 -57/-53 b 22 AF221930
TreeShrew T C G T C C A A T C C G 10/12 -57/-53 a 23 AF221912
Quoll G C G A C C A A T G A G 11/12 -66/-62 a 32 A F221919
Aves Chicken C C G G C C A A TG G G 12/12 -65/-61 a 31 AF221938
(2) M acaw C T G A C C A A T G G A  
G C A G C C A A T G C G  *
11/12
11/12
-64/-60
-91/-87
a 30 A F221924
Reptilia (1) Turtle C T A G C C A A T C C A  
C G A G C C A A T G G G  *
10/12
11/12
-65/-61
-94/-90
a 31 A F221911
Am phibia
(7)
Typhlonectes G G A A C C A A T C A G
C G A A C C A A T C A G *
10/12
11/12
-71/-67
-95/-91
a 37 A F221910
Xenopus A G A A C C A A T C G A 9/12 -95/-91 a 61 A F221908
Toad A T A A C C A A T C A A 10/12 -68Z-64 a 34 A F221913
HornedFrog* C C G G C C A A TG C G 11/12 -12/-8 a 7 AF221926
Bullfrog C C G T C C A A T A A A 9/12 -63/-59 a 29 A F221940
Derm ophis C G A A C C A A T C A G 11/12 -83/-79 a 49 A F221934
Herpele C G A A C C A A T C A G 11/12 -73/-69 a 39 AF221927
Chondri- S tingray T G G A C C A A T G G A 10/12 -71/-67 a 37 AF221914
chthyes CownoseRay T G G A C C A A T G G A 10/12 -71/-67 a 37 AF221935
(4) Sh. Shark A T G G C C A A T G G G 11/12 -79/-75 a 45 AF221915
DogfishShark C T C G C C A A T G G G 11/12 -80/-76 a 46 A F221933
1 8 1
(Zhao, JQ., Sept. 2000) Appendix
The name of the gene is indicated as is the CCAAT sequence in the promoter. The 
CCAAT-box consensus sequence (Matuoka & Chen, 1999; Chen et al., 1997; Pang et al., 
1993) is shown (Y=pyrimidines and R=purines). Bold sequence indicates a proven 
binding site for transcription factor NF-Y. MAT is the number of base pairs matching the 
consensus CCAAT-box sequence and the pink colour shows a mismatch. POS is the 
position of the CCAAT motif with respect to the +1 transcriptional start site (TSS). TATA 
indicates whether the promoter has a consensus TATA signal in the -30/-25 bp region 
shown as "a" or in the -31/-26 bp region shown as "b". DIS indicates the distance 
between the CCAAT and the TATA signals. The CCAAT signal has not been reported by 
Chen (2000) shown as REF is the reference or GeneBank accession number.
Class Mammalia includes Homo sapiens (human), Trichechus manatus (manatee), 
Elephas maximus (elephant), Dasypus novemcinctus (armadillo), Oryctolagus cuniculus 
(rabbit), Tupaia glis belangeri (tree shrew), Chinchilla brevicaudata (chinchilla), Cavia 
porcellus (guinea pig), Equus caballus (horse), Bos taurus (bovine), Sus scrofa (pig), 
Felis catus (cat), Procyon lotor (raccoon), Mustela putorius furo (ferret), Suncus murinus 
(shrew), Geomys breviceps (gopher), Microtus ochrogaster (vole), Cricetulus griseus 
(hamster), Mus musculus (Mouse), Rattus norvegicus (rat), and Dasyurus hallucatus 
(quoll).
Class Aves includes Gallus (Chicken) and Anodorhynchus hyacinthinus (Macaw). Class 
Reptilia includes Chelydra serpentina (Turtle). Class Amphibia includes Xenopus 
laevis (Xenopus), Bombina japonica (Toad), Ceratophrys ornata (HornedFrog),
Pyxicephalus adspersus (Bullfrog), Dermophis mexicanus (Dermophis), Herpele
squalostoma (Herpele), and Typhlonectes natans (Typhlonectes). Class
Chondrichthyes includes Dasyatis sabina (Stingray), Rhinoptera bonasus
(CownoseRay), Rhizoprionodon porosus (SharpnoseShark), and Mustelus canis 
(DogfishShark). (For reference see Chen et al., 2000).
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Appendix VI: World wide web address
The useful web sites in this study:
Telomere and Telomerase
Sequence Interpretation Tools
TFSEARCH
TESS
Gene recognition & assembly 
Gene Cards 
Sequence motif search 
NCBI
TRANSFAC
ExPASy
InforMax
doubletwist
genestream
Chromatin structure & function 
adenovirus 5 homepage 
NF-Y
Top10 link
Online Journals & Impact Factors
Oncogene
Neoplasia
-http://resolution.colorado.edu/~nakamut/telomere/
telomere.html
-http://www.genome.ad.jp/SIT/SIT.html-
-http://pdap1.trc.rwcp.or.jp/research/db/TFSEARCH.html-
-http://agave.humgen.upenn.edu/tess/-
-http://compbio.ornl.gov/ Grail-1.3/.-
-http://bioinformatics.weizmann.ac.il/cards/-
-http://www.motif.genome.ad.jp/-
-http://www.ncbi.nlm.nih.gov/ -
-http://transfac.gbf-braunschweig.de/TRANSFAC/index.html-
-http://www.expasy.ch/-
-http://www.informaxinc.com/-
-http://doubletwist.com/-
-http://vega.crbm.cnrs-mop.fr/-
-http://www.mdanderson.org/%7Egenedev/Bone/
chrom.html-
-http://www.mdanderson.org/%7Egenedev/Bone/
chrom.html-
-http://users.unimi.it/~mantor/-
-http://www.med.rug.nl/mdl/toplink.htm
-http://www.med.rug.nl/mdl/journal.htm
-http://www.stockton-press.co.uk/onc/
-http://www.nature.com/neo
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